Document:

Prepared by MERRILL CORPORATION

QuickLinks
 -- Click here to rapidly navigate through this document
  

Exhibit 10.1  

  
 

    APPLICATION SOLUTION LICENSE AGREEMENT    
  

    This Software License Agreement (the "Agreement") is entered into between Sollen Technologies, LLC, a Texas Limited Liability Company, ("Sollen") with its
principal place of business located at 6009 Beltline Road, Suite 100, Dallas TX 75240, and Monument Mortgage, Inc., a California corporation ("Monument Mortgage") with its principal place of
business located at 2527 Camino Ramon, Suite 200, San Ramon, CA 94583. (Sollen and Monument Mortgage are sometimes individually referred to herein as a "Party" and collectively referred to herein as
the "Parties"). 

    WHEREAS, Monument Mortgage is a mortgage company; and 

    WHEREAS, Sollen is in the business of developing software and application solutions designed to increase the efficiency of the mortgage
industry; and 

    WHEREAS, Monument Mortgage wishes to obtain a license to the Application Solution (as defined in this Agreement) developed by Sollen
for use in its business. 

 
 

AGREEMENT    
  

    NOW, THEREFORE, in consideration of the covenants and agreements set forth herein, and for other good and valuable consideration, Monument Mortgage and Sollen
agree as follows: 

    1.  Term  

	1.1.
	Effective Date. This Agreement and the license granted hereunder shall take effect upon the date that the last Party executes this
Agreement and shall have a term of one year. This Agreement shall automatically be renewed for consecutive one-year terms, unless either party notifies the other party in writing of its
intent not to renew at least 60 days prior to the end of the current term. 
	1.2.
	Termination. Each Party shall have the right to terminate, with immediate effect,
this Agreement and the license granted herein
after the occurrence of any of the following events (an "Event of Default"): 
	(i)
	In
the event the other Party materially breaches any provision of this Agreement that is not cured within 30 days of written notice thereof;
or 
	(ii)
	In
the event the other Party (a) terminates or suspends its business, (b) becomes subject to any bankruptcy or insolvency proceeding
under Federal or State statute, (c) becomes insolvent or subject to direct control by a trustee, receiver or similar authority, or (d) has wound up or liquidated, voluntarily or
otherwise. 

    2.  Definitions  

	2.1.
	"Intellectual Property Rights" shall mean all inventions (whether or not prosecutable under patent laws), works of authorship, moral
rights, mask works, trademarks, trade names, trade dress, trade secrets, and all other subject matter protectable under patent, copyright, moral right, mask work, trademark, trade secret, or other
laws, including without limitation all new or useful art, combinations, discoveries, formulae, manufacturing techniques, technical developments, artwork, software, programming, applets, scripts, and
designs. 
	2.2.
	"Application Solution": The term "Application Solution" shall mean Sollen developed software, databases and technology used to offer
Monument Mortgage a solution package with functionality described in Exhibit A. The Application Solution includes Sollen's single lender back-office software "Sollen Suite," access
to the Sollen Product and Pricing Engine through a Sollen approved or delivered interface, and interfaces between the Product and Pricing Engine and Monument Mortgage's wholesale web site and the
Calyx PTS server. The Application Solution includes Sollen's software, content, databases and features for the operation of the Application Solution. The Application Solution also includes any
corrections, bug fixes, 

1

 

enhancements,
updates or other modifications, including custom modifications made by Sollen to it, subject to the terms of this Agreement. 

    3.  License Grant to Application Solution and Parties' Undertakings.  

	3.1.
	Grant. Subject to the terms and conditions of this Agreement. Sollen grants Monument Mortgage a personal, non-exclusive,
non-transferable US license to use and copy (for back-up purposes only) the Application Solution, subject to the terms and conditions of this Agreement. 
	3.2.
	Title.
Sollen shall have sole and exclusive ownership of all right, title and interest in and to the Application Solution, all
copies thereof, and all derivative works, modifications and enhancements thereto (including ownership of all copyrights and all other Intellectual Property Rights pertaining to the Application
Solution), whether made by Sollen or any third party, subject only to the right and license expressly granted to you herein. This Agreement does not provide Monument Mortgage with title or ownership
of the Sollen Application Solution, any Intellectual Property Rights or software, but only a right of limited use. In particular, Monument Mortgage agrees it will not use, copy, modify, or distribute
the software or any other part of the Application Solution (electronically or otherwise), or any copy, adaptation, transcription or merged portion thereof, except as expressly authorized by Sollen by
a written agreement signed by Sollen. Monument Mortgage agrees it will not reverse assemble, reverse compile, or otherwise translate or reverse engineer the software or any other part of the
Application Solution. 
	3.3.
	Inspection. Monument Mortgage authorizes Sollen to enter its premises in order to inspect the Application Solution and software
during regular business hours for the purpose of verifying compliance with the terms of this Agreement. For the same purpose, Monument Mortgage authorizes Sollen to have electronic access at all times
to all copies of the Application Solution and any parts thereof. 
	3.4.
	Future Enhancements. Sollen shall provide Monument Mortgage, without charge, with the use of
future enhancements and the most
current release of the Application Solution as long as Monument Mortgage is a customer in good standing. 
	3.5.
	Copies.Monument Mortgage may make two copies of the
Application Solution software installed at its premises, if any, for
back-up purposes only, provided that in making such copies Monument Mortgage shall not delete Sollen's copyright and any other proprietary notices. Any copy of the Application Solution
made by Monument Mortgage is the exclusive property of Sollen. Monument Mortgage, at its discretion and expense, may elect to have an on-site server installed to run the Application
Solution to mirror or regularly copy the Application Solution for the purpose of redundancy or disaster recovery. In this case, access to this copy shall be restricted by Monument Mortgage to only
those employees of Monument Mortgage that have a need to access to maintain the system. 
	3.6.
	Suspension of Operations. In the event Sollen suspends or terminates its
business or is otherwise unable to maintain the
functionality of the Application Solution for Monument Mortgage for five (5) consecutive business days during the Term of this Agreement other than caused by Force Majeure (as defined by
Section 14), then Sollen shall sell to Monument Mortgage a stand alone, fully licensed, version of the Application Solution, which includes all of Monument Mortgage's product guidelines and
business rules, and operates within Monument Mortgage's data center, independent of support from Sollen ("Independent Application Solution"). Monument Mortgage shall pay to Sollen a sum equal to
the total of the Transaction Fees paid by Monument Mortgage to Sollen during the prior three months, as the purchase price for the Independent Application Solution. 
	3.7.
	Material Terms and
Conditions. Monument Mortgage and Sollen specifically agree that each of the terms and conditions of this
Section 3 are material and that failure of Monument Mortgage or Sollen to comply with these terms and conditions shall constitute a material 

2

 

breach
and shall be sufficient cause for either Party to terminate this Agreement in accordance with the provisions of Section 12. 

    4.  Delivery, Installation, Data Integrity, and Acceptance  

	4.1.
	Delivery. Both Parties will agree on a schedule for the delivery, testing and acceptance of the wholesale web site interface to be
developed by Sollen. Installation of the PTS software will be done by Calyx and at the discretion of Calyx, and the failure of performance by Calyx to install the Calyx software does not excuse
performance by the Parties to this Agreement. 
	4.2.
	Installation. Sollen has already installed the user interface to the Sollen Suite software at the Monument Mortgage
site and has
trained Monument Mortgage personnel in the use of the software. In the event of any subsequent installation by Sollen at Monument Mortgage, Monument Mortgage shall provide (i) any necessary
hardware and all required peripherals ("Hardware"), and (ii) provide all required third party software ("Third Party Software"). Monument Mortgage at all times is solely responsible for
obtaining and maintaining licenses on the Third Party Software. 
	4.3.
	Data Integrity. Monument Mortgage shall be solely responsible for the verification and integrity
of all of the lender's program
guidelines and pricing data entered into the Application Solution by Sollen or Monument Mortgage personnel. 
	4.4.
	Acceptance. The Application Solution shall be deemed
accepted by Monument Mortgage when the Application Solution has been completely
installed, enabled and made ready for use, and Monument Mortgage and Sollen have tested the Application Solution to ensure that the Application Solution complies in all material respects with the
specifications set forth in Exhibit A. The Parties shall confirm the successful completion of the testing procedure to their mutual satisfaction, by a writing signed and dated by the Parties
("Acceptance"). 
	4.5.
	Performance. Sollen and Monument Mortgage agree that if within thirty days of Acceptance, the Application Solution fails to comply
in all material respects with the specifications set forth in Exhibit A, that Monument Mortgage shall notify Sollen in writing of the manner in which the Application Solution is failing to
comply with the specifications set out in Exhibit A. Sollen shall have 15 working days following such notification to cause the Application Solution to comply in all material respects with the
specifications set forth in Exhibit A. If Sollen fails to achieve timely compliance, such failure shall constitute an Event of Default. Sollen warrants that after Acceptance, the Application
Solution shall continue to perform as accepted. 
	4.6.
	Support. Sollen agrees to provide support between the hours of 7:00 a.m. and 8:00 p.m., Central Time,
Monday through
Friday, excluding federal holidays, to assist Monument Mortgage in using the Application Solution and to assist Monument Mortgage in maintaining its access to the Application Solution. 

    5.  Fees  

	5.1.
	General. In consideration for the right to use the Application Solution granted by Sollen, Monument Mortgage shall pay Sollen fees
("Fees") as set forth in this Section 5 and in Exhibit B, attached hereto and made part of this Agreement for all purposes. 
	5.2.
	Evaluation. Both Parties
agree to meet six months from the Effective Date of this Agreement at a mutually convenient time and place
to discuss and evaluate the economic viability of the Fees of this Agreement for both Parties. However, this is not an agreement to amend the current Fee Schedule in any way. Any changes to the
schedule of Fees can only be made in writing signed by both Parties. 
	5.3.
	Payment of transaction fees. Monument Mortgage shall submit to Sollen within twenty
(20) days after each calendar month, a
transaction report setting forth at least the following information: (a) the number of loans closed, which were generated through PTS and/or any other interface using the Application Solution;
(b) the amount of transaction fees due thereon. An officer of Monument Mortgage shall certify such report as correct. The transaction fees 

3

 

for
the previous calendar month are due and payable upon the submission of each transaction report. All payments due hereunder shall be deemed received when funds are credited to Sollen's bank account
and shall be payable by check or wire transfer. Failure to make a payment when due shall be considered an Event of Default. 

	5.4.
	Taxes. Each party is responsible for the payment of their own taxes, however designated, which are levied or imposed by reason of
the transactions contemplated by this Agreement. 
	5.5.
	Records. Monument Mortgage shall keep accurate records (together with supporting documentation) of transactions
closed using the
Application Solution, appropriate to determine the amount of fees due to Sollen. Such records shall be retained for at least three (3) years following the end of the reporting period to which
they relate. They shall be available during normal business hours for examination by an accountant selected by Sollen, for the sole purpose of verifying reports and payments hereunder. In conducting
examinations pursuant to this paragraph, Sollen's accountant shall have access to all records that Sollen reasonably believes to be relevant to the calculation of transaction fees. Such examination by
Sollen's accountant shall be at Sollen's expense, except that if such examination shows an underreporting or underpayment in excess of five percent (5%) for any twelve (12) month period, then
Monument Mortgage shall pay the cost of such examination as well as any additional sum that would have been payable to Sollen had Monument Mortgage reported correctly, plus interest on said sum at the
rate of one and one half per cent (11/2%) per month or at the rate of the maximum legally allowed interest rate if it is less than one and one half per cent. 

    6.  No Transfer  

    Under
no circumstances shall Monument Mortgage sell, license, publish, or otherwise transfer to a third party the Application Solution or any copy thereof, in whole or in part without
Sollen's prior written consent. 

    7.  Confidential Information  

    In
the performance of this Agreement, each Party may have access to confidential, proprietary or trade secret information owned or provided by the other Party relating to the
Application Solution, software computer programs, object code, source code, marketing plans, business plans, financial information, specifications, flow charts and other data ("Confidential
Information"). All Confidential Information supplied by one Party to another pursuant to this Agreement shall remain the exclusive property of the disclosing Party. The receiving Party shall use such
confidential information only for the purposes of this Agreement and shall not copy, disclose, convey or transfer any of the Confidential Information or any part thereof to any third party. Each Party
will implement adequate procedures with its employees or other persons who have access to the Confidential Information to satisfy their obligations under this Agreement. Neither Party shall have any
obligation with respect to Confidential Information which: (i) is or becomes generally known to the public by any means other than a breach of the obligations of a receiving Party;
(ii) was previously known to the receiving Party or rightly received by a receiving Party from a third party without any obligation of confidentiality; or (iii) can be shown by
contemporaneous written records to have been independently developed by the receiving Party. Monument Mortgage acknowledges that the Application Solution contains proprietary information, including
trade secrets, know-how and confidential information, that is the exclusive property of Sollen. 

    8.  Use and Training  

    Monument
Mortgage shall limit the use of the Application Solution to its employees who have been appropriately trained. Following the installation and acceptance as defined in
Section 4.4, upon request of Monument Mortgage, Sollen shall provide, at a mutually convenient time, a training program at Monument Mortgage's site or at a mutually agreed upon site. Monument
Mortgage shall pay Sollen for reasonable Training Expenses ("Training Expenses"). The Training Expenses shall 

4

 

include reasonable travel, meals, accommodation and miscellaneous charges and are due and payable upon delivery of an invoice to Monument Mortgage. 

    9.  Warranty  

    SOLLEN
WARRANTS THAT FOR A PERIOD OF THIRTY (30) DAYS FROM THE DATE OF ACCEPTANCE THE APPLICATION SOLUTION SHALL COMPLY IN ALL MATERIAL RESPECTS WITH THE SPECIFICATIONS SET
FORTH IN EXHIBIT A TO THIS AGREEMENT. SOLLEN WARRANTS THAT THEREAFTER, THE APPLICATION SOLUTION SHALL CONTINUE TO PERFORM AS ACCEPTED. SOLLEN DOES NOT EXTEND ANY OTHER WARRANTIES, EXPRESS OR IMPLIED,
INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY WITH RESPECT TO THE QUALITY, ACCURACY OR FREEDOM FROM ERROR OF THE
OPERATION, USE AND FUNCTION OF THE APPLICATION SOLUTION. 

    10.  Liability  

    NEITHER
PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR INDIRECT, SPECIAL, INCIDENTAL, EXEMPLARY OR CONSEQUENTIAL DAMAGES (INCLUDING, WITHOUT LIMITATION, LOST PROFITS) RELATED TO THIS
AGREEMENT OR RESULTING FROM MONUMENT MORTGAGE'S USE, RESULTS OF USE, OR INABILITY TO USE THE SOLLEN TECHNOLOGIES APPLICATION SOLUTION, ARISING FROM ANY CAUSE OF ACTION WHATSOEVER, INCLUDING CONTRACT,
WARRANTY, STRICT LIABILITY, OR NEGLIGENCE, EVEN IF THE PARTY HAS BEEN NOTIFIED OF THE POSSIBILITY OF SUCH DAMAGES. IN THE EVENT OF TERMINATION OF THIS AGREEMENT FOR WHATEVER REASON, MONUMENT MORTGAGE
AGREES THAT THE AGGREGATE LIABILITY OF SOLLEN ARISING FROM OR RELATING TO THIS AGREEMENT SHALL NOT EXCEED THE AMOUNT OF THE INITIAL LICENSE FEE AND DEVELOPMENT FEES EFFECTIVELY PAID BY MONUMENT
MORTGAGE UNDER THIS AGREEMENT PRIOR TO ACCEPTANCE. 

    Monument
Mortgage acknowledges that data input (including, without limitation, lender specific guidelines, pricing, rates or any other related information or data), inspection and
management is subject to the likelihood of human and machine errors, omissions, delays, and losses, including inadvertent loss of data or damage to media that may give rise to loss or damage. Sollen
shall not be liable for any such errors, omissions, delays, or losses, unless such errors, omissions, delays, or losses are caused by the gross negligence or the intentional acts of Sollen. 

    Monument
Mortgage is responsible for adopting reasonable measures to limit the impact of such problems, including backing up data and adopting procedures to ensure the accuracy of
input data; examining and confirming results prior to use; and adopting procedures to identify and correct errors and omissions, replace lost or damaged media, and reconstruct data. Monument Mortgage
is also solely responsible for complying with all local, state, and federal laws pertaining to the use and disclosure of any data. 

    11.  Indemnification  

    Each
Party to this Agreement shall indemnify and hold harmless the other Party for any liability, damages, causes of action, or claims arising from or relating to the failure by the
other Party to acquire, maintain, or comply with any and all third party licenses for software necessary for operation of the Application Solution. 

    12.  Notice and Opportunity to Cure  

	12.1
	Notice. Upon the occurrence of an Event of Default, a Party shall deliver to the defaulting Party a Notice of Intent to Terminate
that identifies in detail the Event of Default. If the Event of Default remains uncured for thirty (30) calendar days, the Party may terminate this Agreement and the license granted herein by
delivering to the defaulting Party a Notice of Termination that takes effect immediately. 

5

 

	12.2
	Procedure Upon Termination. Within fifteen (15) days after termination of the license, Monument Mortgage shall return to
Sollen, at Monument Mortgage's expense if terminated by Monument Mortgage or default of Monument Mortgage, the Application Solution and all copies thereof, and deliver to Sollen a certification, in
writing signed by an officer of Monument Mortgage, that all copies of any part of the Application Solution have been returned, all copies deleted or destroyed, and its use discontinued. 

    13.  Assignment  

    Neither
Party may assign this Agreement or any rights or obligations hereunder, whether by operation of law or otherwise, without the prior written consent of the other Party.
Notwithstanding the foregoing, either Party shall have the right to assign this Agreement in connection with the merger or acquisition of such Party or the sale of all or substantially all of its
assets related to this Agreement without such consent. Subject to the foregoing, this Agreement will bind and inure to the benefit of the Parties, their respective successors and permitted assigns.
Any assignment in violation of this Section 13 shall be null and void. 

    14.  Force Majeure  

    Neither
Party shall be in default or otherwise liable for any delay in or failure of its performance under this Agreement if such delay or failure arises by any reason beyond its
reasonable control, including any act of God, any acts of the common enemy, the elements, earthquakes, floods, fires, epidemics, riots, failures or delay in transportation or communications, or any
act or failure to act by the other Party or such other Party's employees, agents or contractors; provided, however, that lack of funds shall not be deemed to be a reason beyond a Party's reasonable
control. The Parties will promptly inform and consult with each other as to any of the above causes that in their judgment may or could be the cause of a delay in the performance of this Agreement. 

    15.  Notices  

    All
notices under this Agreement are to be delivered by (i) depositing the notice in the mail, using registered mail, return receipt requested, addressed to the address below
or to any other address as the Party may designate by providing notice, (ii) faxing the notice by using the telephone number set forth below or any other telephone number as the Party may
designate by providing notice, followed by depositing the notice in the mail as outlined in (i) above, (iii) overnight delivery service addressed to the address below or to any other
address as the Party may designate by providing notice, or (iv) hand delivery to the individual designated below or to any other individual as the Party may designate by providing notice. The
notice shall be deemed delivered (i) if by registered mail, four (4) days after the notice's deposit in the mail, (ii) if by telecopy, on the date the notice is delivered,
(iii) if by overnight delivery service, on the day of delivery, and (iv) if by hand delivery, on the date of hand delivery. 

 SOLLEN:  

Sollen
Technologies, LLC

6009 Beltline Road, Suite 100

Dallas, Texas 75240

Attention: Larry Huff, Executive Vice President

Fax No.: (972) 960-7202 

 MONUMENT MORTGAGE:  

Monument
Mortgage, Inc.

2527 Camino Ramon, Suite 200

San Ramon, CA 94583

Attention: Rob Katz, CTO

With a Copy to: Corporate Counsel 

6

 

    16.  General Provisions  

	 	 	16.1.	 	Complete Agreement. The Parties agree that this Agreement with its exhibits is the complete and exclusive statement of the agreement between the Parties, which supersedes and merges all prior
proposals, understandings and all other agreements, oral or written, between the Parties relating to the Agreement's subject matter.
	 	 	16.2.	 	Amendment. This Agreement may not be modified, altered or amended except by a written instrument duly executed by both Parties.
	 	 	16.3.	 	Waiver. The waiver or failure of either Party to exercise in any respect any right provided for in this Agreement shall not be deemed a waiver of any further right under this
Agreement.
	 	 	16.4.	 	Severability. If any provision of this Agreement is invalid, illegal or unenforceable under any applicable statute or rule of law, it is to that extent to be deemed omitted. The remainder of the
Agreement shall be valid and enforceable to the maximum extent possible.
	 	 	16.5.	 	Governing Law. The laws of the State of Texas, other than the conflict of law provisions thereof, hereunder shall govern this Agreement and its performance.
	 	 	16.6.	 	Forum. Any legal proceedings arising under this Agreement shall be instituted only in the courts of the State of Texas, Dallas County.
	 	 	16.7.	 	Independent Parties. Nothing contained in this Agreement shall be construed as creating a joint venture, partnership, agent or employment relationship between Monument Mortgage and
Sollen.
	 	 	16.8.	 	Headings. The headings in this Agreement are for convenience or reference only and are not intended to be part of or to affect the meaning or interpretation of this Agreement.
	 	 	16.9.	 	Read and Understood. Each Party acknowledges that it has read and understands this Agreement and agrees to be bound by its terms.

AGREED:  

	 	 	 
	SOLLEN TECHNOLOGIES, INC.	 	MONUMENT MORTGAGE, INC.
	

Signature	
 	

Signature
	

Name	
 	

Name
	

Title	
 	

Title
	

Date	
 	

Date

7

  

 
 

EXHIBIT A    
  

SOLLEN TECHNOLOGIES APPLICATION SOLUTION DESCRIPTION  

    Monument Mortgage sends Sollen an electronic rate sheet containing interest rate and fee combinations for multiple loan products, with a frequency determined
at Monument Mortgage's sole discretion. The file is transferred from Monument to Sollen using an FTP agent provided by Sollen. Although the specific technical requirements for the file format to be
used may change, the system will always accept a MS Excel spreadsheet. 

    The
base rates are received by Sollen and applied to the Application Solution. Monument Mortgage agrees to give Sollen advance notice of any change in the rate sheet format, and
Monument Mortgage understands and agrees that Sollen needs at least 72 hours to modify the software to adapt to the changed Monument Mortgage rate sheet format. 

    Sollen
is not responsible for the accuracy of the data contained in the rate sheets received from Monument Mortgage. Monument Mortgage is solely responsible for the accuracy of these
rates and should have appropriate procedures in place for verification and correction. 

    Monument
Mortgage will provide Sollen with detailed product guidelines that clearly include loan program eligibility and pricing adjustments. The Application Solution has two primary
roles: 

	1.
	Screen
various factors of a loan file against the eligibility rules programmed into the system to determine which loan products are not disqualified based on those rules; and

	2.
	For
eligible products, accurately calculate the loan rate and fee combinations by applying the appropriate pricing adjustments, as specified in the product guidelines, based on the
various factors of the loan file. 

    The
eligibility and pricing adjustment rules will be programmed by Sollen and/or Monument Mortgage using a guideline editing software tool provided by Sollen. Sollen is not
responsible for the accuracy of the eligibility and pricing adjustment rules received from Monument Mortgage. Monument Mortgage is solely responsible for the accuracy of these rules and should have
appropriate procedures in place for verification and correction. Sollen is responsible for the accuracy of the Application Solution's execution of determining product eligibility and adjusted pricing
based on the rules provided by Monument Mortgage. 

    Sollen
has delivered the user interface of the single lender version of the Sollen Suite software that interacts with the Product and Pricing Engine. The Sollen Suite software will
allow Monument Mortgage to manage the program disqualifiers and guidelines, the pricing guidelines and the mortgage insurance guidelines. 

    Sollen
will deliver a set of data structures and procedures interfacing with the Calyx PTS server. Sollen will also deliver a set of data structures interfacing with the Monument
Mortgage wholesale website. 

    Sollen
will allow Monument Mortgage access to Sollen's Product and Pricing Engine via the Internet for purposes of operating the transactions for Calyx's PTS initiative. In addition,
Sollen will allow Monument Mortgage access to Sollen's Product and Pricing Engine via the Internet for purposes of operating the transactions for Monument Mortgage's wholesale web site initiative. 

8

 

THIRD PARTY SOFTWARE REQUIREMENTS  

    All Third Party Software, Third Party Software Licenses and hardware installed at Monument Mortgage's site that is necessary for the use of the Sollen
Application Solution shall be provided and maintained by Monument Mortgage, including but not limited to: 

	•
	Microsoft
Windows 98 and/or NT 4.0 Server or workstation or other necessary Microsoft operating systems.

	•
	Whatever
other Microsoft base applications may be required for adequate functionality. 

    Sollen
shall obtain and maintain the required Microsoft SQL Server 7.0 Software, with proper Internet license, ("Licensed Server Software"), as well as a server to run the Licensed
Server Software, in the following or substantially equivalent configuration ("Sollen Server"): 

	•
	Server
type: Dell PowerEdge TM 2450 Server;

	•
	Processor:
Dual 933 Mhz PIII CPU's—256 Kb cache;

	•
	RAM
memory: 1 Gb RAM;

	•
	Hard
Disk: 3x 9 Gb, 10 K SCSI Hard drives—single channel Raid 5. 

    Should
the traffic (number of "hits") on the Sollen Server attributed to Monument Mortgage customers constitute 80% or more of the total traffic on the Sollen Server, and should the
total traffic represent 80% or more of the total capacity of the Sollen Server during a period of five consecutive business days, then Monument Mortgage shall obtain and maintain an additional copy of
the Licensed Server Software ("Monument's Licensed Server Software"). Sollen shall obtain and maintain an additional server, in the same or substantially equivalent configuration as the first Sollen
Server to run Monument's Licensed Server Software. 

9

  

 
 

EXHIBIT B
  
    FEE SCHEDULE    
  

	Fee
 
	 	Subject
	 	Amount
	 	Payment terms
	 	Due date

	Initial Fee	 	Application Solution comprising Sollen Suite, Pricing Engine and interface to Calyx PTS	 	$30,000	 	Two installments of $15,000	 	First installment due upon signature of the Agreement, and the second installment is due within 45 days of signature of Agreement
	Development Fee	 	Development of interface to the Monument Mortgage wholesale web site	 	$5,000	 	Two installments of $2,500	 	First installment due upon signature of Agreement, second installment due upon delivery and acceptance within Q1—2001.
	Transaction Fee	 	Fee per transaction using the Application Solution	 	$5 per closed loan	 	Minimum of $1,500 per month	 	Last calendar day of each month

    NOTES:

	1.1.
	Interface Development Fee. This amount covers the cost of delivering a stored procedure interface to Monument Mortgage to access the
Sollen pricing engine in substantially the same way PTS does.

	1.2.
	Transaction Fees. These transaction fees are due on the last calendar day of each month on any closed loans generated through PTS
and/or any other interface using the Application Solution. Monument Mortgage agrees to pay to Sollen the transaction fee of $5 per closed loan or $1,500 dollars, whichever is greater, on a monthly
basis.

	1.3.
	Other Fees. Sollen has waived the initial program and pricing set-up fee it customarily charges for the
set-up of every loan program (guidelines and pricing adjustments), as Sollen has already completed and enabled this part for Monument Mortgage. Monument Mortgage shall be solely
responsible for editing and maintaining the current database. If Sollen is asked to do so for Monument Mortgage, additional fees will be charged. For Monument Mortgage requested customer work, Sollen
shall charge its standard fee of $125 per hour, and for any training provided under this Agreement, Sollen shall charge $75 per hour. 

10

QuickLinks

APPLICATION SOLUTION LICENSE AGREEMENT

AGREEMENT

EXHIBIT A

EXHIBIT B FEE SCHEDULEPrepared by MERRILL CORPORATION

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.1    
  

    For Purchases Direct From Supplier

Subject to Competitive Bid Process

SUPPLIER AGREEMENT  

 between  

 NOVATION, LLC  

 and  

 Specialty Laboratories, Inc.  

 LB00051  

 Replaces Agreement LAB442 for VHA members  

    
* CONFIDENTIAL TREATMENT IS REQUESTED FOR CONFIDENTIAL INFORMATION ENCLOSED IN THE BRACKETS AND UNDERLINED. 

 
TABLE OF CONTENTS  

	 
	 	 
	 	 
	 	PAGE

	1.	 	INTRODUCTION	 	1
	

 	
 	

a.	
 	

Purchasing Opportunities for Members	
 	

1
	

 	
 	

b.	
 	

Supplier	
 	

1
	

 	
 	

c.	
 	

Bid	
 	

1
	

2.	
 	

CONTRACT AWARD	
 	

1
	

 	
 	

a.	
 	

Letter of Award	
 	

1
	

 	
 	

b.	
 	

Optional Purchasing Arrangement	
 	

1
	

 	
 	

c.	
 	

Market Competitive Terms	
 	

1
	

 	
 	

d.	
 	

Changes in Award Prices	
 	

2
	

 	
 	

e.	
 	

Notification of Changes in Pricing Terms	
 	

2
	

 	
 	

f.	
 	

Underutilized Businesses	
 	

2
	

3.	
 	

TERM AND TERMINATION	
 	

2
	

 	
 	

a.	
 	

Term	
 	

2
	

 	
 	

b.	
 	

Termination by Novation	
 	

2
	

 	
 	

c.	
 	

Termination by Supplier	
 	

3
	

4.	
 	

PRODUCT SUPPLY	
 	

3
	

 	
 	

a.	
 	

Delivery and Invoicing	
 	

3
	

 	
 	

b.	
 	

Product Fill Rates; Confirmation and Delivery Times	
 	

3
	

 	
 	

c.	
 	

Bundled Terms	
 	

3
	

 	
 	

d.	
 	

Discontinuation of Products; Changes in Packaging	
 	

3
	

 	
 	

e.	
 	

Replacement or New Products	
 	

3
	

 	
 	

f.	
 	

Member Services	
 	

4
	

 	
 	

g.	
 	

Product Deletion	
 	

4
	

 	
 	

h.	
 	

Return of Products	
 	

4
	

 	
 	

i.	
 	

Failure to Supply	
 	

4

i

 

	

5.	
 	

PRODUCT QUALITY	
 	

4
	

 	
 	

a.	
 	

Free From Defects	
 	

4
	

 	
 	

b.	
 	

Product Compliance	
 	

4
	

 	
 	

c.	
 	

Patent Infringement	
 	

5
	

 	
 	

d.	
 	

Product Condition	
 	

5
	

 	
 	

e.	
 	

Recall of Products	
 	

5
	

 	
 	

f.	
 	

Shelf Life	
 	

5
	

6.	
 	

CENTURY COMPLIANCE	
 	

5
	

 	
 	

a.	
 	

Definitions	
 	

5
	

 	
 	

b.	
 	

Representations.	
 	

6
	

 	
 	

c.	
 	

Remedies	
 	

6
	

 	
 	

d.	
 	

Noncompliance Notice	
 	

6
	

 	
 	

e.	
 	

Survival	
 	

6
	

7.	
 	

REPORTS AND OTHER INFORMATION REQUIREMENTS	
 	

6
	

 	
 	

a.	
 	

Report Content	
 	

6
	

 	
 	

b.	
 	

Report Format and Delivery	
 	

7
	

 	
 	

c.	
 	

Other Information Requirements	
 	

7
	

8.	
 	

OBLIGATIONS OF NOVATION	
 	

7
	

 	
 	

a.	
 	

Information to Members	
 	

7
	

 	
 	

b.	
 	

Marketing Services	
 	

7
	

9.	
 	

MARKETING FEES	
 	

7
	

 	
 	

a.	
 	

Calculation	
 	

7
	

 	
 	

b.	
 	

Payment	
 	

8
	

10.	
 	

ADMINISTRATIVE DAMAGES	
 	

8
	

11.	
 	

NONPAYMENT OR INSOLVENCY OF A MEMBER	
 	

9

ii

 

	

12.	
 	

INSURANCE	
 	

9
	

 	
 	

a.	
 	

Policy Requirements	
 	

9
	

 	
 	

b.	
 	

Self-Insurance	
 	

9
	

 	
 	

c.	
 	

Amendments, Notices and Endorsements	
 	

9
	

13.	
 	

COMPLIANCE WITH LAW AND GOVERNMENT PROGRAM PARTICIPATION	
 	

9
	

 	
 	

a.	
 	

Compliance With Law	
 	

9
	

 	
 	

b.	
 	

Government Program Participation	
 	

9
	

14.	
 	

RELEASE AND INDEMNITY	
 	

10
	

15.	
 	

BOOKS AND RECORDS; FACILITIES INSPECTIONS	
 	

10
	

16.	
 	

USE OF NAMES, ETC	
 	

10
	

17.	
 	

CONFIDENTIAL INFORMATION	
 	

11
	

 	
 	

a.	
 	

Nondisclosure	
 	

11
	

 	
 	

b.	
 	

Definition	
 	

11
	

18.	
 	

MISCELLANEOUS	
 	

11
	

 	
 	

a.	
 	

Choice of Law	
 	

11
	

 	
 	

b.	
 	

Not Responsible	
 	

11
	

 	
 	

c.	
 	

Third Party Beneficiaries	
 	

11
	

 	
 	

d.	
 	

Notices	
 	

11
	

 	
 	

e.	
 	

No Assignment	
 	

12
	

 	
 	

f.	
 	

Severability	
 	

12
	

 	
 	

g.	
 	

Entire Agreement	
 	

12

iii

 
 

INDEX OF DEFINED TERMS    
  

	 
	 	PAGE
 

	Agreed Percentage	 	10
	Award Letter	 	1
	Award Prices	 	1
	Bid	 	1
	Calendar-Related	 	7
	Century Noncompliance	 	7
	Clients	 	1
	Confidential Information	 	14
	Effective Date	 	3
	FDA	 	12
	Federal health care program	 	12
	Gregorian calendar	 	7
	Guidebook	 	9
	Indemnitees	 	12
	Legal Requirements	 	12
	Marketing Fees	 	9
	Members	 	1
	Non-Price Specifications	 	1
	Novation	 	1
	Novation Database	 	1
	Reporting Month	 	8
	Special Conditions	 	1
	Systems	 	7
	Term	 	3
	timely	 	8

   NOVATION, LLC  

 SUPPLIER AGREEMENT  

1.  INTRODUCTION.  

    a.  Purchasing Opportunities for Members.  Novation, LLC ("Novation") is engaged
in providing purchasing opportunities with respect to high quality products and services to participating health care providers ("Members"). Members are entitled to participate in Novation's programs
through their membership or other participatory status in any of the following client organizations: VHA Inc., University HealthSystem Consortium, and HealthCare Purchasing Partners
International, LLC (collectively, "Clients"). Novation is acting as the exclusive agent for each of the Clients and certain of each Client's subsidiaries and affiliates, respectively, (and not
collectively), with respect to this Agreement. A current listing of Members is maintained by Novation in the electronic database, described in the Guidebook referred to in Subsection 7.c below
("Novation Database"). A provider will become a "Member" for purposes of this Agreement at the time Novation adds the provider to the Novation Database and will cease to be a "Member" for such
purposes at the time Novation deletes the provider from the Novation Database. 

    b.  Supplier.  Supplier is the manufacturer of products listed on
Exhibit A, the provider of installation, training and maintenance services for such products, and the provider of any other services listed on Exhibit A (such products and/or services
are collectively referred to herein as "Products"). 

    c.  Bid.  Supplier has responded to Novation's Invitation to Bid by submitting
its written offer ("Bid") to Novation consisting of this Agreement, the listing of Products and pricing therefor ("Award Prices") attached hereto as Exhibit A, the other specifications attached
hereto as Exhibit B ("Non-Price Specifications"), the Special Conditions attached hereto as Exhibit C ("Special Conditions"), and any other materials required to be submitted
in accordance with the Bid Instructions. 

2.  CONTRACT AWARD.  

    a.  Letter of Award.  By executing and delivering the Letter of Award attached
hereto as Exhibit D ("Award Letter") to Supplier, Novation will have accepted the Bid, and Novation and Supplier therefore agree that Supplier will make the Products available for purchase by
the Members at the Award Prices in accordance with the terms of this Agreement; provided, however, that Novation's award of this Agreement to Supplier will not constitute a commitment by any person to
purchase any of the Products. No obligations of Novation set forth in this Agreement will be valid or enforceable against Novation unless and until the Award Letter has been duly executed by Novation
and attached as an exhibit hereto. Supplier acknowledges that, in making its award to Supplier, Novation has materially relied on all representations, warranties and agreements made by Supplier as
part of the Bid and that all such representations, warranties and agreements will survive acceptance of the Bid. 

    b.  Optional Purchasing Arrangement.  Novation and Supplier agree that each
Member will have the option of purchasing the Products under the terms of this Agreement or under the terms of any other purchasing or pricing arrangement that may exist between such Member and
Supplier at any time during the Term; provided, however, that, regardless of the arrangement, Supplier will comply with Sections 7 and 9 below. If any Member uses any other purchasing or pricing
arrangement with Supplier when ordering products covered by any contract between Supplier and Novation, Supplier will notify such Member of the pricing and other significant terms of the applicable
Novation contract. 

    c.  Market Competitive Terms.  Supplier agrees that the prices, quality, value
and technology of all Products purchased under this Agreement will remain market competitive at all times during the Term. Supplier agrees to provide prompt written notice to Novation of all
[***]* Supplier will [***]* applicable to the purchase of the Products as necessary to assure
market competitiveness. If at any time 

1

 

during the Term Novation receives information from any source suggesting that [***]*, Novation may provide written notice of such information to
Supplier, and Supplier will, [***]*. 

    d.  Changes in Award Prices.  Unless otherwise expressly agreed in any exhibit to
this Agreement, the Award Prices will not be increased and any discount will not be eliminated or reduced during the Term. In addition to any changes made to assure market competitiveness, Supplier
may lower the Award Prices or increase any discount applicable to the purchase of the Products at any time. 

    e.  Notification of Changes in Pricing Terms.  Supplier will provide not less
than sixty (60) days' prior written notice to Novation and not less than forty-five (45) days' prior written notice to all Members of any
change in pricing terms permitted or required by this Agreement. For purposes of the foregoing notification requirements, a change in pricing terms will mean any change that affects the delivered
price to the Member, including, without limitation, changes in list prices, discounts or pricing tiers or schedules. Such prior written notice will be provided in such format and in such detail as may
be required by Novation from time to time, and will include, at a minimum, sufficient information to determine line item pricing of the Products for all affected Members. 

    f.  Underutilized Businesses.  Certain Members may be required by law, regulation
and/or internal policy to do business with underutilized businesses such as Minority Business Enterprises (MBE), Disadvantaged Business Enterprises (DBE), Small Business Enterprises (SBE),
Historically Underutilized Businesses (HUB) and/or Women-owned Business Enterprises (WBE). To assist Novation in helping Members meet these requirements, Supplier will comply with all Novation
policies and programs with respect to such businesses and will provide, on request, Novation or any Member with statistical or other information with respect to Supplier's utilization of such
businesses as a vendor, distributor, contractor or subcontractor. 

3.  TERM AND TERMINATION.  

    a.  Term.  This Agreement will be effective as of the effective date set forth in
the Award Letter ("Effective Date"), and, unless sooner terminated, will continue in full force and effect for the initial term set forth in the Non-Price Specifications and for any
renewal terms set forth in the Non-Price Specifications by Novation's delivery of written notice of renewal to Supplier not less than ten (10) days prior to the end of the initial
term or any renewal term, as applicable. The initial term, together with the renewal terms, if any, are collectively referred to herein as the "Term." 

    b.  Termination by Novation.  Novation may terminate this Agreement at any time
for any reason whatsoever by delivering not less than ninety (90) days' prior written notice thereof to Supplier. In addition, Novation may terminate this Agreement immediately by delivering
written notice thereof to Supplier upon the occurrence of either of the following events: 

    (1) Supplier
breaches this Agreement; or 

    (2) Supplier
becomes bankrupt or insolvent or makes an unauthorized assignment or goes into liquidation or proceedings are initiated for the purpose of having a
receiving order or winding up order made against Supplier, or Supplier applies to the courts for protection from its creditors. 

Novation's
right to terminate this Agreement due to Supplier's breach in accordance with this Subsection is in addition to ally other rights and remedies Novation, the Clients or the Members may have
resulting from such breach, including, but not limited to, Novation's and the Clients' right to recover all loss of Marketing Fees resulting from such breach through the date of termination and for
one hundred eighty (180) days thereafter. 

2

 

    c.  Termination by Supplier.  Supplier may terminate this Agreement at any time
for any reason whatsoever by delivering not less than one hundred eighty (180) days' prior written notice thereof to Novation. 

4.  PRODUCT SUPPLY.  

    a.  Delivery and Invoicing.  On and after the Effective Date, Supplier agrees to
deliver Products ordered by the Members to the Members, FOB destination, and will direct its invoices to the Members in accordance with this Agreement. Supplier agrees to prepay and absorb charges, if
any, for transporting Products to the Members. Payment terms are [***]*. Supplier will make whatever arrangements are reasonably necessary with the
Members to implement the terms of this Agreement; provided, however, Supplier will not impose any purchasing commitment on any Member as a condition to the Member's purchase of any Products pursuant
to this Agreement. 

    b.  Product Fill Rates; Confirmation and Delivery Times.  Supplier agrees to
provide product fill rates to the Members of greater than [***]*, calculated as line item orders. Supplier will provide confirmation of orders from
Members via the electronic data interchange described in the Guidebook referred to in Subsection 7.c below within two (2) business days after placement of the order and will deliver the
Products to the Members within ten (10) business days after placement of the order. 

    c.  Bundled Terms.  Supplier agrees to give Novation prior written notice of any
offer Supplier makes to any Member to sell products that are not covered by this Agreement in conjunction with Products covered by this Agreement under circumstances where the Member has no real
economic choice other than to accept such bundled terms. 

    d.  Discontinuation of Products; Changes in Packaging.  Supplier will have no
unilateral right to discontinue any of the Products or to make any changes in packaging which render any of the Products substantially different in use, function or distribution. Supplier may request
Novation in writing to agree to a proposed discontinuation of any Products or a proposed change in packaging for any
Products at least ninety (90) days prior to the proposed implementation of the discontinuation or change. Under no circumstances will any Product discontinuation or packaging changes be
permitted under this Agreement without Novation's agreement to the discontinuation or change. In the event Supplier implements such proposed discontinuation or change without Novation's agreement
thereto in writing, in addition to any other rights and remedies Novation or the Members may have by reason of such discontinuation or change, (i) Novation will have the right to terminate any
or all of the Product(s) subject to such discontinuation or change or to terminate this Agreement in its entirety immediately upon becoming aware of the discontinuation or change or any time
thereafter by delivering written notice thereof to Supplier; (ii) the Members may purchase products equivalent to the discontinued or changed Products from other sources and Supplier will be
liable to the Members for all reasonable costs in excess of the Award Prices plus any other damages which they may incur; and (iii) Supplier will be liable to Novation and the Clients for any
loss of Marketing Fees resulting from such unacceptable discontinuation or change plus any other damages which they may incur. 

    e.  Replacement or New Products.  Supplier will have no unilateral right to
replace any of the Products listed in Exhibit A with other products or to add new products to this Agreement. Supplier may request Novation in writing to agree to a replacement of any of the
Products or the addition of a new product that is closely related by function or use to an existing Product at least sixty (60) days prior to the proposed implementation of the replacement or
to the new product introduction. Under no circumstances will any Product replacement or new product addition to this Agreement be permitted without Novation's agreement to the replacement or new
product. 

3

       f.  Member Services.  Supplier will consult with each Member to identify the
Member's policies relating to access to facilities and personnel. Supplier will comply with such policies and will establish a specific timetable for sales calls by sales representatives to satisfy
the needs of the Member. Supplier will promptly respond to Members' reasonable requests for verification of purchase history. If requested by Novation or any Members, Supplier will provide, at
Supplier's cost, on-site inservice training to Members' personnel for pertinent Products. 

    g.  Product Deletion.  Notwithstanding anything to the contrary contained in this
Agreement, Novation may delete any one or more of the Products from this Agreement at any time, at will and without cause, upon not less than sixty (60) days' prior written notice to Supplier. 

    h.  Return of Products.  Any Member, in addition to and not in limitation of any
other rights and remedies, will have the right to return Products to Supplier under any of the following circumstances: (1) the Product is ordered or shipped in error; (2) the Product is
no longer needed by the Member due to deletion from its standard supply list or changes in usage patterns, provided the Product is returned at least six (6) months prior to its expiration date
and is in a re-salable condition; (3) the Product is received outdated or is otherwise unusable; (4) the Product is received damaged, or is defective or nonconforming;
(5) the Product is one which a product manufacturer or supplier specifically authorizes for return; and (6) the Product is recalled. Supplier agrees to accept the return of Products
under these circumstances without charge and for full credit. 

    i.  Failure to Supply.  In the event of Supplier's failure to perform its supply
obligations in accordance with the terms of this Section 4, the Member may purchase products equivalent to the Products from other sources and Supplier will be liable to the Member for all
reasonable costs in excess of the Award Prices plus any other damages which they may incur. In such event, Supplier will also be liable to Novation and the Clients for any loss of Marketing Fees
resulting from such failure plus any other damages which they may incur. The remedies set forth in this Subsection are in addition to any other rights and remedies Novation, the Clients or the Members
may have resulting from such failure. 

5.  PRODUCT QUALITY  

    a.  Free From Defects.  Supplier warrants the Products against defects in
material, workmanship, design and manufacturing. Supplier will make all necessary arrangements to assign such warranty to the Members.
Supplier further represents and warrants that the Products will conform to the specifications, drawings, and samples furnished by Supplier or contained in the Non-Price Specifications and
will be safe for their intended use. If any Products are defective and a claim is made by a Member on account of such defect, Supplier will, at the option of the Member, either replace the defective
Products or credit the Member. Supplier will bear all costs of returning and replacing the defective Products, as well as all risk of loss or damage to the defective Products from and after the time
they leave the physical possession of the Member. The warranties contained in this Subsection will survive any inspection, delivery, acceptance or payment by a Member. In addition, if there is at any
time wide-spread failure of the Products, the Member may return all said Products for credit or replacement, at its option. This Subsection and the obligations contained herein will
survive the expiration or earlier termination of this Agreement. The remedies set forth in this Subsection are in addition to and not a limitation on any other rights or remedies that may be available
against Supplier. 

    b.  Product Compliance.  Supplier represents and warrants to Novation, the
Clients and the Members that the Products are, if required, registered, and will not be distributed, sold or priced by Supplier in violation of any federal, state or local law. Supplier represents and
warrants that as of the date of delivery to the Members all Products will not be adulterated or misbranded within the meaning of the Federal Food, Drug and Cosmetic Act and will not violate or cause a
violation of any applicable law, ordinance, rule, regulation or order. Supplier agrees it will comply with all applicable Good 

4

 

Manufacturing Practices and Standards contained in 21 C.F.R. Parts 210, 211, 225, 226, 600, 606, 610, 640, 660, 680 and 820. Supplier represents and warrants that it will provide adequate warnings and
instructions to inform users of the Products of the risks, if any, associated with the use of the Products. Supplier's representations; warranties and agreements in this Subsection will survive the
expiration or earlier termination of this Agreement. 

    c.  Patent Infringement.  Supplier represents and warrants that sale or use of
the Products will not infringe any United States patent. Supplier will, at its own expense, defend every suit which will be brought against Novation or a Member for any alleged infringement of any
patent by reason of the sale or use of the Products and will pay all costs, damages and profits recoverable in any such suit. This Subsection and the obligations contained herein will survive the
expiration or earlier termination of this Agreement. The remedies set forth in this Subsection are in addition to and not a limitation on any other rights or remedies that may be available against
Supplier. 

    d.  Product Condition.  Unless otherwise stated in the Non-Price
Specifications or unless agreed upon by a Member in connection with Products it may order, all Products will be new. Products which are demonstrators, used, obsolete, seconds, or which have been
discontinued are unacceptable unless otherwise specified in the Non-Price Specifications or the Member accepts delivery after receiving notice of the condition of the Products. 

    e.  Recall of Products.  Supplier will reimburse Members for any cost associated
with any Product corrective action, withdrawal or recall requested by Supplier or required by any governmental entity. In the event a product recall or a court action impacting supply occurs, Supplier
will notify Novation in writing within twenty-four (24) hours of any such recall or action. Supplier's obligations in this Subsection will survive the expiration or earlier
termination of this Agreement. 

    f.  Shelf Life.  Sterile Products and other Products with a limited shelf life
sold under this Agreement will have the longest possible shelf life and the latest possible expiration dates. Unless required by stability considerations, there will not be less than an eighteen
(18) month interval between a Product's date of delivery by Supplier to the Member and its expiration date. 

6.  CENTURY COMPLIANCE.  

    a.  Definitions.  For purposes of this Section, the following terms have the
respective meanings given below: 

    (1) "Systems"
means any of the Products, systems of distribution for Products and Product manufacturing systems that consist of or include any computer software,
computer firmware, computer hardware (whether general or special purpose), documentation, data, and other similar or related items of the automated, computerized, and/or software systems that are
provided by or through Supplier or utilized to manufacture or distribute the Products provided by or through Supplier pursuant to this Agreement, or any component part thereof, and any services
provided by or through Supplier in connection therewith. 

    (2) "Calendar-Related"
refers to date values based on the "Gregorian calendar" (as defined in the Encyclopedia Britannica, 15th edition, 1982, page 602) and to all uses
in any manner of those date values, including without limitation manipulations, calculations, conversions, comparisons, and presentations. 

    (3) "Century
Noncompliance" means any aspects of the Systems that fail to satisfy the requirements set forth in Subsection 6.b below. 

5

 

    b.  Representations.  Supplier warrants, represents and agrees that the Systems
satisfy the following requirements: 

    (1) In
connection with the use and processing of Calendar-Related data, the Systems will not malfunction, will not cease to function, will not generate incorrect data,
and will not produce incorrect results. 

    (2) In
connection with providing Calendar-Related data to and accepting Calendar-Related data from other automated, computerized, and/or software systems and users via
user interfaces, electronic interfaces, and data storage, the Systems represent dates without ambiguity as to century. 

    (3) The
year component of Calendar-Related data that is provided by the Systems to or that is accepted by the Systems from other automated, computerized, and/or
software systems and user interfaces, electronic interfaces, and data storage is represented in a four-digit CCYY format, where CC represents the two digits expressing the century and YY
represents the two digits expressing the year within that century (e.g., 1996 or 2003). 

    (4) Supplier
has verified through testing that the Systems satisfy the requirements of this Subsection including, without limitation, testing of each of the following
specific dates and the transition to and from each such date: September 9, 1999; September 10, 1999; December 31, 1999; January 1, 2000; February 28, 2000;
February 29, 2000; March 1, 2000; December 31, 2000; January 1, 2001; December 31, 2004; and January 1, 2005. 

    c.  Remedies.  In the event of any Century Noncompliance in the Systems in any
respect, in addition to my other remedies that may be available to Novation or the Members, Supplier will, at no cost to the Members, promptly under the circumstances (but, in all cases, within thirty
(30) days after receipt of a written request from any Member, unless otherwise agreed by the Member in writing) eliminate the Century Noncompliance from the Systems. 

    d.  Noncompliance Notice.  In the event Supplier becomes aware of (i) any
possible or actual Century Noncompliance in the Systems or (ii) any international, governmental, industrial, or other standard (proposed or adopted) regarding Calendar-Related data and/or
processing, or Supplier begins any significant effort to conform the Systems to any such standard, Supplier will promptly provide the Members with all relevant information in writing and will timely
provide the Members with updates to such information. Supplier will respond promptly and fully to inquiries by the Members, and timely provide updates to any responses provided to the Members, with
respect to (i) any possible or actual Century Noncompliance in the Systems or (ii) any international, governmental, industrial, or other standards. In the foregoing, the use of "timely"
means promptly after the relevant information becomes known to or is developed by or for Supplier. 

    e.  Survival.  Supplier's representations, warranties and agreements in this
Section will continue in effect throughout the Term and will survive the expiration or earlier termination of this Agreement. 

7.  REPORTS AND OTHER INFORMATION REQUIREMENTS.  

    a.  Report Content.  Within twenty (20) days after the end of each full
and partial month during, the Term ("Reporting Month"), Supplier will submit to Novation a report in the form of a diskette containing the following information in form and content reasonably
satisfactory to Novation: 

    (1) the
name of Supplier, the Reporting Month and year and the Agreement number (as provided to Supplier by Novation); 

    (2) with
respect to each Member (described by LIC number (as provided to Supplier by Novation), health industry number (if applicable), full name, street address, city,
state, zip 

6

 

code and, if applicable, tier and committed status), the number of units sold and the amount of net sales for each Product on a line item basis, and the sum of net sales and the associated Marketing
Fees for all Products purchased by such Member directly or indirectly from Supplier during the Reporting Month, whether under the pricing and other terms of this Agreement or under the terms of any
other purchasing or pricing arrangements that may exist between the Member and Supplier; 

    (3) the
sum of the net sales and the associated Marketing Fees for all Products sold to all Members during the Reporting Month; and 

    (4) such
additional information as Novation may reasonably request from time to time. 

    b.  Report Format and Delivery.  The reports required by this Section will be
submitted electronically in Excel Version 7 or Access Version 7 and in accordance with other specifications established by Novation from time to time and will be delivered to: 

Novation

Attn: SRIS Operations

220 East Las Colinas Boulevard

Irving, TX 75039 

    c.  Other Information Requirements.  In addition to the reporting requirements
set forth in Subsections 7.a and 7.b above, the parties agree to facilitate the administration of this Agreement by transmitting and receiving information electronically and by complying with the
information requirements set forth in Exhibit E attached hereto. Supplier further agrees that, except to the extent of any inconsistency with the provisions of this Agreement, it will comply
with all information requirements set forth in the Novation Information Requirements Guidebook ("Guidebook"). On or about the Effective Date, Novation will provide Supplier with a current copy of the
Guidebook and will thereafter provide Supplier with updates and/or revisions to the Guidebook from time to time. 

8.  OBLIGATIONS OF NOVATION.  

    a.  Information to Members.  After issuing the Award Letter, Novation, in
conjunction with the Clients, will deliver a summary of the purchasing arrangements covered by this Agreement to each Member and will, from time to time, at the request of Supplier, deliver to each
Member reasonable and appropriate amounts and types of materials supplied by Supplier to Novation which relate to the purchase of the Products. 

    b.  Marketing Services.  Novation, in conjunction with the Clients, will market
the purchasing arrangements covered by this Agreement to the Members. Such promotional services may include, as appropriate, the use of direct mail, contact by Novation's field service delivery team,
member support services, and regional and national meetings and conferences. As appropriate, Novation, in conjunction with the Clients, will involve Supplier in these promotional activities by
inviting Supplier to participate in meetings and other reasonable networking activities with Members. 

9.  MARKETING FEES.  

    a.  Calculation.  Supplier will pay to Novation, as the authorized collection
agent for each of the Clients and certain of each Client's subsidiaries and affiliates, respectively (and not collectively), marketing fees ("Marketing Fees") belonging to any of the Clients or
certain of their subsidiaries or affiliates equal to the Agreed Percentage of the [***]* of the Products to the Members directly or indirectly from
Supplier, whether under the pricing and other terms of this Agreement or under the terms of any other purchasing or pricing arrangements that may exist between the Members and 

7

 

Supplier. Such [***]*, and will include, but not be limited to, [***]*. The "Agreed
Percentage" will be defined in the Award Letter. 

    b.  Payment.  On or about the Effective Date, Novation will advise Supplier in
writing of the amount determined by Novation to be Supplier's monthly estimated Marketing Fees. Thereafter, Supplier's monthly estimated [***]*
from time to time upon written notice from Novation based on [***]*. No later than the tenth (10th) day of each month, Supplier will remit the
monthly estimated Marketing Fees for such month to Novation. Such payment will be adjusted to reflect the reconciliation between the actual Marketing Fees payable for the second month prior to such
month with the estimated Marketing Fees actually paid during such prior month. Supplier will pay all estimated and adjusted Marketing Fees by check made payable to "Novation, LLC." All checks should
reference the Agreement number. Supplier will include with its check the reconciliation calculation used by Supplier to determine the payment adjustment, with separate amounts shown for each Client's
component thereof. Checks sent by first class mail will be mailed to the following address: 

Novation

75 Remittance Dr., Suite 1420

Chicago, IL 60675-1420 

Checks
sent by courier (Federal Express, United Parcel Service or messenger) will be addressed as follows: 

The
Northern Trust Company

350 North Orleans Street

Receipt & Dispatch 8th Floor

Chicago, IL 60654

Attn: Novation, LLC, Lockbox Number 1420

Telephone: (312) 444-3576 

10. ADMINISTRATIVE DAMAGES.  Novation and Supplier agree that Novation would incur additional administrative costs if
Supplier fails to provide notice of change in pricing terms as required in Subsection 2.e above, fails to provide reports as required in Section 7 above, or fails to pay Marketing
Fees as required in Section 9 above, in each case within the time and manner required by this Agreement. Novation and Supplier further agree, that the additional administrative costs incurred
by Novation by reason of any such failure to Supplier is uncertain, and they therefore agree that the following schedule of administrative damages constitutes a reasonable estimation of such costs and
were determined according to the principles of just compensation: 

	1st failure	 	[***]*
	2nd failure:	 	[***]*
	3rd failure:	 	[***]*
	4th failure:	 	[***]*
	5th failure:	 	[***]*
	6th & each subsequent failure:	 	[***]*

Novation's
right to recover administrative damages in accordance with this Section is in addition to any other rights and remedies Novation or the Clients may have by reason of Supplier's failure to
pay the Marketing Fees or provide the reports or notices within the time and manner required by this Agreement. 

8

  

11. NONPAYMENT OR INSOLVENCY OF A MEMBER.  If a Member fails to pay Supplier for Products, or if a Member becomes bankrupt
or insolvent or makes an assignment for the benefit of creditors or goes into liquidation, or if proceedings are initiated for the purpose of having a receiving order or winding up order made against
a Member, or if a Member applies to the court for protection from its creditors, then, in any such case, this Agreement will not terminate, but Supplier will have the right, upon prior written notice
to Novation and the Member, to discontinue selling Products to that Member. 

12. INSURANCE.  

    a.  Policy Requirements.  Supplier will maintain and keep in force during the
Term product liability, general public liability and property damage insurance against any insurable claim or claims which might or could arise regarding Products purchased from Supplier. Such
insurance will contain a minimum combined single limit of liability for bodily injury and property damage in the amounts of not less than [***]*;
will name Novation, the Clients and the Members, as their interests may appear, as additional insureds, and will contain an endorsement providing that the carrier will provide directly to all named
insured copies of all notices and endorsements. Supplier will provide to Novation in its Bid and thereafter within fifteen (15) days after Novation's request, an insurance certificate
indicating the foregoing coverage, issued by an insurance company licensed to do business in the relevant states and signed by an authorized agent. 

    b.  Self-Insurance.  Notwithstanding anything to the contrary in
Subsection 12.a above, Supplier may maintain a self-insurance program for all or any part of the foregoing liability risks, provided such self-insurance policy in all material
respects complies with the requirements applicable to the product liability, general public liability and property damage insurance set forth in Subsection 12.a. Supplier will provide Novation in its
Bid, and thereafter within fifteen (15) days after Novation's request: (1) the self-insurance policy; (2) the name of the company managing the
self-insurance program and providing reinsurance, if any; (3) the most recent annual reports on claims and reserves for the program; and (4) the most recent annual actuarial
report on such program. 

    c.  Amendments, Notices and Endorsements.  Supplier will not amend, in any
material respect that affects the interests of Novation, the Clients of the Members, or terminate said liability insurance or self-insurance program except after thirty (30) days'
prior written notice to Novation and will provide to Novation copies of all notices and endorsements as soon as practicable after it receives or gives them. 

13. COMPLIANCE WITH LAW AND GOVERNMENT PROGRAM PARTICIPATION.  

    a.  Compliance With Law.  Supplier represents and warrants that to the best of
its knowledge, after due inquiry, it is in compliance with all federal, state and local statutes, laws, ordinances and regulations applicable to it ("Legal Requirements") which are material to the
operation of its business and the conduct of its affairs, including Legal Requirements pertaining to the safety of the Products, occupational health and safety, environmental protection,
nondiscrimination, antitrust, and equal employment opportunity. During the Term, Supplier will: (1) promptly notify Novation of any lawsuits, claims, administrative actions or other proceedings
asserted or commenced against it which assert in whole or in part that Supplier is in noncompliance with any Legal Requirement which is material to the operation of its business and the conduct of its
affairs and (2) promptly provide Novation with true and correct copies of all written notices of adverse findings from the U.S. Food and Drug Administration ("FDA") and all written results of
FDA inspections which pertain to the Products. 

    b.  Government Program Participation.  Supplier represents and warrants that it
is not excluded from participation, and is not otherwise ineligible to participate, in a "Federal health care program" as defined in 42 U.S.C. § 1320a-7b(f) or in any other
government payment program. In the event Supplier is excluded from participation, or becomes otherwise ineligible to participate in any such program 

9

 

during the Term, Supplier will notify Novation in writing within three (3) days after such event, and upon the occurrence of such event, whether or not such notice is given to Novation,
Novation may immediately terminate this Agreement upon written notice to Supplier. 

14. RELEASE AND INDEMNITY.  SUPPLIER WILL RELEASE, INDEMNIFY, HOLD HARMLESS, AND, IF REQUESTED DEFEND NOVATION, THE
CLIENTS AND THE MEMBERS, AND THEIR RESPECTIVE OFFICERS, DIRECTORS, REGENTS, AGENTS, SUBSIDIARIES, AFFILIATES AND EMPLOYEES (COLLECTIVELY, THE "INDEMNITEES"), FROM AND AGAINST ANY CLAIMS, LIABILITIES,
DAMAGES, ACTIONS, COSTS AND EXPENSES (INCLUDING, WITHOUT LIMITATION, REASONABLE ATTORNEYS' FEES, EXPERT FEES AND COURT COSTS) OF ANY KIND OR NATURE, WHETHER AT LAW OR IN EQUITY,  INCLUDING CLAIMS ASSERTING STRICT LIABILITY,
 ARISING FROM OR CAUSED IN ANY PART BY (1) THE BREACH OF ANY REPRESENTATION, WARRANTY, COVENANT OR
AGREEMENT OF SUPPLIER CONTAINED IN THIS AGREEMENT OR IN THE BID; (2) THE CONDITION OF ANY PRODUCT, INCLUDING A DEFECT IN MATERIAL, WORKMANSHIP, DESIGN OR MANUFACTURING; OR (3) THE
WARNINGS AND INSTRUCTIONS ASSOCIATED WITH ANY PRODUCT. SUCH OBLIGATION TO RELEASE, INDEMNIFY, HOLD HARMLESS AND DEFEND WILL APPLY EVEN IF THE CLAIMS, LIABILITIES, DAMAGES,
ACTIONS, COSTS AND EXPENSES ARE CAUSED BY THE NEGLIGENCE, GROSS NEGLIGENCE OR OTHER CULPABLE CONDUCT OF INDEMNITEES; PROVIDED, HOWEVER, THAT SUCH INDEMNIFICATION, HOLD HARMLESS
AND RIGHT TO DEFENSE WILL NOT BE APPLICABLE WHERE THE CLAIM, LIABILITY, DAMAGE, ACTION, COST OR EXPENSE
ARISES SOLELY AS A RESULT OF AN ACT OR FAILURE TO ACT OF INDEMNITEES. THIS SECTION AND THE: OBLIGATIONS CONTAINED HEREIN WILL SURVIVE THE EXPIRATION OR EARLIER TERMINATION OF THIS AGREEMENT. THE
REMEDIES SET FORTH IN THIS SECTION ARE IN ADDITION TO AND NOT A LIMITATION ON ANY OTHER RIGHTS OR REMEDIES THAT MAY BE AVAILABLE AGAINST SUPPLIER. 

15. BOOKS AND RECORDS; FACILITIES INSPECTIONS.  Supplier agrees to keep, maintain and preserve complete, current and
accurate books, records and accounts of the transactions contemplated by this Agreement and such additional books, records and accounts as are necessary to establish and verify Supplier's compliance
with this Agreement. All such books, records and accounts will be available for inspection and audit by Novation representatives at any time during the Term and for two (2) years thereafter,
but only during reasonable business hours and upon reasonable notice. Novation agrees that its routine audits will not be conducted more frequently than twice in any consecutive twelve
(12) month period, subject to Novation's right to conduct special audits whenever it deems it to be necessary. In addition, Supplier will make its manufacturing and packaging facilities
available for inspection from time to time during the Term by Novation representatives, but only during reasonable business hours and upon reasonable notice. The exercise by Novation of the right to
inspect and audit is without prejudice to any other or additional rights or remedies of either party. 

16. USE OF NAMES, ETC.  Supplier agrees that it will not use in any way in its promotional, informational or marketing
activities or materials (i) the names, trademarks, logos, symbols or a description of the business or activities of Novation or any Client or Member without in each instance obtaining the prior
written consent of the person owning the rights thereto; or (ii) the award or the content of this Agreement without in each instance obtaining the prior written consent of Novation. 

10

 

17. CONFIDENTIAL INFORMATION.  

    a.  Nondisclosure.  Supplier agrees that it will: 

    (1) keep
strictly confidential and hold in trust all Confidential Information, as defined in Subsection 17.b below, of Novation. the Clients and the Members; 

    (2) not
use the Confidential Information for any purpose other than the performance of its obligations under this Agreement, without the prior written consent of
Novation; 

    (3) not
disclose the Confidential Information to any third party (unless required by law) without the prior written consent of Novation; and 

    (4) not
later than thirty (30) days after the expiration or earlier termination of this Agreement, return to Novation, the Client or the Member, as the case may
be, the Confidential Information. 

    b.  Definition.  "Confidential Information," as used in Subsection 17.a above,
will consist of all information relating to the prices and usage of the Products (including all information contained in the reports produced by Supplier pursuant to Section 7 above) and all
documents and other materials of Novation, the Clients and the Members containing information relating to the programs of Novation, the Clients or the Members of a proprietary or sensitive nature not
readily available through sources in the public domain. In no event will Supplier provide to any person any information relating to the prices it charges the Members for Products ordered pursuant to
this Agreement without the prior written consent of Novation. 

18. MISCELLANEOUS.  

    a.  Choice of Law.  This Agreement will be governed by and construed in
accordance with the internal substantive laws of the State of Texas and the Texas courts will have jurisdiction over all matters relating to this Agreement; provided, however, the terms of any
agreement between Supplier and a Member will be governed by and construed in accordance with the choice of law and venue provisions set forth in such agreement. 

    b.  Not Responsible.  Novation and the Clients and their subsidiaries and
affiliates will not be responsible or liable for any Member's breach of any purchasing commitment or for any other actions of any Member. In addition, none of the Clients will be responsible or liable
for the obligations of another Client or its subsidiaries or affiliates or the obligations of Novation or Supplier under this Agreement. 

    c.  Third Party Beneficiaries.  All Clients and Members are intended third party
beneficiaries of this Agreement. All terms and conditions of this Agreement which are applicable to the Clients will inure to the benefit of and be enforceable by the Clients and their respective
successors and assigns All terms and conditions of this Agreement which are applicable to the Members will inure to the benefit of and be enforceable by the Members and their respective successors and
assigns. 

    d.  Notices.  Except as otherwise expressly provided herein, all notices or other
communications required or permitted under this Agreement will be in writing and will be deemed sufficient when 

11

 

mailed by United States mail, or delivered in person to the party to which it is to be given, at the address of such party set forth below: 

If
to Supplier: 

    To
the address set forth by Supplier in the Bid 

If
to Novation: 

Novation

Attn: General Counsel

125 John Carpenter Freeway

Irving, TX 75062-2324 

or
such other address as the party will have furnished in writing in accordance with the provisions of this Subsection. 

    e.  No Assignment.  No assignment of all or any part of this Agreement may be
made without the prior written consent of the other party; except that Novation may assign its rights and obligations to any affiliate of Novation. Any assignment of all or any part of this Agreement
by either party will not relieve that party of the responsibility of performing its obligations hereunder to the extent that such obligations are not satisfied in full by the assignee. This Agreement
will be binding upon and inure to the benefit of the parties' respective successors and assigns. 

    f.  Severability.  Whenever possible, each provision of this Agreement will be
interpreted in such a manner as to be effective and valid under applicable law, but if any provision of this Agreement will be prohibited by or invalid under applicable law, such provision will be
ineffective to the extent of such prohibition or invalidity without invalidating the remainder of such provision or the remaining provisions of this Agreement. Each party will, at its own expense,
take such action as is reasonably
necessary to defend the validity and enforceability of this Agreement and will cooperate with the other party as is reasonably necessary in such defense. 

    g.  Entire Agreement.  This Agreement, together with the exhibits listed below,
will constitute the entire agreement between Novation and Supplier. This Agreement, together with the exhibits listed below and each Member's purchase order will constitute the entire agreement
between each Member and Supplier. In the event of any inconsistency between this Agreement and a Member's purchase order, the terms of this Agreement will control, except that the Member's purchase
order will supersede Sections 4 and 5 of this Agreement in the event of any inconsistency with such Sections. No other terms and conditions in any document, acceptance, or acknowledgment will be
effective or binding unless expressly agreed to in writing. The following exhibits are incorporated by reference in this Agreement. 

12

 

	Exhibit A	 	Product and Service Description and Pricing	 	 
	

Exhibit B	
 	

Non-Price Specifications	
 	

 
	

Exhibit C	
 	

Special Conditions	
 	

 
	

Exhibit D	
 	

Award Letter	
 	

 
	

Exhibit E	
 	

Other Information Requirements	
 	

 
	

[Other Exhibits Listed, if any]	
 	

 
	

Exhibit F	
 	

Supplier Agreement, Exception Response Form	
 	

 
	

SUPPLIER:	
 	
Specialty Laboratories, Inc.	
 	

 
	

ADDRESS:	
 	
2211 Michigan Avenue

Santa Monica, California 90404-3900	
 	

 
	SIGNATURE:	 	 	 	 
	 	 	
	 	 
	

TITLE:	
 	

Director, Contract Administration	
 	

DATE: May 4, 2000

13

 
 

EXHIBIT A
  
    PRODUCT AND SERVICE DESCRIPTION AND PRICING    
  

	Pricing:	 	A Letter of Participation is required to activate pricing for this Agreement by Members that are not currently utilizing Supplier and is attached as Exhibit B-1. Members that are currently using Supplier under the VHA
agreement are waived from signing the Letter of Participation.
	

 	
 	

[***]*, as published in the Price List current at the time the testing is ordered, will be granted for all tests not listed on Exhibit A. Tests that are unique to Supplier and tests that are referred to another reference laboratory are not
included in the [***]*. Supplier [***]* for tests referred to other laboratories. To maintain compliance with current California regulations, Supplier is required to charge Members for all testing referred to another laboratory at the
price charged to Supplier. In the event a test currently being performed by Supplier is discontinued and referred to another laboratory, Supplier will be required to charge the Member the price Supplier is being charged.
	

Commitment:	
 	

If necessary to meet competitive situations, upon mutual consent of both Novation and Supplier, Supplier may [***]* from Exhibit A to Participating Members that commit at least [***]*. Supplier retains the right to identify which tests
are further discountable. Additional discounts may include:
	

 	
 	

1.	
 	

Additional discounts of up to [***]*. The selection of these tests must be agreed upon by Member and Supplier prior to pricing being implemented.
	

 	
 	

2.	
 	

Additional discounts of up to [***]* may be offered to [***]* from a multi-hospital system. The selection of these tests must be agreed upon by Member and Supplier prior to pricing being implemented.
	

 	
 	

3.	
 	

Additional discounts of more than [***]* referenced above may be agreed upon by mutual consent of Novation and Supplier.
	

 	
 	

After utilizing the Agreement for one year, Member and Supplier have the option to review the list and make adjustments if necessary.
	

 	
 	

Participating Members shall be deemed to be part of a system or network if they meet either of the following criteria:
	

 	
 	

1.	
 	

Are listed in VHA or UHC membership as part of a system or network under one "parent" member AND are owned, managed, controlled or leased by "parent" member.
	

 	
 	

2.	
 	

Have joined together with other Participating Members in local or regional effort to reduce supply chain costs through standardization. Examples of this might include consolidation logistics centers, local integrated delivery networks (LIDN) or
regional networks of unrelated VHA or UHC facilities who agree to commit and standardize on one Supplier. Eligibility under this criterion will be determined by Novation.
	

Price:	
 	

[***]*
	

Price Protection:	
 	

Pricing on Exhibit A will not [***]* of the Agreement with the [***]*. Supplier agrees that [***]* if Novation so chooses to use them. Prices of tests that are referred to another laboratory are subject to change at any time.
Supplier agrees to provide best efforts to notify Members of changes of prices of tests referred to other laboratories within 30 days of the change.
	

Handling Fees:	
 	

For tests being referred to another reference laboratory, Supplier will [***]* No additional fees or handling charges will be added.

* CONFIDENTIAL TREATMENT IS REQUESTED FOR CONFIDENTIAL INFORMAITON ENCLOSED IN THE BRACKETS AND UNDERLINED. 

  

 
 

Exhibit A
  
    Specialty Laboratories, Inc.    
  

* CONFIDENTIAL TREATMENT IS REQUESTED FOR CONFIDENTIAL INFORMAITON ENCLOSED IN THE BRACKETS AND UNDERLINED. 

1

 

	Test #
 
	 	CPT#
	 	Product Description
	 	u/m
	 	Contract Price

	1000	 	83520; 86038; 86160x2; 86225; 86235x5; 86376; 86431	 	ANAlyzer®	 	each	 	[***]*
	1002	 	86256x6	 	Tissue Total Autoabs Screen [TAbS]	 	each	 	[***]*
	1003	 	86038; 86160x2; 86225; 86235x4	 	Antinuclear Abs Panel	 	each	 	[***]*
	1004	 	86038; 86160x2; 86225; 86235x7	 	Rheumatic Evaluation	 	each	 	[***]*
	1005	 	83520; 86160x2; 86225; 86235x5; 86376; 86431	 	ANAlyzer® without ANA	 	each	 	[***]*
	1006	 	83520; 86038; 86160x2; 86225; 86235x5; 86376	 	ANAlyzer® without Rheumatoid Factor	 	each	 	[***]*
	1007	 	86235x2	 	SS-A & SS-B IgG Autoabs	 	each	 	[***]*
	1008	 	86256x6; 86376	 	Tissue Total Autoabs Screen Plus Thyroid Peroxidase	 	each	 	[***]*
	1010	 	84550; 86038; 86431x2	 	Arthritis Evaluation B	 	each	 	[***]*
	1012	 	86431x3	 	Rheumatoid Factor IgG; IgM; & IgA Autoantibodies	 	each	 	[***]*
	1015	 	86431x2	 	Rheumatoid Factor Autoabs Evaluation	 	each	 	[***]*
	1016	 	86376; 86800	 	Thyroid Autoabs	 	each	 	[***]*
	1020	 	86160x3	 	Complement Evaluation	 	each	 	[***]*
	1021	 	86160x3; 86162	 	Complement Evaluation Plus CH50	 	each	 	[***]*
	1025	 	83519; 86256	 	Myasthenia Gravis Evaluation	 	each	 	[***]*
	1027	 	83520	 	Transglutaminase IgG Autoabs [EIA]	 	each	 	[***]*
	1028	 	83520	 	Transglutaminase IgM Autoabs [EIA]	 	each	 	[***]*
	1029	 	83520	 	Transglutaminase IgA Autoabs [EIA]	 	each	 	[***]*
	1030	 	83520x3	 	Transglutaminase IgG; IgM & IgA Autoabs Evaluation [EIA]	 	each	 	[***]*
	1031	 	86337; 86341x2	 	Diabetes Evaluation	 	each	 	[***]*
	1032	 	83519; 86337; 86341x2	 	Diabetes Mellitus Autoantibody Evaluation	 	each	 	[***]*
	1033	 	83519	 	Glutamic Acid Decarboxylase [GAD] Autoabs	 	each	 	[***]*
	1035	 	86813; 86817	 	HLA: A; B; C & D Typing; Complete	 	each	 	[***]*
	1036	 	86337; 86341x2; 86812x2; 86816x2	 	Diabetes; Genetic Evaluation	 	each	 	[***]*
	1040	 	86160x2; 86332x4	 	Circulating Immune Complex Detector	 	each	 	[***]*
	1043	 	86609x4; 86648; 86774	 	Humoral Immune Evaluation	 	each	 	[***]*
	1045	 	82784x3	 	IgA; IgG & IgM Immunoglobulin Quantitation	 	each	 	[***]*
	1048	 	82784x3; 82785; 82787; 86609x4; 86648; 86774	 	Humoral Immune Status Survey (Pneumo 4)	 	each	 	[***]*
	1051	 	83520	 	Glial Fibrillary Acidic Protein Autoabs [GFAP]	 	each	 	[***]*
	1052	 	83520	 	Neurofilament-heavy Subunit [NF-H] Autoabs	 	each	 	[***]*
	1053	 	83520	 	Tubulin Autoabs	 	each	 	[***]*
	1055	 	82040; 82784x6; 83873; 83883; 83916	 	Multiple Sclerosis Evaluation	 	each	 	[***]*
	1056	 	83520	 	Myelin Basic Protein Autoantibodies [MbP]	 	each	 	[***]*

2

 

	1057	 	82040; 82784x6; 83520x3; 83873; 83883; 83916; 86160; 88180	 	Lupus CNS Evaluation CSF & Serum	 	each	 	[***]*
	1060	 	86353x3	 	Lymphocyte Mitogen Proliferation Analysis	 	each	 	[***]*
	1062	 	86353x6	 	Lymphocyte Antigen & Mitogen Proliferation Analysis	 	each	 	[***]*
	1065	 	86038; 86160; 86225; 86235x5; 86376	 	Antinuclear Abs Evaluation w/ C4	 	each	 	[***]*
	1066	 	86038; 86160; 86225; 86235x5; 86376	 	Antinuclear Abs Evaluation w/ C3	 	each	 	[***]*
	1070	 	86618x2; 86625; 86631; 86632; 86768x3; 86771; 86793x3; 86812	 	Reactive Arthritis Evaluation	 	each	 	[***]*
	1076	 	83520x2; 86256x2	 	Celiac Disease Abs Evaluation	 	each	 	[***]*
	1077	 	83520x3; 86256x2	 	Celiac Disease EvaluatR	 	each	 	[***]*
	1078	 	83891; 83894x3; 83901x3; 83912	 	Celiac Disease Genotypr	 	each	 	[***]*
	1080	 	85613; 86147x3; 86148x3	 	Antiphospholipid Syndrome Evaluation	 	each	 	[***]*
	1082	 	83520x9; 85613; 86147x3; 86148x3	 	Antiphospholipid Syndrome Evaluation; Expanded	 	each	 	[***]*
	1083	 	83520x3	 	[GPI]	 	each	 	[***]*
	1085	 	82164; 86353; 86360	 	Sarcoidosis Evaluation	 	each	 	[***]*
	1086	 	86609x4; 86648; 86684; 86774	 	Humoral Immune Eval + H. influenzae b	 	each	 	[***]*
	1090	 	83519; 84443	 	Thyrotropin Binding Inhibitory Immunoglobulins	 	each	 	[***]*
	1091	 	84443; 84445	 	Thyroid Stimulating Immunoglobulins	 	each	 	[***]*
	1092	 	84445	 	Thyroid Stimulating Immunoglobulins w/o TSH	 	each	 	[***]*
	1093	 	83519	 	Thyrotropin Binding Inhibitory Immunoglobulins w/o TSH	 	each	 	[***]*
	1094	 	85810; 86160x2; 86225	 	Lupus Activity Reporter	 	each	 	[***]*
	1096	 	83520x2; 86160x3; 86225	 	Lupus Monitor	 	each	 	[***]*
	1100	 	86038	 	Antinuclear Abs w/ International Units & Pattern	 	each	 	[***]*
	1102	 	86256	 	Mitochondrial Total Autoabs	 	each	 	[***]*
	1103	 	86256	 	Myocardial Total Autoabs	 	each	 	[***]*
	1104	 	86256	 	Parietal Cell Total Autoabs	 	each	 	[***]*
	1105	 	86256	 	Reticulin Total Autoabs	 	each	 	[***]*
	1106	 	86256	 	Smooth Muscle Total Autoabs	 	each	 	[***]*
	1107	 	86256	 	Striational Total Autoabs	 	each	 	[***]*
	1109	 	86255	 	Centromere Autoabs	 	each	 	[***]*
	1110	 	86800	 	Thyroglobulin Autoabs	 	each	 	[***]*
	1113	 	86431	 	Rheumatoid Factor IgM Autoabs [IHA]	 	each	 	[***]*
	1114	 	86256x2	 	Epidermal	 	each	 	[***]*
	1115	 	86376	 	Liver-Kidney-Microsome Autoabs	 	each	 	[***]*
	1116	 	86256	 	Brush Border Total Autoabs	 	each	 	[***]*
	1118	 	86038	 	ANAlyzer® Reflexive Testing [with Tissue Abs]	 	each	 	[***]*

3

 

	1120	 	86038	 	Antinuclear Abs Reflex to Profile #1	 	each	 	[***]*
	1121	 	86038	 	Antinuclear Abs Reflex to Profile	 	each	 	[***]*
	1122	 	86038	 	Antinuclear Abs w/ International Units & Titer	 	each	 	[***]*
	1124	 	86038	 	TPO	 	each	 	[***]*
	1125	 	86038; 86160x2; 86225; 86235x3	 	Antinuclear Abs Profile #1	 	each	 	[***]*
	1126	 	86038; 86160x2; 86225; 86235x5; 86431	 	Antinuclear Abs Profile	 	each	 	[***]*
	1127	 	86038; 86225; 86235x5	 	ANA; DsDna; SS-A/SS-B; ENA; Scl-70 Autoabs	 	each	 	[***]*
	1130	 	86256	 	Adrenal Total Autoantibodies	 	each	 	[***]*
	1136	 	83520	 	Glomerular Basement Membrane IgG Autoabs	 	each	 	[***]*
	1138	 	83520	 	Cystatin C	 	each	 	[***]*
	1140	 	83520	 	Histone-DNA Complex IgG Autoabs	 	each	 	[***]*
	1145	 	82784	 	IgD	 	each	 	[***]*
	1150	 	82585	 	Cryofibrinogens with Reflex	 	each	 	[***]*
	1151	 	82585	 	Cryofibrinogen	 	each	 	[***]*
	1152	 	82585	 	Cryofibrinogenemia Reflexive Evaluation	 	each	 	[***]*
	1155	 	82595	 	Cryoglobulins with Reflex	 	each	 	[***]*
	1156	 	82595	 	Cryoglobulin	 	each	 	[***]*
	1157	 	82595	 	Cryoglobulinemia Reflexive Evaluation	 	each	 	[***]*
	1158	 	82585; 82595	 	Cryoglobulin & Cryofibrinogen	 	each	 	[***]*
	1160	 	82668	 	Erythropoietin	 	each	 	[***]*
	1162	 	86256	 	Reticulin IgA Autoabs	 	each	 	[***]*
	1165	 	86341	 	Islet Cell IgG Cytoplasmic Antibodies	 	each	 	[***]*
	1166	 	86341	 	Abs	 	each	 	[***]*
	1168	 	86256	 	Neuronal Nuclear IgG Abs Type I (Hu)	 	each	 	[***]*
	1171	 	86256x2	 	Paraneoplastic Syndrome Evaluation	 	each	 	[***]*
	1176	 	86256	 	Purkinje Cell Cytoplasmic IgG Autoabs Type I (Yo)	 	each	 	[***]*
	1178	 	86256	 	Ovary IgG Autoabs	 	each	 	[***]*
	1180	 	86256	 	Testes IgG Autoabs	 	each	 	[***]*
	1186	 	83520	 	Neuronal Nuclear Abs Type I (Hu)	 	each	 	[***]*
	1187	 	84181	 	Purkinje Cell Cytoplasmic Autoabs Type I (Yo)	 	each	 	[***]*
	1191	 	86256	 	Endomysial IgA Autoabs	 	each	 	[***]*
	1198	 	83520	 	Neuronal IgG Autoabs for CNS Lupus	 	each	 	[***]*
	1201	 	86225	 	DNA Autoabs; Double-stranded	 	each	 	[***]*
	1203	 	86256	 	DNA Autoantibodies (Crithidia); Double Stranded	 	each	 	[***]*
	1204	 	86235	 	SS-A IgG Autoabs	 	each	 	[***]*
	1205	 	86235	 	SS-B IgG Autoabs	 	each	 	[***]*
	1207	 	86235	 	Jo-1 Abs [DD]	 	 	 	 
	1208	 	86235	 	Jo-1 IgG Autoabs [EIA]	 	each	 	[***]*
	1210	 	86235x2	 	Extractable Nuclear Ag (ENA) IgG Autoabs	 	each	 	[***]*
	1215	 	86235	 	U1 RNP/snRNP IgG Autoabs	 	each	 	[***]*
	1220	 	86235	 	Sm (Smith) IgG Autoabs	 	each	 	[***]*
	1222	 	86235	 	Ku Autoantibodies	 	each	 	[***]*
	1223	 	86235	 	OJ Autoantibodies	 	each	 	[***]*

4

 

	1224	 	86235	 	PL-12 Autoantibodies	 	each	 	[***]*
	1225	 	86235	 	EJ Autoantibodies	 	each	 	[***]*
	1226	 	86235	 	PL-7 Autoantibodies	 	each	 	[***]*
	1227	 	86235	 	SRP Autoantibodies	 	each	 	[***]*
	1228	 	86235	 	U2 SnRNP Autoantibodies	 	each	 	[***]*
	1230	 	86332	 	Immune Complex Assay; Raji Cell	 	each	 	[***]*
	1232	 	86235	 	Sm Autoabs Quant	 	each	 	[***]*
	1233	 	86235	 	U1 RNP/SnRNP Autoabs Quant	 	each	 	[***]*
	1234	 	86235x2	 	[Ha]	 	each	 	[***]*
	1235	 	86235	 	Scl-70 IgG Autoabs	 	each	 	[***]*
	1240	 	85810	 	Viscosity Serum	 	each	 	[***]*
	1245	 	82785	 	IgE	 	each	 	[***]*
	1251	 	86256	 	Proliferating Cell Nuclear Ag Abs	 	each	 	[***]*
	1257	 	86235	 	PM-ScI Autoabs	 	each	 	[***]*
	1261	 	83520	 	Gliadin IgG Abs	 	each	 	[***]*
	1266	 	83520x2	 	Gliadin IgG & IgA Abs	 	each	 	[***]*
	1271	 	83520	 	Ribosomal P Protein IgG Autoabs	 	each	 	[***]*
	1273	 	82040; 82784x2; 83520x2; 83883	 	Ribosomal P Protein IgG Antibody Index	 	each	 	[***]*
	1281	 	86235	 	Jo-1 IgG Autoabs	 	each	 	[***]*
	1286	 	83520	 	Gliadin IgA Abs	 	each	 	[***]*
	1290	 	86226	 	DNA Autoabs; Single-stranded	 	each	 	[***]*
	1310	 	84550	 	Uric Acid	 	each	 	[***]*
	1320	 	82565	 	Creatinine	 	each	 	[***]*
	1322	 	82575	 	Creatinine Clearance	 	each	 	[***]*
	1324	 	84155	 	Protein; Total	 	each	 	[***]*
	1331	 	86648; 86774	 	Tetanus & Diphtheria Toxoid IgG Abs Single Serum	 	each	 	[***]*
	1334	 	86774	 	Tetanus Toxoid IgG Abs Single Serum	 	each	 	[***]*
	1337	 	86609	 	Streptococcus pyogenes; Group A Abs (Streptozyme)	 	each	 	[***]*
	1340	 	86615; 86648; 86774	 	Immune Status Panel—DPT	 	each	 	[***]*
	1341	 	86735; 86762; 86765	 	Immune Status Panel—MMR	 	each	 	[***]*
	1345	 	84450	 	AST (SGOT)	 	each	 	[***]*
	1346	 	86753	 	Entamoeba histolytica IgG Abs	 	each	 	[***]*
	1347	 	84460	 	ALT (SGPT)	 	each	 	[***]*
	1349	 	86813	 	HLA: A &B Typing; Complete	 	each	 	[***]*
	1350	 	86812	 	HLA: B27 Typing	 	each	 	[***]*
	1351	 	86813	 	HLA: A; B; C Typing; Complete	 	each	 	[***]*
	1352	 	86817	 	HLA: DR Typing; Complete	 	each	 	[***]*
	1353	 	86816	 	HLA: DR3—Celiac Disease	 	each	 	[***]*
	1354	 	86812	 	HLA: BB-Primary Sclerosing Cholangitis	 	each	 	[***]*
	1355	 	86812x2; 86816x2	 	HLA: Diabetes-associated	 	each	 	[***]*
	1356	 	86812	 	HLA: A or B Typing (specify antigen)	 	each	 	[***]*
	1357	 	86816	 	HLA: DR Single Antigen	 	each	 	[***]*
	1358	 	86816x2	 	Arthritis RX SelectR	 	each	 	[***]*
	1362	 	86812	 	HLA: B5 Typing	 	each	 	[***]*
	1364	 	83891; 83894; 83901; 83912	 	HLA B27 GenotypR	 	each	 	[***]*
	1365	 	86160x2	 	Complement: C4 Allotyping	 	each	 	[***]*

5

 

	1375	 	88180	 	Recurrent Spontaneous Abortion: Crossmatch	 	each	 	[***]*
	1382	 	88180	 	Neutrophil Function: Myeloperoxidase	 	each	 	[***]*
	1383	 	88180x4	 	Neutrophil Function: Adherence [CD11a; CD11b; CD11c; CD18]	 	each	 	[***]*
	1386	 	83520	 	Myeloperoxidase Autoabs	 	each	 	[***]*
	1392	 	82085	 	Aldolase	 	each	 	[***]*
	1396	 	83520	 	Proteinase-3Autoabs	 	each	 	[***]*
	1398	 	82955	 	Glucose-6-Phosphate Dehydrogenase [G-6-PDH]	 	each	 	[***]*
	1401	 	86332	 	Immune Complex Assay Clq Binding; Fluid Phase	 	each	 	[***]*
	1402	 	86332	 	Conglutinin Solid Phase Immune Complex Assay	 	each	 	[***]*
	1403	 	86332	 	Immune Complex Assay; Polyethylene Glycol	 	each	 	[***]*
	1410	 	83519	 	Acetylcholine Receptor Binding Autoantibodies	 	each	 	[***]*
	1412	 	83519	 	Acetylcholine Receptor Blocking Autoantibodies	 	each	 	[***]*
	1413	 	83519	 	Acetylcholine Receptor Modulating Autoantibodies	 	each	 	[***]*
	1415	 	86648	 	Diphtheria Toxoid IgG Abs Single Serum	 	each	 	[***]*
	1426	 	85384	 	Fibrinogen	 	each	 	[***]*
	1431	 	82784; 83520	 	IgA Fibronectin Aggregates & Serum IgA	 	each	 	[***]*
	1436	 	82784; 83520x2	 	IgA Nephropathy Evaluation	 	each	 	[***]*
	1438	 	83520	 	IgG Fibronectin Aggregates	 	each	 	[***]*
	1440	 	82731	 	Fetal Fibronectin by Semi-Quantitative EIA	 	each	 	[***]*
	1441	 	83520	 	Ganglioside Monosialic Acid Autoabs	 	each	 	[***]*
	1470	 	86353x8	 	Beryllium-induced Lymphocyte Proliferation	 	each	 	[***]*
	1474	 	83520	 	Collagen Type II IgG Autoabs	 	each	 	[***]*
	1476	 	83520x2	 	Collagen Type I & IV IgG Autoabs	 	each	 	[***]*
	1477	 	83520	 	Collagen Type I IgG Autoabs	 	each	 	[***]*
	1478	 	83520	 	Collagen Type IV IgG Autoabs	 	each	 	[***]*
	1481	 	83520	 	Hyaluronic Acid	 	each	 	[***]*
	1486	 	86160	 	Complement Split Product Concentration: C3a	 	each	 	[***]*
	1491	 	85420	 	Plasminogen; Quantitative	 	each	 	[***]*
	1492	 	85420	 	Plasminogen Activity	 	each	 	[***]*
	1494	 	83520	 	RNA Polymerases I; II and III IgG Autoabs	 	each	 	[***]*
	1498	 	83520x2	 	IgA (Autoantibodies) IgG & IgM Ab Panel	 	each	 	[***]*
	1501	 	86160	 	Complement Protein Concentration: C3	 	each	 	[***]*
	1504	 	86160	 	Complement Protein Concentration: C4	 	each	 	[***]*
	1505	 	82784	 	IgG	 	each	 	[***]*
	1506	 	82784	 	IgA	 	each	 	[***]*
	1508	 	82784	 	IgM	 	each	 	[***]*
	1510	 	82040	 	Albumin	 	each	 	[***]*
	1511	 	86160	 	Complement Protein Concentration: Factor B	 	each	 	[***]*
	1512	 	83883	 	Alpha-2-Macroglobulin	 	each	 	[***]*
	1513	 	82103	 	Alpha-1-Antitrypsin	 	each	 	[***]*
	1514	 	82104	 	Alpha-1-Antitrypsin Phenotyping	 	each	 	[***]*

6

 

	1516	 	82390	 	Ceruloplasmin	 	each	 	[***]*
	1517	 	83010	 	Haptoglobin	 	each	 	[***]*
	1519	 	84466	 	Transferrin	 	each	 	[***]*
	1520	 	83520	 	Transferrin Receptor (TFR); Soluble	 	each	 	[***]*
	1523	 	84311	 	N-Acetyl-B-D-Glucosaminidase	 	each	 	[***]*
	1525	 	82985	 	Alpha-1-Acid Glycoprotein	 	each	 	[***]*
	1529	 	86160; 86161	 	Angioedema Evaluation	 	each	 	[***]*
	1530	 	86160	 	Inhibitor	 	each	 	[***]*
	1531	 	86161	 	Complement Functional Activity: C1 Esterase Inhibitor	 	each	 	[***]*
	1533	 	83520x4	 	T-Cell Helper Types 1 & 2 Evaluation	 	each	 	[***]*
	1535	 	86140	 	C-Reactive Protein	 	each	 	[***]*
	1536	 	86140	 	C-Reactive Protein Ultraquant (High-Sensitivity CRP)	 	each	 	[***]*
	1537	 	82131; 86140; 86631	 	Treatable Ischemia PredictR (TIP)	 	each	 	[***]*
	1540	 	86431	 	Rheumatoid Factor Autoabs	 	each	 	[***]*
	1549	 	84134	 	Prealbumin	 	each	 	[***]*
	1550	 	82040; 82784x2; 83883	 	IgG Synthesis Rate; CNS Index	 	each	 	[***]*
	1555	 	82040; 83883	 	Albumin Quotient	 	each	 	[***]*
	1557	 	83916	 	Oligoclonal Immunoglobulins [IEF/IFIX]	 	each	 	[***]*
	1559	 	83916	 	Oligoclonal Immunoglobulins [AE]	 	each	 	[***]*
	1580	 	84165	 	Electrophoresis; Protein	 	each	 	[***]*
	1592	 	82664x2; 82784x3; 84165	 	Bence-Jones Protein Evaluation (Qual w/Reflex to Quant)	 	each	 	[***]*
	1599	 	83986	 	Gastric pH	 	each	 	[***]*
	1600	 	86162	 	Complement: CH50 Total Functional Activity; Classic Pathway	 	each	 	[***]*
	1605	 	86160	 	Complement Protein Concentration: C2	 	each	 	[***]*
	1610	 	86160	 	Complement Protein Concentration: C5	 	each	 	[***]*
	1612	 	86160; 86161	 	Complement: C3 Nephritic Factor	 	each	 	[***]*
	1615	 	86160	 	Complement Protein Concentration: Clq	 	each	 	[***]*
	1621	 	83520	 	Granulocyte Colony Stimulating Factor	 	each	 	[***]*
	1622	 	86021	 	Granulocyte Autoabs	 	each	 	[***]*
	1623	 	82784; 82787	 	IgG Subclasses 1, 2, 3, & 4	 	each	 	[***]*
	1625	 	83883	 	IgG Subclass 1	 	each	 	[***]*
	1627	 	83883	 	IgG Subclass 2	 	each	 	[***]*
	1628	 	83883	 	IgG Subclass 3	 	each	 	[***]*
	1629	 	83883	 	IgG Subclass 4	 	each	 	[***]*
	1630	 	86023x3	 	Platelet-associated IgG; IgM & IgA Autoabs	 	each	 	[***]*
	1631	 	86022x3	 	Platelet IgG; IgM & IgA Autoabs	 	each	 	[***]*
	1634	 	88180x4	 	Terminal Deoxynucleotidyl Transferase Bone Marrow or Tissue	 	each	 	[***]*
	1635	 	88180x4	 	Terminal Deoxynucleotidyl Transferase with Immunophenotyping	 	each	 	[***]*
	1636	 	86022x3; 86023x3	 	Platelet Autoabs Evaluation	 	each	 	[***]*
	1638	 	86353; 86821x2	 	Human Mixed Lymphocyte Reaction; One Way [MLR]	 	each	 	[***]*
	1639	 	86353; 86821x2	 	Human Mixed Lymphocyte Reaction; Two Way [MLR]	 	each	 	[***]*
	1640	 	86353	 	Lymphocyte Mitogen Proliferation Analysis; PHA	 	each	 	[***]*

7

 

	1641	 	86353	 	Lymphocyte Mitogen Proliferation Analysis; PWM	 	each	 	[***]*
	1642	 	86353	 	Lymphocyte Mitogen Proliferation Analysis; ConA	 	each	 	[***]*
	1643	 	86353	 	Lymphocyte Antigen Proliferation Analysis; Candida	 	each	 	[***]*
	1644	 	86353	 	Lymphocyte Antigen Proliferation Assays; Tetanus	 	each	 	[***]*
	1645	 	86353	 	Lymphocyte Antigen Proliferation Assays; PPD (Tuberculin)	 	each	 	[***]*
	1646	 	86353	 	Borrelia burgdorferi Lymphocyte Proliferation Analysis	 	each	 	[***]*
	1648	 	86353x3	 	Lymphocyte Antigen Proliferation Analysis	 	each	 	[***]*
	1650	 	85048; 85595; 88180x5; 86360	 	Cellular Immune Dysfunction Evaluation	 	each	 	[***]*
	1651	 	85048; 85595; 86663; 86664; 86665x2; 86790x2; 88180x4; 86360	 	Chronic Fatigue & Immune Dysfunction Syndrome Evaluation	 	each	 	[***]*
	1652	 	85048; 86663; 86664; 86665x2; 86790x2; 86849; 88180x4; 86360	 	Chronic Fatigue & Immune Dysfunction Syndrome with NK Cell	 	each	 	[***]*
	1655	 	85048; 85595; 86359; 86360	 	Lymphocyte Enumeration; T Cell	 	each	 	[***]*
	1656	 	85048; 85595; 86361	 	Lymphocyte Enumeration; Helper/Inducer	 	each	 	[***]*
	1657	 	85048; 85595; 86360	 	Lymphocyte Enumeration; Helper/Suppressor	 	each	 	[***]*
	1658	 	85048; 85595; 86359; 88180	 	Lymphocyte Enumeration; T&B Cell	 	each	 	[***]*
	1659	 	85048; 85595; 86360	 	(Limited)	 	each	 	[***]*
	1660	 	85048; 85595; 86359; 86360; 88180x8	 	Lymphocyte Enumeration; Naïve Memory Cell	 	each	 	[***]*
	1661	 	88342x8	 	Lymphoma Panel	 	each	 	[***]*
	1662	 	88342x4	 	Undifferentiated Tumor Panel	 	each	 	[***]*
	1666	 	86359; 86360; 88180x17	 	Leukemia / Lymphoma Tissue or Body Fluid Evaluation	 	each	 	[***]*
	1667	 	86359; 86360; 88180x24	 	Leukemia / Lymphoma Bone Marrow Evaluation	 	each	 	[***]*
	1668	 	85048; 85595; 88180x3; 86360	 	Lymphocyte Enumeration; Basic & NK Cells	 	each	 	[***]*
	1670	 	85048; 86359; 88180x24; 86360	 	Leukemia / Lymphoma Blood Evaluation	 	each	 	[***]*
	1671	 	85048; 85595; 88180x2; 86360	 	Lymphocyte Enumeration; Basic	 	each	 	[***]*
	1672	 	85048; 86359; 88180x25; 86360	 	Leukemia / Lymphoma Blood Reflexive Evaluation	 	each	 	[***]*
	1674	 	85048; 86359; 88180x19; 86360	 	Leukemia / Lymphoma Evaluation Blood	 	each	 	[***]*
	1676	 	85048; 86359; 88180x19; 86360	 	Leukemia / Lymphoma: Comprehensive Blood	 	each	 	[***]*
	1677	 	86360; 88180x18	 	Leukemia / Lymphoma; Comprehensive Bone Marrow or Tissue	 	each	 	[***]*

8

 

	1678	 	88180x2	 	Additional Surface markers	 	each	 	[***]*
	1679	 	86360; 88180x18	 	Leukemia / Lymphoma Evaluation Bone Marrow or Tissue	 	each	 	[***]*
	1682	 	88180x15	 	Leukemia / Lymphoma Panel; Chronic Bone Marrow or Tissue	 	each	 	[***]*
	1683	 	86359	 	CD3 Surface Marker	 	each	 	[***]*
	1684	 	86361	 	CD4 Surface Marker	 	each	 	[***]*
	1685	 	86360	 	CD8 Surface Marker	 	each	 	[***]*
	1686	 	88180	 	CD15/30 Surface Marker	 	each	 	[***]*
	1687	 	88180	 	CD16/56 Surface Marker	 	each	 	[***]*
	1688	 	88180	 	CD19 Surface Marker	 	each	 	[***]*
	1689	 	88180	 	CD38 Surface Marker	 	each	 	[***]*
	1690	 	88180	 	CD41 Surface Marker	 	each	 	[***]*
	1691	 	88180	 	CD42 Surface Marker	 	each	 	[***]*
	1692	 	88180	 	CD103 Surface Marker	 	each	 	[***]*
	1693	 	88180	 	Glycophorin-A	 	each	 	[***]*
	1694	 	88180	 	Terminal Deoxynucleotidyl Transferase Bone Marrow or Tissue	 	each	 	[***]*
	1705	 	83891; 83901X4; 83894X4; 83912	 	Narcolepsy EvaluatR	 	each	 	[***]*
	1706	 	86817	 	HLA: DR2 & DQ1—Narcolepsy Evaluation	 	each	 	[***]*
	1711	 	86148x3	 	Phosphatidyserine IgG; IgM & IgA Autoantibodies	 	each	 	[***]*
	1721	 	86160; 86161	 	Complement: C4 Nephritic Factor	 	each	 	[***]*
	1723	 	86160x2; 86161x2	 	Complement: C3 & C4 Nephritic Factors Evaluation	 	each	 	[***]*
	1726	 	83520x3; 86021; 86038; 86060; 86160x2	 	Rapidly Progressive Glomerulonephritis Evaluation	 	each	 	[***]*
	1751	 	83520x3	 	Phosphatidylcholine IgG; IgM & IgA Abs	 	each	 	[***]*
	1771	 	83520x3	 	Phosphatidic Acid IgG; IgM & IgA Abs	 	each	 	[***]*
	1774	 	86148x3	 	Phosphatidylinositol IgG; IgM; and IgA Autoantibodies	 	each	 	[***]*
	1775	 	84081x3	 	Autoantibodies	 	each	 	[***]*
	1776	 	83520x9; 84081x3; 86147x3; 86148x6	 	Antiphospholipid Eval & Phosphoglycerol/Phosphoinositol	 	each	 	[***]*
	1791	 	83520x3	 	Phosphatidylethanolamine IgG; IgM & IgA Abs	 	each	 	[***]*
	1804	 	84233; 84234; 88182	 	Breast Cancer Profile 1—Paraffin	 	each	 	[***]*
	1811	 	82387; 84233; 84234; 88182; 88342x2	 	Breast Cancer Profile 6—Paraffin	 	each	 	[***]*
	1812	 	84233; 84234; 88182; 88342x2	 	Breast Cancer Profile 5—Paraffin	 	each	 	[***]*
	1813	 	82387; 84233; 84234; 88182	 	Breast Cancer Profile 2—Paraffin	 	each	 	[***]*
	1816	 	82387; 84233; 84234; 88182; 88342x4	 	Breast Cancer Profile 7—Paraffin	 	each	 	[***]*
	1817	 	84233; 84234; 88182; 88342	 	Breast Cancer Profile 4—Paraffin	 	each	 	[***]*
	1818	 	84233; 84234; 88182; 88342	 	Breast Cancer Profile 3 With Her-2/Neu Reflex	 	each	 	[***]*

9

 

	1819	 	84233; 84234; 88182; 88342	 	Breast Cancer Profile 3—Paraffin	 	each	 	[***]*
	1820	 	87620	 	Human Papillomavirus DetectR	 	each	 	[***]*
	1822	 	87622	 	Human Papillomavirus GenotypR	 	each	 	[***]*
	1824	 	87621	 	Human Papillomavirus DetectR reflx to GenotypR	 	each	 	[***]*
	1830	 	84233; 84234	 	Estrogen & Progesterone Receptor Paraffin [IHC]	 	each	 	[***]*
	1831	 	84233	 	Estrogen Receptor	 	each	 	[***]*
	1832	 	84234	 	Progesterone Receptor	 	each	 	[***]*
	1834	 	88342	 	IHC EGFR Block	 	each	 	[***]*
	1840	 	84233; 84234; 88342	 	Breast Cancer Panel; Basic	 	each	 	[***]*
	1842	 	84233; 84234; 88342	 	ER/PGR and Her2/Neu With Reflex to Fish	 	each	 	[***]*
	1852	 	82387	 	IHC Cathepsin D Block	 	each	 	[***]*
	1862	 	86021; 86038	 	Antineutrophil Cytoplasmic Autoantibodies (ANCA)	 	each	 	[***]*
	1866	 	83520x2; 86021; 86038	 	PAN-ANCA Evaluation	 	each	 	[***]*
	1868	 	83520x4; 86021; 86038	 	PAN-ANCA PLUS	 	each	 	[***]*
	1871	 	85245	 	Ristocetin Cofactor Function	 	each	 	[***]*
	1872	 	85048; 85595; 88180	 	Natural Killer Cell Quantitation	 	each	 	[***]*
	1880	 	83890; 83892x3; 83894; 83896; 83897; 83912	 	T-Cell Receptor Gene Rearrangement	 	each	 	[***]*
	1882	 	83890; 83892x3; 83894; 83896; 83897; 83912	 	Immunoglobulin Gene Rearrangement; Heavy -chain JH probe	 	each	 	[***]*
	1884	 	83890; 83892X3; 83894; 83896; 83897; 83912	 	Immunoglobulin Gene Rearrangement; Kappa Light-chain Probe	 	each	 	[***]*
	1888	 	83890; 83892x3; 83894; 83896; 83897; 83912	 	bcl-2 Gene Translocation [SB]	 	each	 	[***]*
	1890	 	83890; 83892x3; 83894; 83896; 83912	 	bcr/abl Gene Rearrangement [SB]	 	each	 	[***]*
	1891	 	82040; 82784x2; 83883	 	IgM (loc) CNS	 	each	 	[***]*
	1896	 	82040; 82784x2; 83883	 	IgA (loc) CNS	 	each	 	[***]*
	1900	 	82172x3	 	Apolipoprotein Evaluation	 	each	 	[***]*
	1901	 	82172	 	Apolipoprotein A-1	 	each	 	[***]*
	1903	 	82172	 	Apolipoprotein B	 	each	 	[***]*
	1905	 	85246; 85247	 	von Willebrand Factor Multimers Panel	 	each	 	[***]*
	1906	 	85247	 	von Willebrand Multimers	 	each	 	[***]*
	1907	 	85246	 	von Willebrand Factor Ag	 	each	 	[***]*
	1911	 	85613	 	Lupus Anticoagulant: DRVVT	 	each	 	[***]*
	1915	 	85597	 	Lupus Anticoagulant: Hexagonal Phase	 	each	 	[***]*
	1916	 	83890; 83892; 83894; 83898; 83912	 	Apo E GenotypR (for all purp except late-onset Alzheimers)	 	each	 	[***]*
	1926	 	83520	 	Myelin-Associated Glycoprotein (MAG) IgM Autoabs	 	each	 	[***]*
	1931	 	82784; 8352x2	 	IgA Subclasses 1 & 2	 	each	 	[***]*
	1938	 	86160	 	Complement Protein Concentration: C5a	 	each	 	[***]*
	1941	 	85210	 	Factor II Activity	 	each	 	[***]*
	1942	 	86161	 	Complement Functional Activity: C2	 	each	 	[***]*
	1943	 	85220	 	Factor V Activity	 	each	 	[***]*
	1944	 	86161	 	Complement Functional Activity: C3	 	each	 	[***]*

10

 

	1945	 	85230	 	Factor VII Activity	 	each	 	[***]*
	1946	 	86161	 	Complement Functional Activity: C4	 	each	 	[***]*
	1947	 	85240	 	Factor VIII Activity	 	each	 	[***]*
	1948	 	86161	 	Complement Functional Activity: C5	 	each	 	[***]*
	1949	 	85250	 	Factor IX Activity	 	each	 	[***]*
	1950	 	86161	 	Complement Functional Activity: C6	 	each	 	[***]*
	1951	 	85260	 	Factor X Activity	 	each	 	[***]*
	1952	 	86161	 	Complement Functional Activity: C7	 	each	 	[***]*
	1953	 	85270	 	Factor XI Activity	 	each	 	[***]*
	1954	 	86161	 	Complement Functional Activity: C8	 	each	 	[***]*
	1955	 	85280	 	Factor XII Activity	 	each	 	[***]*
	1956	 	86161	 	Complement Functional Activity: C9	 	each	 	[***]*
	1957	 	85290	 	Factor XIII Activity Qual w/ relex Quantitation	 	each	 	[***]*
	1959	 	85280	 	Factor XIIa; (Activated)	 	each	 	[***]*
	1960	 	86162	 	Complement: AH50 Total Factor Activity Alternate Pathway	 	each	 	[***]*
	1962	 	86161	 	Complement: Alternate Pathway Function	 	each	 	[***]*
	1964	 	83520	 	Factor IX Ag	 	each	 	[***]*
	1965	 	83520	 	Factor X Ag	 	each	 	[***]*
	1966	 	83890; 83892; 83894; 83898; 83912	 	Factor V Mutation (Leiden)	 	each	 	[***]*
	1967	 	85240; 85335	 	Factor VIII Inactivator	 	each	 	[***]*
	1968	 	83520	 	Complement Split Product Concentration: Factor Bb Fragment	 	each	 	[***]*
	1971	 	84999	 	Tissue Factor	 	each	 	[***]*
	1976	 	86160	 	Complement Protein Concentration: C6	 	each	 	[***]*
	1978	 	86160	 	Complement Protein Concentration: C7	 	each	 	[***]*
	1980	 	86160	 	Complement Protein Concentration: C8	 	each	 	[***]*
	1982	 	86160	 	Complement Protein Concentration: C9	 	each	 	[***]*
	1984	 	86160	 	Complement Protein Concentration: Factor H	 	each	 	[***]*
	1986	 	86160	 	Complement Protein Concentration: Factor I	 	each	 	[***]*
	1988	 	86160	 	Complement Protein Concentration: Properdin	 	each	 	[***]*
	1990	 	86160x2	 	Complement: C4d/C4 Ratio	 	each	 	[***]*
	1992	 	83520	 	Complex	 	each	 	[***]*
	1994	 	83520	 	Complement: C1r:C1s:C1 Inhibitor Complex	 	each	 	[***]*
	1995	 	86329	 	Complement: C4 Binding Protein	 	each	 	[***]*
	1996	 	86161	 	Complement: C3b:Bb:Properdin Complex	 	each	 	[***]*
	1998	 	83520	 	Complement Split Product Concentration: iC3b	 	each	 	[***]*
	2011	 	86631; 86632; 86713x12; 86738x3	 	Atypical Pneumonia Abs Evaluation	 	each	 	[***]*
	2016	 	82627; 83001; 83002; 84144; 84146; 84443	 	Infertility: Endocrine Evaluation (Female)	 	each	 	[***]*
	2017	 	83001; 83002; 84146; 84402; 84403	 	Infertility: Endocrine Evaluation (Male)	 	each	 	[***]*
	2019	 	82627; 82670; 83001; 83002; 84146	 	Anovulatory Evaluation	 	each	 	[***]*

11

 

	2020	 	83001; 83002	 	Follicle-Stimulating Hormone & Luteinizing Hormone Eval	 	each	 	[***]*
	2023	 	82627; 83001; 83002; 84402; 84403	 	Polycystic Ovary Evaluation	 	each	 	[***]*
	2025	 	82627; 84146; 84403; 84443	 	Recurrent Spontaneous Abortion: Endocrine Evaluation	 	each	 	[***]*
	2026	 	86812x2; 86816x2; 88180	 	Recurrent Spontaneous Abortion: Immunology Evaluation	 	each	 	[***]*
	2027	 	86631x3; 87109; 87490	 	Recurrent Spontaneous Abortion: Infectious Disease Evaluation	 	each	 	[***]*
	2028	 	85613; 86147x3; 86143x3	 	Recurrent Spontaneous Abortion: Autoimmune Evaluation	 	each	 	[***]*
	2030	 	86635x3	 	Coccidioides Total Abs Evaluation	 	each	 	[***]*
	2034	 	87109; 87490; 87590	 	Sexually Transmitted Disease Agents	 	each	 	[***]*
	2050	 	82040; 82784x2; 83883; 86762x2; 86765x3; 86787x2	 	MRZ Reaction Evaluation	 	each	 	[***]*
	2101	 	86256	 	Antibody-coated Bacteria	 	each	 	[***]*
	2102	 	86781	 	Treponema pallidum IgM Abs; FTA	 	each	 	[***]*
	2104	 	86781	 	Treponema pallidum Total Abs; FTA	 	each	 	[***]*
	2106	 	87299	 	Cytomegalovirus Immediate-early Ag Whole Blood	 	each	 	[***]*
	2116	 	86665	 	Epstein-Barr Virus Viral Capsid Ag (VCA) IgG Abs	 	each	 	[***]*
	2121	 	86665	 	Epstein-Barr Virus Viral Capsid Ag (VCA) IgM Abs	 	each	 	[***]*
	2122	 	86665x2	 	Abs	 	each	 	[***]*
	2126	 	86663	 	Epstein-Barr Virus Early Ag (EA) IgG Abs; diff/rest patterns	 	each	 	[***]*
	2131	 	86663	 	Epstein-Barr Virus Early Ag (EA) IgA Abs	 	each	 	[***]*
	2136	 	86753	 	Babesia microti IgG Abs	 	each	 	[***]*
	2141	 	86753	 	Babesia microti IgM Abs	 	each	 	[***]*
	2146	 	87207	 	Babesia spp. Organism Detection	 	each	 	[***]*
	2151	 	86753x2; 87207	 	Babesiosis Evaluation	 	each	 	[***]*
	2152	 	86713x4	 	Legionella Non-Pneumophila IgG & IgM Abs	 	each	 	[***]*
	2153	 	86713x28	 	Legionella pneumophila IgG & IgM Abs; Serotypes 1-14	 	each	 	[***]*
	2154	 	86713x14	 	Legionella pneumophila IgG Abs; Serotypes 1-14	 	each	 	[***]*
	2156	 	86713x12	 	Legionella pneumophila IgG & IgM Abs; Serotypes 1-6	 	each	 	[***]*
	2159	 	86713x14	 	Legionella pneumophila IgM Abs; Serotypes 1-14	 	each	 	[***]*
	2161	 	86753x2	 	Babesia microti IgG & IgM Abs	 	each	 	[***]*
	2199	 	87290	 	Varicella-zoster Virus Ag Detection	 	each	 	[***]*
	2211	 	86663; 86664; 86665x2	 	Epstein-Barr Virus Evaluation	 	each	 	[***]*

12

  

	2231	 	86645;86694; 86695; 86762; 86778	 	TORCH IgM Abs Evaluation	 	each	 	[***]*
	2261	 	86777x2; 86778x2	 	Toxoplasma Antibody Evaluation	 	each	 	[***]*
	2266	 	86664	 	Epstein-Barr Virus Nuclear Ag (EBNA) IgG Abs	 	each	 	[***]*
	2271	 	86664	 	Epstein-Barr Virus Nuclear Ag (EBNA) IgM Abs	 	each	 	[***]*
	2316	 	86606x2	 	Aspergillus Evaluation	 	each	 	[***]*
	2321	 	86609	 	Teichoic Acid Abs	 	each	 	[***]*
	2326	 	866606	 	Aspergillus Abs [DD]	 	each	 	[***]*
	2328	 	86612	 	Blastomyces Total Abs [DD]	 	each	 	[***]*
	2330	 	86628	 	Candida albicans Total Abs	 	each	 	[***]*
	2332	 	86635	 	Coccidioides Total Abs [DD]	 	each	 	[***]*
	2334	 	86698x2	 	Histoplasma Abs [DD]	 	each	 	[***]*
	2343	 	86628x3	 	Candida albicans Evaluation without Ag	 	each	 	[***]*
	2344	 	86628x3; 87449	 	Candida albicans Evaluation	 	each	 	[***]*
	2346	 	86628	 	Candida albicans Abs-Titer	 	each	 	[***]*
	2351	 	86215	 	Antideoxyribonuclease-B Abs	 	each	 	[***]*
	2360	 	87207	 	Filaria Organism Detection	 	each	 	[***]*
	2361	 	87177	 	Ova & Parasite: Routine Exam	 	each	 	[***]*
	2362	 	87177; 88313	 	Ova & Parasite: Comprehensive Exam w/ Coccidia Evaluation	 	each	 	[***]*
	2363	 	87206; 88313	 	Ova & Parasite: Coccidia Evaluation	 	each	 	[***]*
	2364	 	86592	 	Rapid Plasma Reagin [RPR]	 	each	 	[***]*
	2366	 	86592	 	VDRL	 	each	 	[***]*
	2367	 	87208	 	Ova & Parasite: Arthropod Identification	 	each	 	[***]*
	2368	 	87208	 	Ova & Parasite: Worm Identification	 	each	 	[***]*
	2370	 	86609x4	 	Streptococcus pneumoniae IgG Abs; 4 Serotypes	 	each	 	[***]*
	2376	 	86060	 	Antistreptolysin O Abs (ASO)	 	each	 	[***]*
	2381	 	87449	 	Escherichia coli K1 / N. meningitidis Type B Ag	 	each	 	[***]*
	2386	 	866609x12	 	Streptococcus pneumoniae IgG Abs; 12 Serotypes	 	each	 	[***]*
	2398	 	87070; 87166	 	Leptospira Culture & Darkfield Microscopy	 	each	 	[***]*
	2399	 	87109	 	Mycoplasma Hominis Culture	 	each	 	[***]*
	2400	 	87110	 	Chlamydia trachomatis Culture	 	each	 	[***]*
	2401	 	87110	 	Chlamydia pneumoniae Culture	 	each	 	[***]*
	2402	 	87252	 	Herpes Simplex Virus Types 1 & 2 Culture	 	each	 	[***]*
	2403	 	87081	 	Helicobacter pylori Culture	 	each	 	[***]*
	2404	 	87070	 	Legionella spp. Culture	 	each	 	[***]*
	2406	 	87109	 	Mycoplasma pneumoniae Culture	 	each	 	[***]*
	2407	 	87070	 	Corynebacterium diphtheriae Culture	 	each	 	[***]*
	2408	 	87109	 	Culture	 	each	 	[***]*
	2410	 	87252	 	Viral Culture	 	each	 	[***]*
	2411	 	87075	 	Clostridium difficile Culture	 	each	 	[***]*
	2412	 	87230	 	Clostridium difficile Toxin B Detection	 	each	 	[***]*
	2413	 	87040	 	Bartonella spp. Culture	 	each	 	[***]*
	2414	 	87081	 	Neisseria gonorrhoeae Culture	 	each	 	[***]*
	2415	 	87040	 	Borrelia spp. Culture	 	each	 	[***]*
	2416	 	87081x2	 	Bordetella pertussis/parapertussis Culture	 	each	 	[***]*

12

 

	2417	 	87117x2	 	AFB Culture	 	each	 	[***]*
	2418	 	87252	 	Cytomegalovirus Culture	 	each	 	[***]*
	2419	 	87117x2; 87206	 	AFB Culture & Stain	 	each	 	[***]*
	2421	 	87299	 	Cytomegalovirus Ag Detection	 	each	 	[***]*
	2422	 	87278	 	Legionella pneumophila Ag Detection	 	each	 	[***]*
	2423	 	87276; 87299	 	Influenza Virus; Types A & B Detection	 	each	 	[***]*
	2424	 	87299x3	 	Parainfluenza Virus Types 1-3 Detection	 	each	 	[***]*
	2425	 	87260; 87276; 87280; 87299x4	 	Respiratory Infection Evaluation; Viral	 	each	 	[***]*
	2426	 	87274	 	Herpes Simplex Virus Types 1 & 2 Ag Detection [DFA]	 	each	 	[***]*
	2428	 	87265x2	 	Bordetella pertussis/parapertussis Ag Detection	 	each	 	[***]*
	2430	 	87081x2; 87265x2	 	Bordetella pertussis/parapertussis Evaluation	 	each	 	[***]*
	2432	 	87070; 87278	 	Legionella pneumophila Evaluation	 	each	 	[***]*
	2433	 	87081	 	Streptococcus; Beta Group B Culture Screen	 	each	 	[***]*
	2434	 	87070	 	Acanthamoeba Culture	 	each	 	[***]*
	2436	 	86609	 	Toxic Shock Syndrome Abs	 	each	 	[***]*
	2437	 	87174	 	Toxic Shock Syndrome Evaluation	 	each	 	[***]*
	2438	 	87205	 	Gram Stain	 	each	 	[***]*
	2439	 	87328	 	Cryptosporidium Ag Detection	 	each	 	[***]*
	2440	 	87270	 	Chlamydia trachomatis Ag Detection [DFA]	 	each	 	[***]*
	2442	 	87301; 87425	 	Viral Diarrhea Ag Detection	 	each	 	[***]*
	2443	 	87338	 	Helicobacter pylori Specific Ag	 	each	 	[***]*
	2444	 	87301	 	Adenovirus Enteric Types 40/41 Ag Detection	 	each	 	[***]*
	2445	 	86803	 	Hepatitis C Virus IgG Abs w/ reflex RIBA	 	each	 	[***]*
	2446	 	86803	 	Hepatitis C Virus IgG Abs	 	each	 	[***]*
	2447	 	86804	 	Hepatitis C Virus Abs RIBA Confirmation	 	each	 	[***]*
	2448	 	86706	 	Hepatitis B Virus Surface Ab Quantitation	 	each	 	[***]*
	2449	 	87340	 	Hepatitis B Virus Surface Ag Neutralization	 	each	 	[***]*
	2450	 	86708	 	Hepatitis A Virus Total Abs	 	each	 	[***]*
	2451	 	86709	 	Hepatitis A Virus IgM Abs	 	each	 	[***]*
	2452	 	86704	 	Hepatitis B Virus Core Total Abs	 	each	 	[***]*
	2453	 	86706	 	Hepatitis B Virus Surface Total Abs	 	each	 	[***]*
	2454	 	87340	 	Hepatitis B Virus Surface Ag	 	each	 	[***]*
	2455	 	86707	 	Hepatitis Be Virus Total Abs	 	each	 	[***]*
	2456	 	87350	 	Hepatitis Be Virus Ag	 	each	 	[***]*
	2457	 	86705	 	Hepatitis B Virus Core IgM Abs	 	each	 	[***]*
	2458	 	86692	 	Hepatitis Delta Virus Total Abs	 	each	 	[***]*
	2459	 	86692	 	Hepatitis Delta Virus IgM Abs	 	each	 	[***]*
	2460	 	86708	 	Hepatitis A Virus Total & IgM Abs	 	each	 	[***]*
	2461	 	86704; 86706; 87340	 	Hepatitis B Virus Evaluation	 	each	 	[***]*
	2462	 	86707; 87350	 	Hepatitis Be Virus Antigen/Antibody Evaluation	 	each	 	[***]*
	2463	 	86704; 86706; 86707; 86708; 87340; 87350	 	Hepatitis A & B Virus Evaluation	 	each	 	[***]*
	2464	 	86704; 80074; 86706; 86708	 	Hepatitis A; B; & C Virus Evaluation	 	each	 	[***]*
	2465	 	86692x2	 	Hepatitis Delta Virus Total & IgM Abs	 	each	 	[***]*
	2466	 	86790x2	 	Hepatitis E IgG & IgM Evaluation	 	each	 	[***]*

13

 

	2467	 	86790	 	Hepatitis E IgG	 	each	 	[***]*
	2468	 	87526	 	Hepatitis G Virus RNA DetectR	 	each	 	[***]*
	2469	 	86790	 	Hepatitis E IgM	 	each	 	[***]*
	2470	 	87340	 	Hepatitis B Virus Surface Ag without confirmation	 	each	 	[***]*
	2472	 	87425	 	Rotavirus Ag Detection	 	each	 	[***]*
	2473	 	87272	 	Giardia/Cryptosporidium Ag Detection [DFA]	 	each	 	[***]*
	2475	 	86762	 	Rubella IgM Abs	 	each	 	[***]*
	2476	 	86704	 	Hepatitis B Virus Core Total Abs w/reflex IgM	 	each	 	[***]*
	2486	 	86645	 	Cytomegalovirus IgM Abs	 	each	 	[***]*
	2490	 	84182	 	Creutzfeldt-Jakob Disease DetectR	 	each	 	[***]*
	2491	 	86793	 	Yersinia enterocolitica IgG Abs	 	each	 	[***]*
	2496	 	86793	 	Yersinia enterocolitica IgM Abs	 	each	 	[***]*
	2501	 	86603	 	Adenovirus Abs	 	each	 	[***]*
	2504	 	87070	 	Legionella Culture: Environmental	 	each	 	[***]*
	2506	 	86606	 	Aspergillus Total Abs [CF]	 	each	 	[***]*
	2509	 	87260	 	Adenovirus Ag Detection	 	each	 	[***]*
	2511	 	86612	 	Blastomyces Total Abs [CF]	 	each	 	[***]*
	2516	 	86609	 	Neisseria gonorrhoeae Abs	 	each	 	[***]*
	2521	 	86631	 	Chlamydia spp. Total Abs [CF]	 	each	 	[***]*
	2526	 	86635	 	Coccidioides Total Abs [CF]	 	each	 	[***]*
	2536	 	86658x4	 	Coxsackievirus A Abs; Serotypes 7; 9; 10; 16	 	each	 	[***]*
	2541	 	86658x6	 	Coxsackievirus B Abs; Serotypes 1-6	 	each	 	[***]*
	2546	 	86658x10	 	Coxsackievirus A & B Abs Evaluation	 	each	 	[***]*
	2551	 	86644	 	Cytomegalovirus Total Abs	 	each	 	[***]*
	2566	 	86658x4	 	Echovirus Abs; Serotypes 4; 9; 11 & 30	 	each	 	[***]*
	2571	 	86694	 	Herpes Simplex Virus Total Abs [CF]	 	each	 	[***]*
	2581	 	86698x2	 	Histoplasma Abs [CF]	 	each	 	[***]*
	2586	 	86710	 	Influenza Virus Abs; Type A	 	each	 	[***]*
	2591	 	86710	 	Influenza Virus Abs; Type B	 	each	 	[***]*
	2594	 	83901x2; 83912	 	Influenza A & B MultiplexR	 	each	 	[***]*
	2601	 	86727	 	Lymphocytic Choriomeningitis Abs	 	each	 	[***]*
	2606	 	86729	 	Lymphogranuloma Venereum Abs	 	each	 	[***]*
	2621	 	86790x3	 	Parainfluenza Virus Types 1-3 Abs	 	each	 	[***]*
	2626	 	86658x3	 	Poliovirus Abs Serotypes 1-3	 	each	 	[***]*
	2631	 	86631	 	Chlamydia spp. Total Abs	 	each	 	[***]*
	2641	 	86790	 	Reovirus Abs	 	each	 	[***]*
	2646	 	86756	 	Respiratory Syncytial Virus Total Abs	 	each	 	[***]*
	2650	 	87798	 	Enterovirus RNA DetectR [PCR]	 	each	 	[***]*
	2651	 	87798	 	Enterovirus RNA DetectR reflex to Speciation	 	each	 	[***]*
	2654	 	87798	 	Flavivirus Rna DetectR	 	each	 	[***]*
	2655	 	87798	 	Flavivirus DetectR Reflex to Speciation	 	each	 	[***]*
	2676	 	86790	 	Polyomavirus Abs	 	each	 	[***]*
	2701	 	86603; 86631; 86710x2; 86738; 86790x3	 	Respiratory Infection Abs; Adult	 	each	 	[***]*
	2704	 	87280	 	Respiratory Syncytial Virus Detection [DFA]	 	each	 	[***]*
	2711	 	86603; 86631; 86710x2; 86738; 86756; 86790x3	 	Respiratory Infection Abs; Child/Infant	 	each	 	[***]*

14

 

	2726	 	86694; 86727; 86735x2; 86765x2; 86787x2	 	Encephalitis Virul Abs	 	each	 	[***]*
	2731	 	86606; 86612; 86635; 86698x2	 	Fungal Abs [CF]	 	each	 	[***]*
	2741	 	86710x2	 	Influenza Virus Abs; Types A & B	 	each	 	[***]*
	2746	 	86658x17	 	Paralytic Viral Ab Evaluation	 	each	 	[***]*
	2771	 	86603; 86644; 86651; 86652; 86653; 86654; 86658x14; 86694; 86710x2; 86727; 86735x2; 86765x2; 86787x2	 	Meningoencephalomyelitis Viral Ab Evaluation	 	each	 	[***]*
	2780	 	86612; 86635; 86698x2	 	Fungal Antibody Panel: Invasive	 	each	 	[***]*
	2785	 	86606; 86635; 86641; 86698x2; 87449	 	Fungal Antibody Panel: Opportunistic	 	each	 	[***]*
	2790	 	86612; 86635; 86641; 86698x2; 87449	 	Fungal Antibody Panel: Systemic	 	each	 	[***]*
	2871	 	86317; 86622; 86632; 86645; 86668; 86778	 	Lymphadenopathy; Infectious IgM Abs Evaluation	 	each	 	[***]*
	2920	 	87541	 	Legionella pneumophila DNA DetectR	 	each	 	[***]*
	2922	 	87486	 	Chlamydia pneumoniae DNA DetectR	 	each	 	[***]*
	2924	 	87581	 	Mycoplasma pneumoniae DNA DetectR	 	each	 	[***]*
	2925	 	87490	 	Chlamydia trachomatis Detection rRNA	 	each	 	[***]*
	2927	 	87490; 87590	 	rRNA	 	each	 	[***]*
	2928	 	87486; 87541; 87581	 	Atypical Pneumonia DNA DetectR	 	each	 	[***]*
	2929	 	87798x3	 	Mycoplasma MultiplexR	 	each	 	[***]*
	2930	 	87590	 	Neisseria gonorrhoeae Detection rRNA	 	each	 	[***]*
	2932	 	87591	 	Neisseria gonorrhoeae DNA LCR	 	each	 	[***]*
	2934	 	84999x2; 87798	 	Staph Resist MultipleXR	 	each	 	[***]*
	2935	 	87555; 87560	 	AFB Identification Mycobacterium spp. rRNA	 	each	 	[***]*
	2940	 	87106	 	Fungus Identification; rRNA	 	each	 	[***]*
	2941	 	87205	 	Fungus Stain	 	each	 	[***]*
	2945	 	87207	 	Malaria Organism Detection	 	each	 	[***]*
	2948	 	87207	 	Giemsa Stain	 	each	 	[***]*
	2950	 	87072	 	Bacterial Identification; Aerobic Organism ID	 	each	 	[***]*
	2955	 	87070	 	Haemophilus ducreyi Culture	 	each	 	[***]*
	2960	 	87205	 	Fecal Leukocytes	 	each	 	[***]*
	3012	 	86689	 	HIV-1 Abs Confirmation Immunoblot	 	each	 	[***]*
	3015	 	86689x2	 	HIV-1 & 2 IgG Abs Confirmation [IB]	 	each	 	[***]*
	3017	 	84275; 86316	 	Uterine Cancer Monitor	 	each	 	[***]*
	3020	 	82607; 82746	 	Vitamin B12 (Cyanocobalamin) & Folate	 	each	 	[***]*
	3021	 	86689	 	HIV-1 Abs Confirmation Immunoblot Plus Conf HIV-2 Abs IB	 	each	 	[***]*
	3024	 	82378; 86316	 	Colorectal Cancer Monitor	 	each	 	[***]*
	3028	 	82105; 84702	 	Alpha-Fetoprotein & Human Chorionic Gonadotropin	 	each	 	[***]*
	3030	 	82550; 84066; 84153	 	ProstAsure	 	each	 	[***]*
	3032	 	84066; 84153	 	Prostate Cancer Monitor	 	each	 	[***]*
	3051	 	88342; 88358	 	Micrometastases DetectrR	 	each	 	[***]*

15

 

	3060	 	83519; 84443; 84445x2; 86376; 86800	 	Thyroid Autoabs Evaluation	 	each	 	[***]*
	3062	 	86376	 	Thyroid Peroxidase Autoabs	 	each	 	[***]*
	3066	 	86341	 	Islet Cell Autoantibodies; Complement Fixing	 	each	 	[***]*
	3069	 	86341x2	 	Islet Cell Autoabs Evaluation	 	each	 	[***]*
	3070	 	82570; 83497; 84260x2	 	Carcinoid Evaluation	 	each	 	[***]*
	3072	 	84439; 84443; 84480	 	Thyroid Panel; Hyperthyroidism	 	each	 	[***]*
	3074	 	84439; 84443	 	Thyroid Panel; Hypothyroidism [MEIA/ICMA]	 	each	 	[***]*
	3076	 	84439; 84443	 	Thyroid Screen	 	each	 	[***]*
	3080	 	83520; 85048; 86361	 	HIV-1 Immune Status Monitor	 	each	 	[***]*
	3090	 	82105	 	Alpha-Fetoprotein—Maternal; 2.5 Mom	 	each	 	[***]*
	3091	 	82105; 82677; 84702	 	Screen)	 	each	 	[***]*
	3092	 	82105; 82677; 84702	 	Alpha-Fetoprotein Quad Screen; 2.5 Mom (incl. Inhibin s/o @ $25)	 	each	 	[***]*
	3100	 	84066	 	Prostatic Acid Phosphatase	 	each	 	[***]*
	3102	 	82024	 	Adrenocorticotropic Hormone	 	each	 	[***]*
	3104	 	82088	 	Aldosterone	 	each	 	[***]*
	3106	 	82154	 	Androstanediol Glucuronide	 	each	 	[***]*
	3108	 	82105	 	Alpha-Fetoprotein—Maternal; Serum	 	each	 	[***]*
	3109	 	82105	 	Alpha-Fetoprotein—Tumor Marker	 	each	 	[***]*
	3110	 	82105; 82677; 84702	 	Screen)	 	each	 	[***]*
	3111	 	82106	 	Alpha-Fetoprotein—Prenatal; Amniotic Fluid	 	each	 	[***]*
	3112	 	82157	 	Androstenedione	 	each	 	[***]*
	3114	 	82164	 	Angiotensin Converting Enzyme	 	each	 	[***]*
	3116	 	84588	 	Antidiuretic Hormone	 	each	 	[***]*
	3119	 	86316	 	CA 15-3	 	each	 	[***]*
	3120	 	86316	 	CA 19-9	 	each	 	[***]*
	3121	 	86316	 	CA 125 [MEIA]	 	each	 	[***]*
	3123	 	82480	 	Cholinesterase Serum	 	each	 	[***]*
	3124	 	82634	 	11-Deoxycortisol	 	each	 	[***]*
	3125	 	86334	 	Monoclonal Gammapathies; Serum	 	each	 	[***]*
	3126	 	82308	 	Calcitonin	 	each	 	[***]*
	3127	 	84379	 	Disaccharidases	 	each	 	[***]*
	3128	 	82533	 	Cortisol	 	each	 	[***]*
	3131	 	84311	 	Adenosine Deaminase	 	each	 	[***]*
	3134	 	86316	 	CA27.29	 	each	 	[***]*
	3136	 	82533	 	Cortisol Plasma [HPLC]	 	each	 	[***]*
	3140	 	84681	 	C-Peptide	 	each	 	[***]*
	3143	 	82232	 	Beta-2-Microglobulin	 	each	 	[***]*
	3146	 	82626	 	Dehydroepiandrosterone	 	each	 	[***]*
	3150	 	82627	 	Dehydroepiandrosterone-Sulfate	 	each	 	[***]*
	3154	 	82679	 	Estrone	 	each	 	[***]*
	3155	 	82670	 	Estradiol	 	each	 	[***]*
	3156	 	82677	 	Estriol; Unconjugated	 	each	 	[***]*
	3158	 	82677	 	Estriol; Total	 	each	 	[***]*
	3163	 	84144	 	Progesterone	 	each	 	[***]*
	3164	 	82672	 	Estrogens; Total	 	each	 	[***]*
	3166	 	82671	 	Estrogens; Fractionated	 	each	 	[***]*
	3170	 	82728	 	Ferritin	 	each	 	[***]*

16

 

	3172	 	82728; 86316	 	Neuroblastoma Monitor	 	each	 	[***]*
	3174	 	83001	 	Follicle-Stimulating Hormone	 	each	 	[***]*
	3176	 	82941	 	Gastrin	 	each	 	[***]*
	3181	 	82985	 	Glycosylated Albumin	 	each	 	[***]*
	3182	 	83003	 	Growth Hormone	 	each	 	[***]*
	3184	 	84702	 	Human Chorionic Ganadotropin	 	each	 	[***]*
	3186	 	83632	 	Human Placental Lactogen	 	each	 	[***]*
	3187	 	84702	 	Beta-hCG Pregnancy	 	each	 	[***]*
	3188	 	82154; 82627; 83498; 84402; 84403	 	Hirsutism Evaluation; Female	 	each	 	[***]*
	3190	 	83498	 	17-Hydroxyprogesterone	 	each	 	[***]*
	3192	 	83525	 	Insulin	 	each	 	[***]*
	3193	 	83525; 83527	 	Insulin; Free and Bound	 	each	 	[***]*
	3196	 	86340	 	Intrinsic Factor Blocking Autoabs	 	each	 	[***]*
	3198	 	83002	 	Luteinizing Hormone	 	each	 	[***]*
	3204	 	83930	 	Osmolality Serum	 	each	 	[***]*
	3206	 	84146	 	Prolactin	 	each	 	[***]*
	3208	 	82310; 82330; 83970	 	PTH; C Terminal; including Ionized & Total Calcium	 	each	 	[***]*
	3209	 	83970	 	PTH; Mid-Molecule only	 	each	 	[***]*
	3210	 	82310; 82330; 83970	 	PTH; Mid-Molecule; including Ionized & Total Calcium	 	each	 	[***]*
	3211	 	82310; 82330; 83970x2	 	PTH; Mid-Molecule & Intact; incl. Ionized & Total Calcium	 	each	 	[***]*
	3213	 	82310; 82330; 83970x2	 	PTH; C Terminal & Intact including Ionized & Total Calcium	 	each	 	[***]*
	3214	 	84244	 	Renin Activity Plasma	 	each	 	[***]*
	3218	 	84270	 	Sex Hormone Binding Globulin	 	each	 	[***]*
	3220	 	84305	 	Insulin-like Growth Factor 1	 	each	 	[***]*
	3222	 	84307	 	Somatostatin	 	each	 	[***]*
	3224	 	84480	 	Triiodothyronine (T3)	 	each	 	[***]*
	3225	 	84480; 84481	 	T3 Free; Tracer Dialysis	 	each	 	[***]*
	3226	 	84436	 	Thyroxine (T4)	 	each	 	[***]*
	3228	 	84439	 	Thyroxine; Free	 	each	 	[***]*
	3232	 	84479	 	T Uptake	 	each	 	[***]*
	3234	 	84481	 	Triiodothyronine; Free	 	each	 	[***]*
	3236	 	84482	 	Reverse Triidothyronine (RT3)	 	each	 	[***]*
	3238	 	84442	 	Thyroxine Binding Globulin	 	each	 	[***]*
	3240	 	83519; 86235x7	 	Myositis AssessR	 	each	 	[***]*
	3241	 	83519	 	Mi-2 Autoantibodies	 	each	 	[***]*
	3242	 	83519; 86235x8	 	Myositis AssessR Plus Jo-1 Autoantibodies	 	each	 	[***]*
	3244	 	84403	 	Testosterone; Total	 	each	 	[***]*
	3247	 	84402	 	Testosterone; Free	 	each	 	[***]*
	3248	 	84402; 84403	 	Testosterone; Free & Total	 	each	 	[***]*
	3250	 	84443	 	Thyroid Stimulating Hormone; 3rd Generation	 	each	 	[***]*
	3251	 	84432; 86800	 	Thyroglobulin	 	each	 	[***]*
	3252	 	84586	 	Vasoactive Intestinal Peptide	 	each	 	[***]*
	3253	 	85301	 	Antithrombin III Plasma Ag	 	each	 	[***]*
	3254	 	82378; 86316	 	Small-cell Carcinoma Monitor; Lung	 	each	 	[***]*
	3255	 	84432	 	Thyroglobulin Serum	 	each	 	[***]*

17

 

	3258	 	82378	 	Carinoembryonic Ag [CEA]	 	each	 	[***]*
	3261	 	82088; 84132; 84244	 	Hyperaldosteronism Evaluation	 	each	 	[***]*
	3262	 	82382; 82570; 83835	 	Pheochromocytoma Evaluation	 	each	 	[***]*
	3264	 	82024; 82533	 	Hypertension IV: Cushing Syndrome Evaluation	 	each	 	[***]*
	3265	 	82088; 82157; 82533; 82634;83498; 84402; 84403	 	Congenital Adrenal Hyperplasia Evaluation	 	each	 	[***]*
	3270	 	82383	 	Epinephrine Plasma	 	each	 	[***]*
	3272	 	84202	 	Erythrocyte Protoporphyrin	 	each	 	[***]*
	3275	 	84202	 	Zinc Protoporphyrin	 	each	 	[***]*
	3280	 	85410	 	Alpha-2-Antiplasmin	 	each	 	[***]*
	3282	 	83520	 	Neopterin	 	each	 	[***]*
	3286	 	84260	 	5-Hydroxytryptamine [Serotonin]	 	each	 	[***]*
	3288	 	85415	 	Tissue Plasminogen Activator Ag	 	each	 	[***]*
	3290	 	83520	 	Interferon-alpha	 	each	 	[***]*
	3292	 	83520	 	Interferon-gamma	 	each	 	[***]*
	3294	 	82397	 	Tumor Necrosis Factor-alpha Plasma	 	each	 	[***]*
	3295	 	83520	 	Interferon-Beta Autoabs (Anti-Interferon-B)	 	each	 	[***]*
	3296	 	85420	 	Tissue Plasminogen Activator Inhibitor	 	each	 	[***]*
	3297	 	83520	 	Interferon-Beta 1A IgG Autoantibodies	 	each	 	[***]*
	3298	 	85384; 85415; 85420x2	 	Thrombotic Risk Evaluation 4	 	each	 	[***]*
	3304	 	82384	 	Catecholamines; Fractionated Plasma	 	each	 	[***]*
	3310	 	82570; 83497	 	5-Hydroxyindoleacetic Acid 24hr Urine	 	each	 	[***]*
	3315	 	82570; 83835	 	Metanephrines; Fractionated 24hr Urine	 	each	 	[***]*
	3316	 	82570; 83835	 	Metanephrines; Total 24hr Urine	 	each	 	[***]*
	3319	 	84585	 	Vanillylmandelic Acid—Pediatric	 	each	 	[***]*
	3320	 	82975	 	L-Glutamine CSF	 	each	 	[***]*
	3334	 	82131	 	Homocyst(e)ine UltraQuant	 	each	 	[***]*
	3346	 	84478	 	Triglycerides	 	each	 	[***]*
	3350	 	82465	 	Cholesterol; Total	 	each	 	[***]*
	3351	 	83721	 	Direct LDL Cholesterol	 	each	 	[***]*
	3352	 	83718	 	Cholesterol HDL	 	each	 	[***]*
	3354	 	83088	 	Histamine	 	each	 	[***]*
	3356	 	86280	 	Isohemagglutinin Titer	 	each	 	[***]*
	3360	 	80164	 	Valproic Acid	 	each	 	[***]*
	3361	 	80299	 	Valproic Acid Free	 	each	 	[***]*
	3364	 	80299	 	Gabapentin	 	each	 	[***]*
	3369	 	83690	 	Lipase	 	each	 	[***]*
	3371	 	86147x3	 	Cardiolipin IgG; IgM & IgA Autoabs	 	each	 	[***]*
	3372	 	86147	 	Cardiolipin IgG Autoabs	 	each	 	[***]*
	3373	 	86147	 	Cardiolipin IgM Autoabs	 	each	 	[***]*
	3374	 	86147	 	Cardiolipin IgA Autoabs	 	each	 	[***]*
	3390	 	84484	 	Troponin (I&T) DetectR	 	each	 	[***]*
	3392	 	84484	 	Troponin T	 	each	 	[***]*
	3393	 	84484	 	Troponin I	 	each	 	[***]*
	3420	 	86717	 	Leishmania IgG Abs	 	each	 	[***]*
	3441	 	82042; 82043	 	Microalbumin; 24Hr Urine	 	each	 	[***]*
	3442	 	82043; 82570	 	Microalbumin Random Urine	 	each	 	[***]*
	3445	 	83715	 	Lipoprotein Electrophoresis	 	each	 	[***]*
	3446	 	82172	 	Lipoprotein (a)	 	each	 	[***]*

18

 

	3452	 	83615	 	Lactate Dehydrogenase	 	each	 	[***]*
	3453	 	83625	 	Lactate Dehydrogenase (LD) Isoenzymes	 	each	 	[***]*
	3454	 	80061	 	Cholesterol Evaluation	 	each	 	[***]*
	3460	 	83520	 	Tryptase	 	each	 	[***]*
	3462	 	83520	 	Immunoreactive Trypsin	 	each	 	[***]*
	3492	 	82131	 	2-Methylcitric Acid	 	each	 	[***]*
	3494	 	82131	 	Cystathionine	 	each	 	[***]*
	3496	 	83918	 	Methylmalonic Acid	 	each	 	[***]*
	3500	 	84252	 	Vitamin B2 (Riboflavin) Functional Assessment	 	each	 	[***]*
	3502	 	84590	 	Vitamin A	 	each	 	[***]*
	3504	 	82607	 	Vitamin B12 (Cyanocobalamin)	 	each	 	[***]*
	3505	 	84207	 	Pyridoxal Phosphate (Vitamin B6)	 	each	 	[***]*
	3508	 	82180	 	Vitamin C (Ascorbic Acid)	 	each	 	[***]*
	3515	 	84425	 	Vitamin B1	 	each	 	[***]*
	3518	 	84311	 	Vitamin B1 Functional Assessment	 	each	 	[***]*
	3519	 	84311; 84425	 	Vitamin B1 & Transketolase	 	each	 	[***]*
	3520	 	82652	 	Vitamin D; 1; 25-Dihydroxy (Calcifidol)	 	each	 	[***]*
	3521	 	82306	 	Vitamin D; 25-Hydroxy (Calciferol)	 	each	 	[***]*
	3522	 	82746	 	Folate	 	each	 	[***]*
	3530	 	84446	 	Vitamin E	 	each	 	[***]*
	3532	 	83540	 	Iron	 	each	 	[***]*
	3534	 	83540; 83550	 	Iron Binding Capacity & % Saturation	 	each	 	[***]*
	3535	 	82728; 83520; 83540; 83550	 	Iron Status MonitR	 	each	 	[***]*
	3536	 	83540	 	Iron Liver Tissue	 	each	 	[***]*
	3546	 	84153	 	Prostate-Specific Ag	 	each	 	[***]*
	3547	 	84153; 84154	 	Prostate-Specific Antigen; Free & Total	 	each	 	[***]*
	3550	 	83937	 	Osteocalcin	 	each	 	[***]*
	3554	 	82247	 	Bilirubin; Total	 	each	 	[***]*
	3556	 	83520	 	Elastase Abs	 	each	 	[***]*
	3560	 	84311	 	Antioxidant AssessR	 	each	 	[***]*
	3562	 	82180; 83735; 84255; 84446; 84590; 84630	 	Antioxidant Index, Blood	 	each	 	[***]*
	3565	 	82978	 	Glutathione Peroxidase	 	each	 	[***]*
	3575	 	84311	 	Beta-Hydroxybutrate	 	each	 	[***]*
	3587	 	82784; 83883x2	 	IgG Subclasses 2 & 4	 	each	 	[***]*
	3616	 	82943	 	Glucagon	 	each	 	[***]*
	3624	 	85130	 	Endotoxin Plasma	 	each	 	[***]*
	3700	 	86003x4	 	RAST Food—Pediatric Panel	 	each	 	[***]*
	3701	 	82785; 86003x4	 	RAST Food—Pediatric Panel + Total IgE	 	each	 	[***]*
	3702	 	86003x10	 	RAST Food Panel	 	each	 	[***]*
	3703	 	82785; 86003x10	 	RAST Food Panel + Total IgE	 	each	 	[***]*
	3704	 	86003x6	 	RAST Mold Panel	 	each	 	[***]*
	3705	 	82785; 86003x6	 	RAST Mold Panel + Total IgE	 	each	 	[***]*
	3710	 	86003x10	 	RAST Southern California Panel	 	each	 	[***]*
	3711	 	82785; 86003x10	 	RAST Southern California Panel + Total IgE	 	each	 	[***]*
	3712	 	86003x10	 	RAST Northern California Panel	 	each	 	[***]*
	3713	 	82785; 86003x10	 	RAST Nothern California Panel + Total IgE	 	each	 	[***]*
	3714	 	86003x10	 	RAST Southwest Panel	 	each	 	[***]*
	3715	 	82785; 86003x10	 	RAST Southwest Panel + Total IgE	 	each	 	[***]*

19

 

	3716	 	86003x10	 	RAST Midwest Panel	 	each	 	[***]*
	3717	 	82785; 86003x10	 	RAST Midwest Panel + Total IgE	 	each	 	[***]*
	3718	 	86003x10	 	RAST Northeast Panel	 	each	 	[***]*
	3719	 	82785; 86003x10	 	RAST Northeast Panel + Total IgE	 	each	 	[***]*
	3720	 	86003x10	 	RAST Southeast Panel	 	each	 	[***]*
	3721	 	82785; 86003x10	 	RAST Southeast Panel + Total IgE	 	each	 	[***]*
	3722	 	86003x12	 	RAST West Coast Panel	 	each	 	[***]*
	3723	 	82785; 86003x12	 	RAST West Coast Panel + Total IgE	 	each	 	[***]*
	3745	 	86003	 	RAST—Phadiatop	 	each	 	[***]*
	3812	 	83520	 	Interleukin-12	 	each	 	[***]*
	3814	 	83520	 	Interleukin-4	 	each	 	[***]*
	3816	 	83520	 	Interleukin-1 RA	 	each	 	[***]*
	3822	 	83520	 	Interleukin-8	 	each	 	[***]*
	3823	 	83520	 	Interleukin-10	 	each	 	[***]*
	3827	 	83520	 	Interleukin-5	 	each	 	[***]*
	3828	 	83520	 	Interleukin-6	 	each	 	[***]*
	3830	 	83520	 	Mannose-binding Protein	 	each	 	[***]*
	3832	 	83520	 	Interleukin-2 Receptor; Soluble	 	each	 	[***]*
	3836	 	85303	 	Protein C Activity	 	each	 	[***]*
	3837	 	85306	 	Protein S Activity	 	each	 	[***]*
	3844	 	82150	 	Amylase	 	each	 	[***]*
	3846	 	82150x3	 	Amylase Isoenzymes	 	each	 	[***]*
	3851	 	82550	 	Creatine Kinase Isoenzymes (CK)	 	each	 	[***]*
	3852	 	82550; 82553	 	Creatine Kinase-MB Mass & Relative Index	 	each	 	[***]*
	3856	 	86329	 	Immunosuppressive Acidic Protein	 	each	 	[***]*
	3857	 	84275; 86316	 	Melanoma Monitor	 	each	 	[***]*
	3858	 	84275	 	Lipid-Associated Sialic Acid	 	each	 	[***]*
	3860	 	86316	 	Neuron-specific Enolase	 	each	 	[***]*
	3868	 	83520	 	Interleukin-1 beta	 	each	 	[***]*
	3870	 	83520	 	Interleukin-2	 	each	 	[***]*
	3872	 	83520	 	Pancreatitis DetectR	 	each	 	[***]*
	3876	 	86337	 	Insulin Antibodies	 	each	 	[***]*
	3882	 	83520	 	Macrophage Inflammatory Protein-1 alpha	 	each	 	[***]*
	3883	 	83520	 	Macrophage Inflammatory Protein-1 beta	 	each	 	[***]*
	3885	 	83520	 	Rantes	 	each	 	[***]*
	3886	 	83520x3	 	Beta-chemokine Panel	 	each	 	[***]*
	3892	 	85610	 	Prothrombin Time (PTT)	 	each	 	[***]*
	3893	 	85610; 85611x2	 	Prothrombin Time Mixing Studies	 	each	 	[***]*
	3895	 	85730	 	Partial Thromboplastin Time (PT)	 	each	 	[***]*
	3896	 	85730; 85732x2	 	Partial Thromboplastin Time Mixing Studies	 	each	 	[***]*
	3900	 	83873	 	Myelin Basic Protein CSF	 	each	 	[***]*
	3904	 	82397	 	Eosinophil Cationic Protein	 	each	 	[***]*
	3908	 	83520	 	Tumor Necrosis Factor-binding Proteins	 	each	 	[***]*
	3916	 	84402; 84403	 	Testosterone; Bioavailable	 	each	 	[***]*
	3917	 	84402; 84403	 	Testosterone; Weakly Binding	 	each	 	[***]*
	3930	 	84075	 	Alkaline Phosphatase; Total	 	each	 	[***]*
	3934	 	82985	 	Fructosamine	 	each	 	[***]*
	3941	 	83970	 	PTH; Intact only	 	each	 	[***]*
	3943	 	82310; 83970	 	PTH; Intact including Total Calcium only	 	each	 	[***]*
	3944	 	82310; 82330; 83970	 	PTH; Intact including Ionized & Total Calcium	 	each	 	[***]*

20

 

	3945	 	82310; 83970	 	PTH; C Terminal; including Total Calcium only	 	each	 	[***]*
	3946	 	83150	 	Homovanillic Acid; 24hr Urine	 	each	 	[***]*
	3947	 	83150	 	Homovanillic Acid; Pediatric	 	each	 	[***]*
	3952	 	83519	 	Chromogranin-A	 	each	 	[***]*
	3954	 	84436; 84439	 	Thyroxine (T4) Free; Direct Dialysis	 	each	 	[***]*
	3959	 	83519	 	Insulin-like Growth Factor Binding Protein (IGFBP-3)	 	each	 	[***]*
	3973	 	82523; 82570	 	Deoxypyridinoline Cross-links	 	each	 	[***]*
	3974	 	84075	 	Alkaline Phosphatase; Bone Specific	 	each	 	[***]*
	3976	 	82550	 	Creatine Phosphokinase	 	each	 	[***]*
	3978	 	85540	 	Leukocyte Alkaline Phosphatase Stain	 	each	 	[***]*
	3984	 	83520	 	Inhibin	 	each	 	[***]*
	3990	 	83519	 	PTH-related Protein	 	each	 	[***]*
	3996	 	84080	 	Alkaline Phosphatase Isoenzymes	 	each	 	[***]*
	3998	 	82380x2	 	Carotenes; alpha and beta	 	each	 	[***]*
	3999	 	84181	 	Carbohydrate-deficient Transferrin; Qualitative	 	each	 	[***]*
	4002	 	84181	 	Transferrin Genetic D Variants	 	each	 	[***]*
	4004	 	84181	 	Tau-Transferrin	 	each	 	[***]*
	4005	 	83883	 	Carbohydrate-Deficient Transferrin (CDT) Ultraquant	 	each	 	[***]*
	4006	 	83520	 	Ganglioside GD1a Autoabs	 	each	 	[***]*
	4007	 	83883	 	CDT UltraQuant with reflex to Genetic D Variants	 	each	 	[***]*
	4011	 	83520	 	Ganglioside Asialo-GM1 Autoabs	 	each	 	[***]*
	4020	 	83520x7; 83883; 86256; 86334	 	Motor & Sensory Neuropathy EvaluatR	 	each	 	[***]*
	4021	 	83520x7; 86256; 86334	 	Motor & Sensory Neuropathy Evaluation	 	each	 	[***]*
	4026	 	83520x7; 86334	 	Motor Neuropathy Evaluation	 	each	 	[***]*
	4030	 	83520x2; 83883; 86256; 86334	 	Sensory Neuropathy EvaluatR	 	each	 	[***]*
	4031	 	83520x2; 86256; 86334	 	Sensory Neuropathy Evaluation	 	each	 	[***]*
	4041	 	83520	 	Ganglioside GD1b Autoabs	 	each	 	[***]*
	4043	 	83520	 	Ganglioside GQ1b Autoabs	 	each	 	[***]*
	4046	 	83520	 	Sulfoglucuronyl Paragloboside Autoabs	 	each	 	[***]*
	4051	 	83520x2	 	Myelin-Assoc Glycoprot & Sulfoglucuronyl Paragloboside Eval	 	each	 	[***]*
	4056	 	83520x5	 	Ganglioside Autoabs Evaluation	 	each	 	[***]*
	4058	 	83520x3	 	Ganglioside GM1 Triple Evaluation	 	each	 	[***]*
	4061	 	84181	 	Myelin-Associated Glycoprotein (MAG) Autoabs	 	each	 	[***]*
	4070	 	83520	 	Lysosomal-associated Membrane Protein IgG Autoantibodies	 	each	 	[***]*
	4072	 	83520x3	 	Bacterial Permeability-increasing (BPI) Protein Autoabs Eval	 	each	 	[***]*
	4073	 	80299	 	Benztropine [cogentin]	 	each	 	[***]*
	4080	 	82175; 83655; 83825	 	Heavy Metal Panel; Serum	 	each	 	[***]*
	4095	 	84150	 	Prostaglandin E2 (PGE2) EIA	 	each	 	[***]*
	4100	 	82003	 	Acetaminophen	 	each	 	[***]*
	4102	 	82055	 	Alcohol; Ethyl	 	each	 	[***]*

21

 

	4103	 	80101	 	Lysergic Acid Diethylamide (LSD) Screen	 	each	 	[***]*
	4108	 	80100	 	Barbiturates	 	each	 	[***]*
	4110	 	80101	 	Benzodiazepine Screen Serum	 	each	 	[***]*
	4114	 	80156	 	Carbamazepine	 	each	 	[***]*
	4116	 	80156	 	Carbamazepine; Free	 	each	 	[***]*
	4118	 	80100	 	Cocaine Metabolites Screen; Serum	 	each	 	[***]*
	4120	 	80299	 	Digitoxin	 	each	 	[***]*
	4122	 	80162	 	Digoxin	 	each	 	[***]*
	4124	 	80299	 	Disopyramide	 	each	 	[***]*
	4125	 	80100	 	Drugs of Abuse Screen Serum	 	each	 	[***]*
	4126	 	80168	 	Ethosuximide	 	each	 	[***]*
	4128	 	83605	 	Lactic Acid Plasma	 	each	 	[***]*
	4130	 	80176	 	Lidocaine	 	each	 	[***]*
	4132	 	80100	 	Cannabinoids Screen; Serum	 	each	 	[***]*
	4135	 	80299	 	Methotrexate	 	each	 	[***]*
	4138	 	80100	 	Opiates Screen; Serum	 	each	 	[***]*
	4142	 	80184	 	Phenobarbital	 	each	 	[***]*
	4144	 	80185; 80186	 	Phenytoin Free & Total	 	each	 	[***]*
	4146	 	80188	 	Primidone	 	each	 	[***]*
	4147	 	80299	 	Amiodarone and Metabolites	 	each	 	[***]*
	4148	 	80192	 	Procainamide + NAPA	 	each	 	[***]*
	4150	 	80194	 	Quinidine	 	each	 	[***]*
	4152	 	80196	 	Salicylate	 	each	 	[***]*
	4155	 	82365	 	Stone Analysis; Kidney	 	each	 	[***]*
	4156	 	80198	 	Theophylline	 	each	 	[***]*
	4158	 	80101	 	Tricyclics Screen	 	each	 	[***]*
	4160	 	82365	 	Stone-A-Lyzer	 	each	 	[***]*
	4162	 	82108; 82175; 82300; 83655; 83825	 	Toxic Element Analysis Whole Blood	 	each	 	[***]*
	4163	 	82379	 	Carnitine Evaluation	 	each	 	[***]*
	4165	 	82525; 83735; 83785; 84132; 84255; 84630	 	Minerals Analysis RBC w/K+	 	each	 	[***]*
	4168	 	82340; 82436; 82507; 82570; 83735; 83935; 83945; 83986; 84105; 84133; 84300; 84560	 	Kidney Stone Risk AssessR	 	each	 	[***]*
	4174	 	83915	 	5-Nucleotidase	 	each	 	[***]*
	4195	 	80299	 	Sertraline [Zoloft]	 	each	 	[***]*
	4196	 	80299	 	Lamotrigine	 	each	 	[***]*
	4200	 	85378	 	D-Dimer	 	each	 	[***]*
	4204	 	85362	 	Fibrin Monomer; Soluble	 	each	 	[***]*
	4208	 	85362	 	Fibrinolytic Degradation Product	 	each	 	[***]*
	4210	 	85670	 	Thrombin Time	 	each	 	[***]*
	4212	 	83520	 	Thrombin Anti-Thrombin [TAT] Complex	 	each	 	[***]*
	4311	 	80158	 	Cyclosporine A and Metabolites Whole Blood [FPIA]	 	each	 	[***]*
	4313	 	80158	 	Cyclosporine A [HPLC]	 	each	 	[***]*
	4397	 	83018	 	Antimony	 	each	 	[***]*
	4426	 	82705	 	Fecal Fat (Lipids); Qualitative	 	each	 	[***]*
	4427	 	82710	 	Fecal Fat; Quantitative	 	each	 	[***]*
	4428	 	82710	 	Fecal Fat Acid Steatocrit	 	each	 	[***]*

22

 

	4500	 	82232; 82300x2; 82570	 	Cadmium Exposure Panel—OSHA—24hr Urine	 	each	 	[***]*
	4556	 	83890; 83892x3; 83894x3; 83898x3; 83912	 	Obstetric Complications AssessR	 	each	 	[***]*
	4558	 	83890; 83892; 83894; 83898; 83912	 	5;10-Methylenetetrahydrofolate Reductase (MTHFR) C677T Mutation	 	each	 	[***]*
	4559	 	83890; 83892; 83894; 83898; 83912	 	MTHFR A1298C Mutation	 	each	 	[***]*
	4560	 	83890; 83892x2; 83894x2; 83898x2; 83912	 	5;10-MTHFR C677T Mutation Reflex to A1298C Mutation	 	each	 	[***]*
	4831	 	82330	 	Calcium; Ionized	 	each	 	[***]*
	4834	 	83519	 	Voltage-Gated Calcium Channel IgG Autoabs	 	each	 	[***]*
	4836	 	82310	 	Calcium; Total	 	each	 	[***]*
	4859	 	82525	 	Copper Liver Tissue	 	each	 	[***]*
	4861	 	83655	 	Lead Serum	 	each	 	[***]*
	4862	 	82108	 	Aluminum Serum	 	each	 	[***]*
	4866	 	83735	 	Magnesium Serum	 	each	 	[***]*
	4867	 	82175	 	Arsenic Serum	 	each	 	[***]*
	4868	 	82300	 	Cadmium Serum	 	each	 	[***]*
	4870	 	82525	 	Copper Serum	 	each	 	[***]*
	4871	 	80178	 	Lithium Serum	 	each	 	[***]*
	4872	 	83785	 	Manganese	 	each	 	[***]*
	4873	 	83825	 	Mercury Serum	 	each	 	[***]*
	4875	 	84255	 	Selenium	 	each	 	[***]*
	4877	 	84630	 	Zinc Serum	 	each	 	[***]*
	4900	 	80150	 	Amikacin	 	each	 	[***]*
	4901	 	80170	 	Gentamicin	 	each	 	[***]*
	4902	 	80200	 	Tobramycin	 	each	 	[***]*
	4903	 	80202	 	Vancomycin	 	each	 	[***]*
	4904	 	80299	 	Fluconazole	 	each	 	[***]*
	4905	 	80299	 	Itraconazole	 	each	 	[***]*
	4906	 	80299	 	Ketoconazole	 	each	 	[***]*
	4908	 	80299	 	5-Fluorocytosine	 	each	 	[***]*
	4910	 	82491	 	Mycophenolic Acid	 	each	 	[***]*
	4912	 	80154	 	Alprazolam	 	each	 	[***]*
	4914	 	80152; 80182	 	Amitriptyline and Nortriptyline	 	each	 	[***]*
	4915	 	80299	 	Isoniazid	 	each	 	[***]*
	4916	 	80154	 	Chlordiazepoxide [Librium]	 	each	 	[***]*
	4918	 	80154	 	Clonazepam	 	each	 	[***]*
	4919	 	80299	 	Rifampin	 	each	 	[***]*
	4920	 	80299	 	Desalkylflurazepam	 	each	 	[***]*
	4921	 	80299	 	Flecainide [HPLC]	 	each	 	[***]*
	4922	 	80160	 	Desipramine [Norpramin]	 	each	 	[***]*
	4924	 	80166; 80299	 	Doxepin & Nordoxepin	 	each	 	[***]*
	4925	 	80201	 	Topiramate	 	each	 	[***]*
	4926	 	80154	 	Diazepam & Nordiazepam	 	each	 	[***]*
	4928	 	80154	 	Nordiazepam [Zofran]	 	each	 	[***]*
	4930	 	80182	 	Nortriptyline	 	each	 	[***]*

23

  

	4932	 	80160; 80174	 	Imipramine & Desipramine [Norpramin]	 	each	 	[***]*
	4934	 	80154	 	Oxazepam [Serax]	 	each	 	[***]*
	4950	 	80299x2	 	Fluoxetine & Norfluoxetine [Prozac]	 	each	 	[***]*
	4951	 	80299	 	Nelfinavir MonitR	 	each	 	[***]*
	4952	 	80299	 	Ritonavir MonitR	 	each	 	[***]*
	4953	 	80299	 	Stavudine (d4T) MonitR	 	each	 	[***]*
	4954	 	80299	 	Nevirapine MonitR	 	each	 	[***]*
	4956	 	80299	 	Delavirdine MonitR	 	each	 	[***]*
	4957	 	80299	 	Didanosine (ddl) MonitR	 	each	 	[***]*
	4958	 	80299	 	Zalcitabine (DDC) MonitR	 	each	 	[***]*
	4959	 	80299	 	Zidovudine (AZT) MonitR	 	each	 	[***]*
	4960	 	80299	 	Trazodone	 	each	 	[***]*
	4962	 	80299x2	 	Clomipramine [Anafranil] & each	 	each	 	[***]*
	4964	 	80299	 	Clozapine Plasma	 	each	 	[***]*
	4965	 	80299	 	Indinavir MonitR	 	each	 	[***]*
	4966	 	80299	 	Lamivudine (3TC) MonitR	 	each	 	[***]*
	4967	 	80299	 	Saquinavir MonitR	 	each	 	[***]*
	4970	 	83021	 	Beta-Thalassemia and Hemoglobinopathy Screen	 	each	 	[***]*
	4972	 	83036	 	Hemoglobin A1c	 	each	 	[***]*
	4974	 	83021	 	Hemoglobin A2; Quantitative	 	each	 	[***]*
	4976	 	83021	 	Hemoglobin F; Quant	 	each	 	[***]*
	4978	 	83021	 	Hemoglobin S Screen	 	each	 	[***]*
	4982	 	83020; 83021	 	Hemoglobin Variant Screen	 	each	 	[***]*
	4986	 	85660	 	Sickle Cell Screen	 	each	 	[***]*
	4988	 	83874	 	Myoglobin	 	each	 	[***]*
	4991	 	82139	 	Amino Acid Profile Quant Plasma	 	each	 	[***]*
	4992	 	82131; 83918; 86256	 	Pernicious Anemia AssessR	 	each	 	[***]*
	4993	 	82139	 	Amino Acid Profile Quant Plasma with Interpretation	 	each	 	[***]*
	4994	 	82131; 83918	 	Megaloblastic Anemia AssessR	 	each	 	[***]*
	4995	 	82131x3; 83918	 	Megaloblastic Anemia EvaluatR	 	each	 	[***]*
	5001	 	84550; 85810; 86038; 86431	 	Arthritis Evaluation #1	 	each	 	[***]*
	5002	 	85810; 86038; 86431	 	Arthritis Evaluation A	 	each	 	[***]*
	5003	 	84550; 85810; 86038	 	Arthritis Evaluation #3	 	each	 	[***]*
	5004	 	85810; 86038	 	Arthritis Evaluation	 	each	 	[***]*
	5011	 	84550; 85810; 86038; 86431; 86812	 	Arthritis-Spondylitis Evaluation	 	each	 	[***]*
	5012	 	85810; 86038; 86431; 86812	 	Arthritis-Spondylitis Evaluation #2	 	each	 	[***]*
	5013	 	84550; 85810; 86038; 86812	 	Arthritis-Spondylitis Evaluation #3	 	each	 	[***]*
	5014	 	85810; 86038; 86812	 	Arthritis-Spondylitis Evaluation #4	 	each	 	[***]*
	5015	 	85810; 86812	 	Arthritis-Spondylitis Evaluation #5	 	each	 	[***]*
	5021	 	82565; 84165; 86160x3; 86225	 	Lupus Renal Evaluation #1	 	each	 	[***]*
	5022	 	82565; 84165; 86160x2; 86225	 	Lupus Renal Evaluation #2	 	each	 	[***]*
	5023	 	86160x2; 86225	 	Lupus Renal Evaluation B	 	each	 	[***]*
	5031	 	86160x3; 86225	 	Lupus Renal Evaluation A	 	each	 	[***]*

24

 

	5036	 	83520x2; 86160x3; 86225	 	Lupus CNS Evaluation	 	each	 	[***]*
	5045	 	86147x3; 86148x3; 86235	 	Lupus Pregnancy Monitor	 	each	 	[***]*
	5050	 	83520; 85810; 86160; 86431; 86816x2	 	Rheumatoid Arthritis Prognosticator	 	each	 	[***]*
	5052	 	83520; 85810; 86140; 86160; 86431	 	Rheumatoid Arthritis Monitor #2	 	each	 	[***]*
	5053	 	83520; 85810; 86160	 	Rheumatoid Arthritis Monitor #3	 	each	 	[***]*
	5110	 	85025	 	Complete Blood Count; Platelet Count & Differential	 	each	 	[***]*
	5111	 	85025	 	Complete Blood Count & Differential	 	each	 	[***]*
	5112	 	85014; 85018	 	Hemoglobin & Hematocrit	 	each	 	[***]*
	5116	 	85018	 	Hemoglobin	 	each	 	[***]*
	5150	 	85999	 	Lupus Erythematosus Cell Preparation	 	each	 	[***]*
	5160	 	85595	 	Platelet Count	 	each	 	[***]*
	5180	 	85651	 	Erythrocyte Sedimentation Rate	 	each	 	[***]*
	5200	 	81003	 	Urinalysis	 	each	 	[***]*
	5225	 	89325	 	Sperm IgG Autoabs	 	each	 	[***]*
	5250	 	82270	 	Occult Blood (Hemoccult)	 	each	 	[***]*
	5295	 	82947	 	Glucose 2 hour Post Tolerance	 	each	 	[***]*
	5297	 	82947	 	Glucose 2 hour Post Prandial	 	each	 	[***]*
	5300	 	82374	 	Bicarbonate	 	each	 	[***]*
	5301	 	82947	 	Glucose	 	each	 	[***]*
	5302	 	82977	 	GGT	 	each	 	[***]*
	5303	 	82435	 	Chloride	 	each	 	[***]*
	5306	 	84295	 	Sodium	 	each	 	[***]*
	5308	 	84100	 	Phosphorus Inorganic	 	each	 	[***]*
	5311	 	84132	 	Potassium	 	each	 	[***]*
	5313	 	82247; 82248	 	Bilirubin Fractionated	 	each	 	[***]*
	5314	 	82040; 82310; 80048; 84100	 	Renal Function Panel	 	each	 	[***]*
	5315	 	80048	 	Metabolic Panel; Basic	 	each	 	[***]*
	5316	 	82374; 82435; 84132; 84295	 	Electrolyte Panel	 	each	 	[***]*
	5317	 	80053	 	Metabolic Panel; Comprehensive	 	each	 	[***]*
	5318	 	80076	 	Hepatic Function Panel	 	each	 	[***]*
	5319	 	84520	 	Urea Nitrogen	 	each	 	[***]*
	5320	 	87206	 	AFB Stain	 	each	 	[***]*
	5322	 	87102; 87205	 	Fungus Culture & Stain	 	each	 	[***]*
	5324	 	87106	 	Fungus Identification	 	each	 	[***]*
	5350	 	83890x4; 89894x3; 83898x2; 83912	 	bcr/abl Gene Translocation (PCR)	 	each	 	[***]*
	5362	 	83890; 83892x3; 83894x3; 83896x2; 83897x2; 83898; 83912	 	Fragile X DNA Probe Analysis [SB/PCR]	 	each	 	[***]*
	5364	 	83890; 82892x3; 83894x3; 83896x2; 83897; 83912; 88248; 83898	 	Fragile X DNA Probe Analysis with Chromosome Analysis	 	each	 	[***]*

25

 

	5368	 	83890; 83894; 83898; 83912	 	CC-CKR5 Delta 32 Mutation	 	each	 	[***]*
	5369	 	83890; 83893x4; 83896x4; 83901; 83912	 	Hemochromatosis DNA GenotypR	 	each	 	[***]*
	5372	 	83890; 83892; 83894; 83898 83912	 	Prothrombin G20210A Mutation	 	each	 	[***]*
	5374	 	83890; 83892; 83894; 83898x3; 83912	 	Cytochrome P450 2D6 EvaluatR—Poor-Metabolizers	 	each	 	[***]*
	5402	 	88182	 	DNA Ploidy	 	each	 	[***]*
	5420	 	86849	 	Natural Killer Cell Function	 	each	 	[***]*
	5421	 	86821; 86849	 	Natural Killer Cell & LAK Cell Function	 	each	 	[***]*
	5422	 	85048; 85595; 86849; 88180	 	Natural Killer Cell Evaluation	 	each	 	[***]*
	5635	 	87147x6	 	Salmonella Serotyping	 	each	 	[***]*
	5636	 	87147x4	 	Shigella Serotyping	 	each	 	[***]*
	5637	 	87147x6	 	Haemophilus influenzae Serotyping	 	each	 	[***]*
	5639	 	87045	 	Escherichia coli Enterohemorrhagic (0157:H7) Stool Culture	 	each	 	[***]*
	5640	 	87147	 	Escherichia coli 0157:H7 Culture Confirmation	 	each	 	[***]*
	5641	 	87230x3	 	Escherichia coli Pathogenicity Evaluation for Diarrhea	 	each	 	[***]*
	5642	 	87230	 	Escherichia coli Enteroinvasive Toxin	 	each	 	[***]*
	5643	 	87230	 	Escherichia coli Enterotoxigenic Toxin	 	each	 	[***]*
	5644	 	87230	 	Escherichia coli Verotoxin	 	each	 	[***]*
	5645	 	87147	 	Escherichia coli Enteropathogenic Toxin	 	each	 	[***]*
	5646	 	87190x7	 	Prop]	 	each	 	[***]*
	5647	 	87190x6	 	Prop]	 	each	 	[***]*
	5648	 	87118	 	AFB Identification Mycobacterium ssp. by HPLC	 	each	 	[***]*
	5649	 	87190x6	 	Panel	 	each	 	[***]*
	5650	 	87190x6	 	AFB Suscept M. tuberculosis Secondary Radiometric Panel	 	each	 	[***]*
	5651	 	87190x7	 	AFB Suscept: MAI (MAC) Radiometric MIC Panel	 	each	 	[***]*
	5652	 	87190x11	 	AFB Suscept: Mycobacterium ssp. Rapid Grower Panel	 	each	 	[***]*
	5653	 	87190x21	 	AFB Suscept: Mycobaceterium ssp. Panel	 	each	 	[***]*
	5656	 	87190x21	 	AFB Suscept: MAI (MAC) Synergy Study (Drug Combination)	 	each	 	[***]*
	5657	 	87190x11	 	AFB Suscept M. tuberculosis Comprehensive Panel [Agar Prop]	 	each	 	[***]*
	5659	 	87190x10	 	AFB Suscept: MAI (MAC) Comprehensive Panel [Agar Prop]	 	each	 	[***]*
	5660	 	87192x5	 	Fungus Susceptibility: MIC Panel	 	each	 	[***]*
	5665	 	87184x2	 	urine	 	each	 	[***]*
	5666	 	87184x2	 	Aerobic Suscept: Gram Positive Panel Urine/Non-urine	 	each	 	[***]*
	5667	 	87184	 	urine	 	each	 	[***]*
	5677	 	87194	 	Antimicrobial Serum Inhibitory-Cidal Level	 	each	 	[***]*
	5680	 	87999	 	Viral Susceptibility: Acyclovir	 	each	 	[***]*

26

 

	5681	 	80299	 	Viral Susceptibility: Foscarnet	 	each	 	[***]*
	5682	 	80299	 	Viral Susceptibility: Ganciclovir	 	each	 	[***]*
	5683	 	80299	 	Viral Susceptibility: Penciclovir	 	each	 	[***]*
	5685	 	87186	 	Aerobic Suscept: Gram Negative MIC Panel Urine/Non-urine	 	each	 	[***]*
	5686	 	87186	 	Aerobic Suscept: Gram Positive MIC Panel Urine/Non-urine	 	each	 	[***]*
	5687	 	87186	 	Aerobic Suscept: Gram Neg Resist MIC Panel Urine/Non-Urine	 	each	 	[***]*
	5690	 	87106	 	Fungus Identification; Exoantigen	 	each	 	[***]*
	5695	 	87449	 	Entamoeba histolytica Ag Detection	 	each	 	[***]*
	5697	 	87420	 	Respiratory Synctial Virgus Ag Detection [EIA]	 	each	 	[***]*
	5700	 	87045	 	Aerobic Bacterial Culture: Stool Comprehensive	 	each	 	[***]*
	5702	 	87070	 	Yersinia Culture	 	each	 	[***]*
	5704	 	87045	 	Campylobacter Culture	 	each	 	[***]*
	5708	 	87075x2	 	Anaerobic Bacterial Culture	 	each	 	[***]*
	5709	 	87076	 	Anaerobic Bacterial Identification	 	each	 	[***]*
	5711	 	87186	 	Anaerobic Bacterial MIC Susceptibility	 	each	 	[***]*
	5712	 	87186	 	Aerobic Suscept: Streptococcus pneumoniae MIC panel	 	each	 	[***]*
	5713	 	87186	 	Aerobic Suscept: Haemophilus influenzae MIC Panel	 	each	 	[***]*
	5714	 	87186	 	Aerobic Suscept:Aminoglycoside MIC; High Level	 	each	 	[***]*
	5720	 	87207	 	Microsporidia Spore Stain	 	each	 	[***]*
	5723	 	87252x3; 87390x3	 	HIV-1 Anti-Viral Drug Study: Phenotypic Resistence	 	each	 	[***]*
	5725	 	87252	 	HIV-1 Culture; Qualitative	 	each	 	[***]*
	5727	 	87252	 	HIV-1 Culture; Quantitative	 	each	 	[***]*
	5729	 	87252	 	HIV-1 Culture; Quantitative; Plasma	 	each	 	[***]*
	5732	 	87536	 	HIV-1 Proviral DNA Accuquant	 	each	 	[***]*
	5742	 	88230; 88262; 88271; 88273; 88291	 	Chromosome Analysis: KAL Gene Deletion by FISH	 	each	 	[***]*
	5771	 	87070x2; 87205	 	Aerobic Bacterial Culture; Routine Miscellaneous	 	each	 	[***]*
	5772	 	87060x2	 	Aerobic Bacterial Culture: Throat	 	each	 	[***]*
	5773	 	87086x2	 	Aerobic Bacterial Culture: Urine	 	each	 	[***]*
	5774	 	87070x2	 	Aerobic Bacterial Culture: Blood	 	each	 	[***]*
	5775	 	87070x2; 87205	 	Aerobic Bacterial Culture; Respiratory	 	each	 	[***]*
	5776	 	87070x2	 	Aerobic Bacterial Culture; Genital	 	each	 	[***]*
	5777	 	87081	 	Streptococcus; Beta Group A Culture Screen	 	each	 	[***]*
	5778	 	87070	 	Gardnerella vaginalis & Grp B Streptococcus Culture Screen	 	each	 	[***]*
	5779	 	87102	 	Fungus Culture: Yeast Screen	 	each	 	[***]*
	5800	 	88237; 88264; 88291	 	Chromosome Analysis: Hematological Disorders I	 	each	 	[***]*
	5801	 	87070x2; 87205	 	Aerobic Bacterial Culture: Eye/Ear	 	each	 	[***]*
	5802	 	87020x2	 	Aerobic Bacterial Culture: Environmental	 	each	 	[***]*

27

 

	5806	 	88230; 88233; 88237; 88263; 88291	 	Chromosome Analysis: Mosaicism	 	each	 	[***]*
	5808	 	88237; 88271; 88275; 88291	 	Chromosome Analysis; Trisomy 8 by FISH	 	each	 	[***]*
	5810	 	83890; 83892; 83894; 83898x2; 83912; 88237; 88264	 	Chromosome Analysis: Hematological Disorders II	 	each	 	[***]*
	5812	 	88237; 88271; 88275; 88291	 	Chromosome Analysis: Trisomy 12 by FISH	 	each	 	[***]*
	5814	 	88230; 88262; 88291	 	Chromosome Analysis: Cogenital Disorders; Blood	 	each	 	[***]*
	5818	 	88233; 88262; 88291	 	Chromosome Analysis: Products of Conception/Skin Biopsies	 	each	 	[***]*
	5822	 	88235; 88267; 88280; 88291	 	Chromosome Analysis: Amniotic Fluid	 	each	 	[***]*
	5830	 	88230; 88262; 88271; 88273; 88291	 	Chromosome Analysis: FISH for Genetic Diseases	 	each	 	[***]*
	5832	 	88230; 88262; 88271; 88273; 88291	 	Chromosome & FISH for Genetic Disorders Evaluation	 	each	 	[***]*
	5834	 	88237; 88271; 88275; 88291	 	Chromosome Analysis: bcr/abl Gene Rearrangement by FISH	 	each	 	[***]*
	5836	 	88342	 	Chromosome Analysis: HER-2/neu Gene Amplification	 	each	 	[***]*
	5838	 	88237; 88271x2; 88275; 88291	 	Chromosome Analysis: X and Y Probe for Opposite Sex Bone Marrow Transplant	 	each	 	[***]*
	5840	 	88237; 88271; 88275	 	Chromosome Analysis: Acute Promyelo Leukemia	 	each	 	[***]*
	5842	 	88342x2	 	Her-2/neu [IHC] and Gene Amplification [FISH]	 	each	 	[***]*
	5844	 	88230; 88262; 88271; 88273; 88291	 	Chromosome Analysis: STS Gene Detection	 	each	 	[***]*
	5846	 	88342	 	Her-2/neu [IHC] reflex to Gene Amplification [FISH]	 	each	 	[***]*
	5900	 	85335	 	Activated Protein C Resistance	 	each	 	[***]*
	5902	 	86162x2	 	Complement Deficiency Detector Evaluation	 	each	 	[***]*
	5910	 	83520	 	OKT3 (Anti-) IgG Abs	 	each	 	[***]*
	5912	 	83520	 	OKT3 Ab Quantitation	 	each	 	[***]*
	5914	 	83519	 	Human Anti-Mouse Abs [for Cytogen use only]	 	each	 	[***]*
	5915	 	83519	 	Human Anti-Mouse Abs	 	each	 	[***]*
	5916	 	83520x2; 86038; 86256; 86376x3; 87522	 	Autoimmune Hepatits EvaluatR PLUS	 	each	 	[***]*
	5917	 	83520	 	Cytokeratin Autoabs	 	each	 	[***]*
	5918	 	83520x2; 86376x3	 	Autoimmune Hepatitis EvaluatR	 	each	 	[***]*
	5920	 	83520	 	F-actin IgG Autabs	 	each	 	[***]*
	5922	 	86376	 	Liver Cytosol Autoabs	 	each	 	[***]*
	5923	 	86376	 	Liver-Specific Membrane Lipoprotein Autabs	 	each	 	[***]*
	5926	 	83789	 	S-Adenosyl-Methionine [Sam(E)] AssessR	 	each	 	[***]*
	5932	 	85302	 	Protein C Ag	 	each	 	[***]*
	5933	 	85302; 85303	 	Protein C Evaluation 1	 	each	 	[***]*
	5935	 	85306	 	Protein S Antigen; Free	 	each	 	[***]*

28

 

	5937	 	85305	 	Protein S Antigen; Total	 	each	 	[***]*
	5938	 	85305; 85306	 	Protein S Evaluation 1	 	each	 	[***]*
	5939	 	83520	 	Prothrombin Fragment 1.2	 	each	 	[***]*
	5940	 	85576x4	 	Platelet Autoabs; Drug-induced including Heparin	 	each	 	[***]*
	5941	 	83520	 	Beta-Thromboglobulin	 	each	 	[***]*
	5942	 	83520	 	Platelet Factor 4	 	each	 	[***]*
	5943	 	85130	 	Heparin Antifactor Xa	 	each	 	[***]*
	5945	 	83520	 	Heparin-Induced Thrombocytopenia (HIT Assay)	 	each	 	[***]*
	5948	 	80197	 	Tacrolimus	 	each	 	[***]*
	5951	 	85300	 	Antithrombin III Functional	 	each	 	[***]*
	5952	 	85300; 85301	 	Antithrombin III Evaluation	 	each	 	[***]*
	5955	 	86022	 	Platelet Glycoprotein Ib/IX Total Autoantibodies	 	each	 	[***]*
	5956	 	86022	 	Platelet Glycoprotein IIb/IIIa Total Autoantibodies	 	each	 	[***]*
	5957	 	86022	 	Platelet Glycoprotein Ia/IIa Total Autoantibodies	 	each	 	[***]*
	5958	 	86022x3	 	Platelet Glycoprotein Autoantibody AssessR	 	each	 	[***]*
	5960	 	85240; 85245; 85246; 85730	 	von Willebrand Profile with reflex to Multimers	 	each	 	[***]*
	5961	 	85240; 85245; 85246; 85730	 	von Willebrand Profile	 	each	 	[***]*
	5962	 	85597; 85610; 85611x2; 85613; 85670; 85730; 85732x2	 	Lupus Anticoagulant Screen 3	 	each	 	[***]*
	5963	 	85613; 85730; 85732x2; 86147x3	 	Lupus Anticoagulant Screen 1	 	each	 	[***]*
	5964	 	85240; 85246	 	Hemophilia A Carrier Screen	 	each	 	[***]*
	5965	 	85300; 85303; 85306	 	Hereditary Thrombosis Screen A; No Heparin or Coumadin	 	each	 	[***]*
	5966	 	83520; 85300; 85302; 85305; 85306	 	Hereditary Thrombosis Screen B; Patients on Coumadin	 	each	 	[***]*
	5967	 	83520; 85576x5	 	Platelet Function Evaluation	 	each	 	[***]*
	5968	 	85305; 85306x2; 86329	 	Protein S Evaluation 3	 	each	 	[***]*
	5969	 	83520; 85250	 	Hemophilia B Carrier Screen	 	each	 	[***]*
	5971	 	82131; 85300; 85303; 85306; 85335; 85384	 	Thrombotic Risk Evaluation 2	 	each	 	[***]*
	5972	 	85300; 85303; 85306; 85335	 	Thrombotic Risk Evaluation 1	 	each	 	[***]*
	5973	 	82131; 82172; 85300; 85301; 85302; 85303; 85305; 85306x2; 85335; 85384; 85410; 85415; 85420	 	Thrombotic Risk Evaluation 3	 	each	 	[***]*
	5975	 	82131	 	Venous Thromboembolism (VTE) AssessR	 	each	 	[***]*
	5976	 	85597; 85610; 85613; 85670; 85730; 86147x3	 	Lupus Anticoagulant: Screen 2	 	each	 	[***]*
	5977	 	85362; 85378; 85410; 85415; 85420x2	 	Fibrinolysis Evaluation	 	each	 	[***]*

29

 

	5978	 	83520; 85378	 	Thrombotic Markers Evaluation	 	each	 	[***]*
	5980	 	85300; 85362; 85378; 85610; 85730	 	Disseminated Intravascular Coagulopathy Evaluation	 	each	 	[***]*
	5981	 	85240; 85245; 85246; 85247	 	von Willebrand Evaluation with Multimers	 	each	 	[***]*
	5983	 	85210; 85220; 85230; 85240; 85250; 85260; 85270; 85280; 85384; 85610; 85611x2 85613; 85730; 85732x2	 	Factor Deficiency Detector	 	each	 	[***]*
	5984	 	85240; 85245; 85246	 	von Willebrand Evaluation without Multimers	 	each	 	[***]*
	5985	 	83520	 	Thrombus Precursor Prot	 	each	 	[***]*
	5988	 	83520; 85302; 85303	 	Protein C Evaluation 2	 	each	 	[***]*
	5989	 	83520; 85302	 	Protein C Evaluation 3	 	each	 	[***]*
	5990	 	82131; 82172; 85384	 	Thrombotic Risk AssessR	 	each	 	[***]*
	5991	 	82172; 85246; 85384; 85420	 	Cadiovascular Thrombotic Risk AssessR	 	each	 	[***]*
	5992	 	85303; 85306	 	Protein C&S Activity	 	each	 	[***]*
	5993	 	83520; 85305; 85306	 	Protein S Evaluation 2	 	each	 	[***]*
	5994	 	83520; 85305	 	Protein S Evaluation 4	 	each	 	[***]*
	5995	 	86022x6; 86023x3	 	Platelet Autoantibodies; Comprehensive	 	each	 	[***]*
	5996	 	85292	 	Prekallikrein [PKK]	 	each	 	[***]*
	5998	 	85130	 	Heparin Co-factor II [HCII]	 	each	 	[***]*
	7221	 	86606x3; 86612; 86635x3; 86698x3	 	Fungal IgG & IgM Abs [EIA]	 	each	 	[***]*
	7224	 	86606; 86612; 86635; 86698	 	Fungal IgG Abs	 	each	 	[***]*
	7437	 	87491	 	Chlamydia trachomatis DNA LCR	 	each	 	[***]*
	7439	 	87491; 87591	 	Ur-Sure Chlamydia trachomatis/Neisseria gonorrhoeae by LCR	 	each	 	[***]*
	7441	 	83520	 	Pyruvate Dehydrogenase IgG Autoabs	 	each	 	[***]*
	7447	 	82523; 82570; 83937	 	Osteoporosis Monitor	 	each	 	[***]*
	7452	 	82523x2; 82570; 83937; 84075	 	Osteoporosis EvaluatR	 	each	 	[***]*
	7458	 	86677	 	Helicobacter pylori Cytotoxin A IgG Abs	 	each	 	[***]*
	7460	 	86677x4	 	Helicobacter pylori IgG; IgM & IgA Abs and Cytotoxin A IgG	 	each	 	[***]*
	7470	 	87556	 	Mycobacterium Tuberculosis GenotypR	 	each	 	[***]*
	7472	 	87522	 	Hepatitis C Virus RNA Quantitation by Branched DNA	 	each	 	[***]*
	7473	 	83891x3; 83898x2; 83904; 83912	 	Hepatitis C Virus SubtypR	 	each	 	[***]*
	7475	 	87556	 	Mycobacterium Tuberculosis DNA PCR	 	each	 	[***]*
	7476	 	87522	 	Hepatitis C Virus RNA AccuQuant reflex GenotypR	 	each	 	[***]*
	7477	 	83891x14; 83898x4; 83904x6; 83912	 	HIV-1 GenotypR (Reverse Transcriptase Inhibitor)	 	each	 	[***]*
	7478	 	87536	 	HIV-1 RNA UltraQuant reflx to HIV GenotypR (RTI)	 	each	 	[***]*

30

 

	7479	 	83891x4; 83898x2; 83904x2; 83912	 	HIV-1 GenotypR (Protease Inhibitor)	 	each	 	[***]*
	7480	 	83891x13; 83898x5; 83904x8; 83912	 	HIV-1 GenotypR PLUS (Rev Trans & Prot Inhib)	 	each	 	[***]*
	7481	 	86677	 	Helicobacter pylori Total Abs	 	each	 	[***]*
	7482	 	87536	 	HIV-1 RNA UltraQuant reflx to HIV GenotypR PLUS (RTI&PI)	 	each	 	[***]*
	7483	 	87536	 	HIV-1 RNA UltraQuant reflx to HIV GenotypR (PI)	 	each	 	[***]*
	7486	 	87522	 	Hepatitis C Virus RNA AccuQuant	 	each	 	[***]*
	7491	 	86804	 	Hepatitis C Virus RIBA Evaluation + reflex PCR	 	each	 	[***]*
	7494	 	87532	 	Herpesvirus-6 Human DNA DetectR	 	each	 	[***]*
	7496	 	86790x2	 	Hantavirus Puumala IgG & IgM Abs	 	each	 	[***]*
	7501	 	86790x2	 	Hantavirus Hantaan IgG & IgM Abs	 	each	 	[***]*
	7506	 	86790x4	 	Hantavirus Hantaan & Puumala IgG & IgM Abs	 	each	 	[***]*
	7507	 	86790x2	 	Hantavirus Hantaan & Puumala IgG Abs	 	each	 	[***]*
	7508	 	86790x2	 	Hantavirus Hantaan & Puumala IgM Abs	 	each	 	[***]*
	7511	 	87472	 	Bartonella quintana DNA DetectR	 	each	 	[***]*
	7514	 	87798	 	Hepatitis Delta Virus RNA DetectR	 	each	 	[***]*
	7516	 	87521	 	Hepatitis C Virus RNA DetectR	 	each	 	[***]*
	7518	 	87522	 	Hepatitis C Virus RNA Detector with reflex Quant	 	each	 	[***]*
	7521	 	87798	 	Toxoplasma DNA DetectR	 	each	 	[***]*
	7522	 	86812	 	Respiratory Synctyial Virus RNA DetectR	 	each	 	[***]*
	7526	 	87328	 	Giardia/Cryptosporidium Ag Detection [EIA]	 	each	 	[***]*
	7531	 	86021; 86038; 86812	 	Primary Sclerosing Cholangitis Evaluation	 	each	 	[***]*
	7536	 	87301; 87324; 87328x2; 87425	 	Infectious Gastroenteritis Evaluation	 	each	 	[***]*
	7546	 	86720	 	Leptospira IgG Abs	 	each	 	[***]*
	7551	 	86720	 	Leptospira IgM Abs	 	each	 	[***]*
	7555	 	82040; 82784x2; 83883; 86781x2	 	Treponema pallidum IgG Antibody Index	 	each	 	[***]*
	7560	 	86781	 	Treponema pallidum IgG Antibodies; FTA-ABS Quantitative	 	each	 	[***]*
	7561	 	86781	 	Treponema pallidum IgG Abs	 	each	 	[***]*
	7565	 	86781x2	 	Treponema pallidum IgG & IgM Abs	 	each	 	[***]*
	7565	 	86781	 	Treponema pallidum IgG Abs	 	each	 	[***]*
	7566	 	86781	 	Treponema pallidum IgM Abs	 	each	 	[***]*
	7570	 	87476	 	Borrelia burgordorferi DNA DetectR	 	each	 	[***]*
	7573	 	87798	 	Tropheryma Whippelii DNA DetectR	 	each	 	[***]*
	7574	 	83891x3; 83898x2; 83904; 83912	 	Cytomegalovirus GenotypR	 	each	 	[***]*
	7575	 	87496	 	Cytomegalovirus DNA Detector	 	each	 	[***]*
	7576	 	87522	 	Hepatitis C Virus RNA UltraQuant	 	each	 	[***]*
	7578	 	87522	 	Hepatitis C Virus RNA UltraQuant reflex to HCV Genotyper	 	each	 	[***]*
	7581	 	87529x2	 	Herpes Simplex Virus DNA DetectR	 	each	 	[***]*
	7583	 	87798	 	Epstein-Barr Virus DNA Detector	 	each	 	[***]*
	7584	 	87799	 	Epstein-Barr Virus DNA UltraQuant	 	each	 	[***]*

31

 

	7585	 	87798	 	Varicella-zoster Virus DNA DetectR	 	each	 	[***]*
	7587	 	87798	 	Histoplasma DNA DetectR	 	each	 	[***]*
	7589	 	87798	 	Advenovirus DNA DetectR	 	each	 	[***]*
	7596	 	86790	 	Japanese Encephalitis Virus Total Abs	 	each	 	[***]*
	7598	 	83891x2; 83898; 83904; 83912; 87798	 	Aseptic Meningitis/Encephalitis DetectR	 	each	 	[***]*
	7601	 	86790	 	Dengue Virus Total Abs	 	each	 	[***]*
	7602	 	83891x2; 83898; 83904; 83912;	 	Dengue Virus RNA DetectR/Speciaton Types 1-4	 	each	 	[***]*
	7621	 	86720x2	 	Leptospira IgG & IgM Abs	 	each	 	[***]*
	7626	 	86720x2; 87070; 87166	 	Leptospirosis Evaluation	 	each	 	[***]*
	7631	 	86768x3	 	Salmonella IgG; IgM & IgA Abs	 	each	 	[***]*
	7646	 	86790	 	Dengue Virgus IgM Abs	 	each	 	[***]*
	7661	 	86778	 	Toxoplasma IgM Abs [SAGA]	 	each	 	[***]*
	7666	 	86777	 	Toxoplasma IgA Abs	 	eac	 	[***]*
	7670	 	87230; 87324	 	Clostridium difficile Toxin Evaluation	 	each	 	[***]*
	7672	 	87075; 87230; 87324	 	Clostridium difficile Culture & Toxin Evaluation	 	each	 	[***]*
	7675	 	86778	 	Toxoplasma IgM Abs [MAC EIA]	 	each	 	[***]*
	7685	 	82040; 82784x2; 83883; 86723x2	 	Listeria monocytogenes IgG Antibodiy Index	 	each	 	[***]*
	7691	 	87324	 	Clostridium difficile Toxin A Detection	 	each	 	[***]*
	7695	 	82040; 82784x2; 83883; 86622x2	 	Brucella abortus IgG Antibody Index	 	each	 	[***]*
	7700	 	82040; 82784x2; 83883; 86603x3	 	Advenovirus IgG Antibody Index	 	each	 	[***]*
	7705	 	82040; 82784x2; 83883; 86698x2	 	Histoplasma IgG Antibody Index	 	each	 	[***]*
	7711	 	86617x2	 	Borrelia burgdorferi IgG & IgM Abs [IB]	 	each	 	[***]*
	7716	 	86617x2; 86618x2	 	Borrelia burgdorferi IgG & IgM Abs with IB	 	each	 	[***]*
	7726	 	86674	 	Giardia lamblia IgG Abs	 	each	 	[***]*
	7736	 	86677	 	Helicobacter pylori IgM Abs	 	each	 	[***]*
	7741	 	86677x3	 	Helicobacter pylori IgG; IgM & IgA Abs	 	each	 	[***]*
	7742	 	86677x3; 87338	 	Helicobacter pylori EvaluateR	 	each	 	[***]*
	7744	 	86677x3; 87081	 	Helicobacter pylori Evaluation	 	each	 	[***]*
	7745	 	87299	 	Pneumocystis carinii Ag Detection	 	each	 	[***]*
	7751	 	86674x3	 	Giardia lamblia IgG; IgM & IgA Abs	 	each	 	[***]*
	7756	 	86705; 86709; 87340	 	Hepatitis A & B Virus Acute Evaluation	 	each	 	[***]*
	7757	 	80074	 	Hepatitis Acute Profile	 	each	 	[***]*
	7758	 	86704; 86706; 86708; 86803; 87340	 	Hepatitis A; B & C Virus Post Exposure Panel	 	each	 	[***]*
	7760	 	87328	 	Giardia Lamblia Ag Detection	 	each	 	[***]*
	7761	 	86677	 	Helicobacter pylori IgG Abs	 	each	 	[***]*
	7762	 	86674x3; 87328	 	Giardiasis Evaluation	 	each	 	[***]*
	7770	 	82040; 82784x2; 83883; 86762x2	 	Rubella IgG Antibody Index	 	each	 	[***]*
	7774	 	82040; 82784x2; 83883; 86790x2	 	Herpesvirus-6 Human IgG Antibody Index	 	each	 	[***]*
	7775	 	86790	 	Herpesvirus 7 Human IgG Abs	 	each	 	[***]*
	7776	 	86790x2	 	Herpesvirus-6 Human Early Ag IgG & IgM Abs	 	each	 	[***]*

32

 

	7777	 	86790x2	 	Herpesvirus-7 Human IgG & IgM Abs	 	each	 	[***]*
	7778	 	86790	 	Herpesvirus-7 Human IgM Abs	 	each	 	[***]*
	7780	 	86689	 	HTLV-I / II Abs Confirmation	 	each	 	[***]*
	7784	 	86790	 	Herpesvirus-8; Human Antibodies	 	each	 	[***]*
	7785	 	87798	 	Herpesvirus-8; Human DNA DetectR	 	each	 	[***]*
	7786	 	86790	 	Herpesvirus-6 Human Early Ag IgG Abs	 	each	 	[***]*
	7796	 	86790	 	Herpesvirus-6 Human Early Ag IgM Abs	 	each	 	[***]*
	7800	 	82040; 82784x2; 83883; 86651x2; 86652x2; 86653x2; 86654x2	 	Arbovirus IgM Antibody Index	 	each	 	[***]*
	7810	 	82040; 82784x2; 83883; 86653x2	 	St. Louis Encephalitis IgM Antibody Index	 	each	 	[***]*
	7820	 	82040; 82784x2; 83883; 86651x2	 	California-La Crosse Encephalitis IgM Antibody Index	 	each	 	[***]*
	7830	 	82040; 82784x2; 83883; 86654x2	 	Western Equine Encephalitis IgM Antibody Index	 	each	 	[***]*
	7840	 	82040; 82784x2; 83883; 86652x2	 	Eastern Equine Encephalitis IgM Antibody Index	 	each	 	[***]*
	7844	 	86609x2	 	Ehrlichia equi IgG & IgM (HGE) Abs	 	each	 	[***]*
	7846	 	86609x2; 86618x2	 	Ehrlichiosis (Granulocytic) & Lyme Disease Evaluation	 	each	 	[***]*
	7848	 	86609x4	 	Ehrlichia chaffeensis (HME) & E. equi (HGE) IgG & IgM Abs Ev	 	each	 	[***]*
	7851	 	86609x2	 	Ehrlichia chaffeensis (HME) IgG & IgM Abs;	 	each	 	[***]*
	7856	 	86759	 	Rotavirus Abs	 	each	 	[***]*
	7871	 	86609x2	 	Rickettsia ricketsii & R typhi IgG Abs Evaluation	 	each	 	[***]*
	7876	 	86609x4	 	Rickettsia ricketsii & R. typhi IgG & IgM Abs Eval	 	each	 	[***]*
	7881	 	86609x2	 	Rickettsia ricketsii & R. typhi IgM Abs Evaluation	 	each	 	[***]*
	7886	 	86609	 	Rickettsia ricketsii IgG Abs	 	each	 	[***]*
	7891	 	86609	 	Rickettsia ricketsii IgM Abs	 	each	 	[***]*
	7896	 	86609x2	 	Rickettsia ricketsii IgG & IgM Abs	 	each	 	[***]*
	7901	 	86609	 	Rickettsia typhi IgG Abs	 	each	 	[***]*
	7906	 	86609	 	Rickettsia typhi IgM Abs	 	each	 	[***]*
	7911	 	86609x2	 	Rickettsia typhi IgG & IgM Abs	 	each	 	[***]*
	7951	 	86609x2	 	Rickettsia conorii IgG & IgM Abs	 	each	 	[***]*
	7960	 	82040; 82784x4; 83883; 86618x4; 87476	 	Neuroborreliosis AccuDx	 	each	 	[***]*
	7965	 	82040; 82784x4 83883; 86618x4	 	Neuroborreliosis Evaluation	 	each	 	[***]*
	7970	 	82040; 82784x4; 83883; 86618x4	 	Borrelia burgdorferi IgG & IgM Antibody Index	 	each	 	[***]*
	7975	 	82040; 82784x2; 83883; 86618x2	 	Borrelia burgdorferi IgM Antibody Index	 	each	 	[***]*
	7980	 	82040; 82784x2; 83883; 86787x2	 	Varicella-zoster Virus IgG Antibody Index	 	each	 	[***]*
	7986	 	86677	 	Helicobacter pylori IgA Abs	 	each	 	[***]*
	8006	 	86631x4; 86632x3	 	Chlamydia spp. Abs Evaluation	 	each	 	[***]*

33

 

	8011	 	86632x4	 	Chlamydia spp IgM Abs	 	each	 	[***]*
	8016	 	86631x4	 	Chlamydia spp. Total Abs [MICRO-IF]	 	each	 	[***]*
	8021	 	86632	 	Chlamydia psittaci IgM Abs	 	each	 	[***]*
	8026	 	86631	 	Chlamydia psittaci Total Abs	 	each	 	[***]*
	8031	 	86631; 86632	 	Chlamydia psittaci Total & IgM Abs	 	each	 	[***]*
	8036	 	86631x3; 86632x3	 	Chlamydia trachomatis Total & IgM Abs	 	each	 	[***]*
	8041	 	86631x3	 	Chlamydia trachomatis Total Abs	 	each	 	[***]*
	8046	 	86632x3	 	Chlamydia tracomatis IgM Abs [MICRO-IF]	 	each	 	[***]*
	8051	 	86694; 86695x3	 	Herpes Simplex Virus Types 1 & 2 IgG & IgM Abs	 	each	 	[***]*
	8056	 	86603	 	Advenovirus IgG Abs	 	each	 	[***]*
	8061	 	86631x4; 86632x4	 	Lymphogranuloma Venereum Abs Panel	 	each	 	[***]*
	8066	 	86631x4; 86632x4	 	Chlamydia spp. Total & IgM Abs	 	each	 	[***]*
	8071	 	86631; 86632	 	Chlamydia pneumoniae Total & IgM Abs	 	each	 	[***]*
	8076	 	86631	 	Chlamydia pneumoniae Total Abs	 	each	 	[***]*
	8081	 	86632	 	Chlamydia pneumoniae IgM Abs	 	each	 	[***]*
	8091	 	86658x3	 	Polovirus Abs	 	eacg	 	[***]*
	8126	 	86609	 	Rickettsia tsutsugamushi IgG Abs	 	each	 	[***]*
	8131	 	87380	 	Hepatitis Delta Virus Ag	 	each	 	[***]*
	8137	 	87517	 	Hepatitis B Virus DNA UltraQuant	 	each	 	[***]*
	8141	 	87516	 	Hepatitis B Virus DNA Detector	 	each	 	[***]*
	8143	 	87517	 	Hepatitis B Virus DNA Quantitation by Branched DNA	 	each	 	[***]*
	8145	 	87798	 	JC Virus DNA DetectR	 	each	 	[***]*
	8147	 	87799	 	JC Virus Ultraquant	 	each	 	[***]*
	8151	 	86744	 	Nocardia IgG Abs	 	each	 	[***]*
	8156	 	83520x9; 86005; 86331x6; 86606	 	Hypersensitivity Pneumonitis Evaluation	 	each	 	[***]*
	8157	 	86331x5; 86606	 	Hypersensitivity Evaluation II	 	each	 	[***]*
	8158	 	86331	 	Pigeon Serum Antibodies	 	each	 	[***]*
	8166	 	86668	 	Francisella tularensis Total Abs [Agglutinins]	 	each	 	[***]*
	8171	 	86668x3	 	Francisella tularensis IgG; IgM & IgA Abs	 	each	 	[***]*
	8176	 	86651	 	California-La Crosse Encephalitis IgM Abs	 	each	 	[***]*
	8181	 	86652	 	Eastern Equine Encephalitis IgM Abs	 	each	 	[***]*
	8186	 	86653	 	St. Louis Encephalitis IgM Abs	 	each	 	[***]*
	8191	 	86654	 	Western Equine Encephalitis IgM Abs	 	each	 	[***]*
	8221	 	86747x2	 	Parvovirus B19 IgG & IgM Abs [EIA]	 	each	 	[***]*
	8226	 	86651; 86652; 86653; 86654	 	Arbovirus IgM Abs [IFA]	 	each	 	[***]*
	8236	 	86747x2	 	Parvovirus B19 IgG & IgM Abs [IB]	 	each	 	[***]*
	8241	 	86609x2	 	Abs	 	each	 	[***]*
	8246	 	86713	 	6	 	each	 	[***]*
	8251	 	86723	 	Listeria monocytogenes IgG Abs	 	each	 	[***]*
	8260	 	83891; 83896x2; 83898x2; 83912	 	Parvovirus B19 DNA UltraQuant	 	each	 	[***]*
	8261	 	86747x2; 87798	 	Parvovirus B19 Evaluation	 	each	 	[***]*
	8266	 	87798	 	Parvovirus B19 DNA DetectR	 	each	 	[***]*
	8286	 	86671x3	 	Sporothrix IgG; IgM & IgA Abs	 	each	 	[***]*
	8311	 	86698x3	 	Histoplasma IgG; IgM & IgA Abs	 	each	 	[***]*
	8312	 	86698	 	Histoplasma IgG Abs	 	each	 	[***]*
	8313	 	86698	 	Histoplasma IgM Antibodies	 	each	 	[***]*

34

 

	8316	 	86635	 	Coccidioides IgM Abs	 	each	 	[***]*
	8321	 	86635	 	Coccidioides IgM Abs	 	each	 	[***]*
	8326	 	86682	 	Schistosoma IgG Abs	 	each	 	[***]*
	8331	 	86635x3	 	Coccidioides IgG IgM & IgA Abs	 	eacg	 	[***]*
	8336	 	86003; 86682x2	 	Schistosoma IgG; IgM & IgE Abs	 	each	 	[***]*
	8340	 	82040; 82784x2; 83883; 86612x2	 	Blastomyces IgG Antibody Index	 	each	 	[***]*
	8346	 	86612	 	Blastomyces IgG Abs	 	each	 	[***]*
	8351	 	86682x2	 	Schistosoma IgG and IgM Abs	 	each	 	[***]*
	8370	 	87798x2	 	Malaria DNA DetectR	 	each	 	[***]*
	8371	 	86750x2	 	Malaria IgG & IgM Abs	 	each	 	[***]*
	8386	 	82784; 82787; 86003; 86682x2	 	Schistosoma Abs Evaluation	 	each	 	[***]*
	8421	 	86682	 	Fasciola IgG Abs [EIA]	 	each	 	[***]*
	8426	 	86682x2	 	Fasciola IgG & IgM Abs	 	each	 	[***]*
	8441	 	86753x3	 	Entamoeba histolytica IgG; IgM & IgA Abs	 	each	 	[***]*
	8451	 	86682	 	Echinococcus IgG Abs	 	each	 	[***]*
	8456	 	86003; 86682x2	 	Echinococcus IgG; IgM & IgE Abs	 	each	 	[***]*
	8476	 	86682x6; 86784x2	 	Fever of Unknown Origin Antibody Panel	 	each	 	[***]*
	8516	 	86710x6	 	Influenza Virus A & B IgG; IgM & IgA Abs	 	each	 	[***]*
	8521	 	86710x6; 87276; 87299	 	Influenza Evaluation	 	each	 	[***]*
	8560	 	82040; 82784x2; 83883; 86644x2	 	Cytomegalovirus IgG Antibody Index	 	each	 	[***]*
	8562	 	82040; 82784x2; 83883; 86644x2; 87496	 	Cytomegalovirus CNS Infection AccuDx	 	each	 	[***]*
	8566	 	86682	 	Strongyloides IgG Abs	 	each	 	[***]*
	8576	 	86771x4	 	Shigella Abs	 	each	 	[***]*
	8581	 	86771	 	Shigella IgG Abs	 	each	 	[***]*
	8600	 	82040; 82784x2; 83883; 86765x3	 	Measles IgG Antibody Index	 	each	 	[***]*
	8636	 	86790	 	Colorado Tick Fever Total Abs	 	each	 	[***]*
	8660	 	82040; 82784x2; 83883; 86738x2	 	Mycroplasma pnemoniae IgG Antibody Index	 	each	 	[***]*
	8666	 	86658x10; 86710x2	 	Myopericarditis Viral Antibodies Evaluation	 	each	 	[***]*
	8676	 	86793	 	Yersinia enterocolitica Abs Serotype 0:3	 	each	 	[***]*
	8681	 	86793	 	Yersinia enterocolitica Abs Serotype 0:8	 	each	 	[***]*
	8686	 	86793	 	Yersinia enterocolitica Abs Serotype 0:9	 	each	 	[***]*
	8691	 	86756x2	 	Respiratory Syncytial Virus IgG & IgM Abs	 	each	 	[***]*
	8696	 	86793x3	 	Yersinia enterocolitica Abs Serotypes 0:3; 0:8; 0:9	 	each	 	[***]*
	8711	 	86793	 	Yersinia pseudotuberculosis Total Abs	 	each	 	[***]*
	8721	 	86793	 	Yersinia enterocolitica IgA Abs	 	each	 	[***]*
	8731	 	86738	 	Mycoplasma pneumoniae IgA Abs	 	each	 	[***]*
	8736	 	86738x3	 	Mycoplasma pneumoniae IgG; IgM & IgA Abs SeroDx	 	each	 	[***]*
	8741	 	86738x2	 	Mycoplasma pneumoniae IgG & IgM Abs	 	each	 	[***]*
	8746	 	86738	 	Mycoplasma pneumoniae IgG Abs	 	each	 	[***]*
	8751	 	86738	 	Mycoplasma pneumoniae IgM Abs	 	each	 	[***]*
	8756	 	86787x2	 	Varicella-zoster Virus SeroDx; IgG & IgM Abs	 	each	 	[***]*

35

  

	8760	 	83891x2; 83898x2; 83912	 	Varicella-Zoster Virus DNA Ultraquant	 	each	 	[***]*
	8761	 	86787	 	Varicella-zoster Virus IgG Abs	 	each	 	[***]*
	8766	 	86787	 	Varicella-zoster Virus IgM Abs	 	each	 	[***]*
	8771	 	86765x2	 	Measles IgG & IgM Abs	 	each	 	[***]*
	8776	 	86765	 	Measles IgG Abs	 	each	 	[***]*
	8781	 	86765	 	Measles IgM Abs	 	each	 	[***]*
	8831	 	86622x3	 	Brucella abortus IgG; IgM & IgA Abs	 	each	 	[***]*
	8836	 	86622	 	Brucella abortus IgG Abs	 	each	 	[***]*
	8841	 	86723	 	Listeria monocytogenes Abs	 	each	 	[***]*
	8851	 	86317x2	 	Bartonella henselae IgG & IgM Abs	 	each	 	[***]*
	8855	 	82040; 82784x4; 83883; 86317x4	 	Bartonella henselae IgG & IgM Antibody Index	 	each	 	[***]*
	8857	 	82040; 82784x4; 83883; 86317x4; 87472	 	Bartonella henselae CNS Infection Evaluation	 	each	 	[***]*
	8861	 	87471	 	Bartonella henselae & B. quintana DNA DetectR	 	each	 	[***]*
	8863	 	86317x4	 	SeroDx	 	each	 	[***]*
	8864	 	86317x2	 	Bartonella quintana IgG & IgM Abs	 	each	 	[***]*
	8866	 	86625	 	Campylobacter jejuni Total Abs [EIA]	 	each	 	[***]*
	8881	 	86625	 	Campylobacter fetus Total Abs	 	each	 	[***]*
	8886	 	86625	 	Campylobacter jejuni Total Abs [CF]	 	each	 	[***]*
	8921	 	86653	 	St. Louis encephalitis Total Abs	 	each	 	[***]*
	8926	 	86651	 	California-La Crosse Encephalitis Total Abs	 	each	 	[***]*
	8931	 	86654	 	Western Equine Encephalitis Total Abs	 	each	 	[***]*
	8936	 	86652	 	Eastern Equine Encephalitis Total Abs	 	each	 	[***]*
	8941	 	86618x2	 	Borrelia burgdorferi IgG & IgM Abs [EIA]	 	each	 	[***]*
	8942	 	86618x2	 	bands	 	each	 	[***]*
	8945	 	82040; 82784x2; 83883; 86618x2	 	Borrelia burgdorferi IgG Antibody Index	 	each	 	[***]*
	8951	 	86618	 	Borrelia burgdorferi IgG Abs	 	each	 	[***]*
	8961	 	86618	 	Borrelia burgdorferi IgM Abs	 	each	 	[***]*
	8968	 	86609x2; 86618; 86753	 	Lyme Co-infection Panel	 	each	 	[***]*
	8970	 	82040; 82784x2; 83883; 86777x2	 	Toxoplasma IgG Antibody Index	 	each	 	[***]*
	8972	 	82040; 82784x2; 83883; 86777x2; 87798	 	Toxoplasma Encephalitis AccuDx	 	each	 	[***]*
	8981	 	86665	 	Epstein-Barr Virus Viral Capsid Ag (VCA) IgA Abs	 	each	 	[***]*
	9014	 	87186	 	Aerobic Suscept: Nocardia/Streptomyces MIC Panel	 	each	 	[***]*
	9015	 	87186; 87187	 	Aerobic Suscept: Nocardia/Streptomyces MIC & MBC Panel	 	each	 	[***]*
	9022	 	86781	 	Treponema pallidum Abs; TP-PA	 	each	 	[***]*
	9026	 	86157	 	Cold Agglutinins	 	each	 	[***]*
	9076	 	86768x4	 	WIDAL Evaluation; Salmonella spp. Abs	 	each	 	[***]*
	9095	 	86308	 	Heterophile Agglutination	 	each	 	[***]*
	9099	 	86641	 	Cryptococcus Abs	 	each	 	[***]*
	9101	 	86000x3; 86622; 86668; 86768x4	 	Febrile Agglutinins	 	each	 	[***]*
	9121	 	86000x3	 	Weil-Felix Test	 	each	 	[***]*

36

 

	9151	 	86671	 	Sporothrix Abs	 	each	 	[***]*
	9166	 	86635	 	Coccidioides Total Abs[LPA]	 	each	 	[***]*
	9189	 	87449	 	Cryptococcus Ag	 	each	 	[***]*
	9190	 	87449	 	Candida Ag Detection	 	each	 	[***]*
	9301	 	86682x2	 	Filaria IgG & IgM Abs	 	each	 	[***]*
	9316	 	86753	 	Trypanosoma cruzi IgG Abs	 	each	 	[***]*
	9326	 	86619	 	Borrelia hermsii IgG Abs	 	each	 	[***]*
	9331	 	86619	 	Borrelia hermsii IgM Abs	 	each	 	[***]*
	9371	 	86638x2	 	Coxiella burnetii IgG Abs; Phase 1 & 2	 	each	 	[***]*
	9376	 	86638x2	 	Coxiella burnetii IgM Abs; Phase 1 & 2	 	each	 	[***]*
	9381	 	86638x6	 	Coxiella burnetii IgG; IgM; & IgA Abs; Phase 1 & 2	 	each	 	[***]*
	9386	 	86784	 	Trichinella IgG Abs	 	each	 	[***]*
	9391	 	86631	 	Chlamydia trachomatis IgA Abs	 	each	 	[***]*
	9396	 	86619x2	 	Borrelia hermsii IgG & IgM Abs	 	each	 	[***]*
	9401	 	86631x2; 86632	 	Chlamydia trachomatis IgG; IgM & IgA Abs	 	each	 	[***]*
	9406	 	86631	 	Chlamydia trachomatis IgG Abs [EIA]	 	each	 	[***]*
	9411	 	86632	 	Chlamydia trachomatis IgM Abs [EIA]	 	each	 	[***]*
	9416	 	86762	 	Rubella IgG Abs	 	each	 	[***]*
	9421	 	86762x2	 	Rubella IgG & IgM Abs	 	each	 	[***]*
	9426	 	86777	 	Toxoplasma IgG Abs	 	each	 	[***]*
	9430	 	87497	 	Cytomegalovirus DNA UltraQuant	 	each	 	[***]*
	9431	 	86644	 	Cytomegalovirus IgG Abs	 	each	 	[***]*
	9436	 	86644; 86645	 	Cytomegalovirus IgG & IgM Abs	 	each	 	[***]*
	9437	 	86631	 	Chlamydia pneumoniae Abs UltraQuant	 	each	 	[***]*
	9446	 	86695x2	 	Herpes Simplex Virus Types 1 & 2 IgG Abs	 	each	 	[***]*
	9451	 	86695	 	Herpes Simplex Virus Type 1 IgG Abs	 	each	 	[***]*
	9456	 	86695	 	Herpes Simplex Virus Type 1 IgM Abs	 	each	 	[***]*
	9461	 	86695	 	Herpes Simplex Virus Type 2 IgG Abs	 	each	 	[***]*
	9466	 	86694	 	Herpes Simplex Virus Type 2 IgM Abs	 	each	 	[***]*
	9471	 	86694; 86695	 	Herpes Simplex Virus Types 1 & 2 IgM Abs	 	each	 	[***]*
	9474	 	87530x2	 	Herpes Simplex Virus DNA UltraQuant	 	each	 	[***]*
	9476	 	86695x2	 	Herpes Simplex Virus Type 1 IgG & IgM Abs	 	each	 	[***]*
	9481	 	86694; 86695	 	Herpes Simplex Virus Type 2 IgG & IgM Abs	 	each	 	[***]*
	9491	 	86694; 86695	 	Herpes Simplex Virus SeroDx; Types 1 & 2-specific IgG Abs	 	each	 	[***]*
	9496	 	86694; 86695; 87529x2	 	Herpes Simplex Virus Types 1 & 2 AccuDx [EIA]	 	each	 	[***]*
	9501	 	87449	 	Legionella pneumophila Ag Detection Urine	 	each	 	[***]*
	9510	 	82040; 82784x2; 83883; 86317x2	 	Viral Antibody Index; CSF	 	each	 	[***]*
	9515	 	82040; 82784x2; 83883; 86694; 86695x3	 	Herpes Simplex Virus IgG Antibody Index	 	each	 	[***]*
	9517	 	82040; 82784x2; 83883; 86694; 86695x3; 87530x2	 	Herpes Simplex Virus Encephalitis AccuDx	 	each	 	[***]*
	9521	 	86651; 86652; 86653; 86654	 	Arbovirus Total Abs	 	each	 	[***]*

37

 

	9525	 	83891x2; 83898x3; 83912	 	Arbovirus RNA DetectR	 	each	 	[***]*
	9530	 	83901x2; 83912; 87496; 87529x2	 	Viral Encephalitis DetectR	 	each	 	[***]*
	9601	 	86588x2; 87449x7	 	Bacterial Ag Detection	 	each	 	[***]*
	9606	 	87449	 	Haemophilus influenzae b Ag	 	each	 	[***]*
	9617	 	83516	 	Bladder Tumor Antigen	 	each	 	[***]*
	9620	 	83516	 	NMP22 Bladder Tumor marker	 	each	 	[***]*
	9636	 	86588	 	Streptococcus pneumoniae Ag	 	each	 	[***]*
	9641	 	86588	 	Streptococcus Group B Ag	 	each	 	[***]*
	9671	 	86615	 	Bordetella pertussis / parapertussis IgG Abs	 	each	 	[***]*
	9676	 	86615x3	 	Abs	 	each	 	[***]*
	9681	 	86615x2	 	Bordetella pertussis / parapertussis IgM & IgA Abs	 	each	 	[***]*
	9686	 	86615	 	Bordetella pertussis / parapertussis IgM Abs	 	each	 	[***]*
	9711	 	86735x2	 	Mumps IgG & IgM Abs	 	each	 	[***]*
	9716	 	86735	 	Mumps IgG Abs	 	each	 	[***]*
	9721	 	86735	 	Mumps IgM Abs	 	each	 	[***]*
	9728	 	87798	 	Mumps RNA DetectR	 	each	 	[***]*
	9741	 	86784x3	 	Trichinella IgG; IgM & IgA Abs	 	each	 	[***]*
	9745	 	82040; 82784x2; 83883; 86784x2	 	Trichinella IgG Antibody Index	 	each	 	[***]*
	9751	 	86793x3	 	Yersinia enterocolitica IgG; IgM & IgA Abs	 	each	 	[***]*
	9761	 	86682x3	 	Toxocara IgG; IgM; & IgA Abs	 	each	 	[***]*
	9766	 	86682	 	Toxocara IgG Abs	 	each	 	[***]*
	9816	 	86682	 	Cysticercus IgG Abs	 	each	 	[***]*
	9846	 	87390	 	HIV-1 Total Ag; Immune Complex Disruption (ICD)	 	each	 	[***]*
	9848	 	87390x2	 	HIV-1 Free & Total Ag	 	each	 	[***]*
	9850	 	82040; 82784x2; 83883; 86317x2	 	Antibody Index	 	each	 	[***]*
	9861	 	86684	 	Haemophilus influenzae b IgG Abs Single Serum	 	each	 	[***]*
	9866	 	87390	 	HIV-1 Ag Neutralization Confirmation Test	 	each	 	[***]*
	9872	 	85048; 85595; 86361; 87536	 	HIV-1 RNA UltraQuant & CD4 Cell Count	 	each	 	[***]*
	9874	 	87536	 	HIV-1 RNA UltraQuant	 	each	 	[***]*
	9876	 	87539	 	HIV-2 DNA DetectR	 	each	 	[***]*
	9881	 	87390	 	HIV-1 Free Ag	 	each	 	[***]*
	9882	 	87390	 	HIV-1 Ag without Neutralization	 	each	 	[***]*
	9885	 	87535	 	HIV-1 DNA DetectR	 	each	 	[***]*
	9886	 	87536	 	HIV-1 RNA Quantitation by Branched DNA	 	each	 	[***]*
	9896	 	87798x2	 	HTLV-1/ II DNA DetectR	 	each	 	[***]*
	9898	 	86790	 	HTLV I/II IgG Abs	 	each	 	[***]*
	9899	 	86790	 	HTLV I/II IgG Abs w/reflex HTLV I/II IB + bands	 	each	 	[***]*
	9901	 	80090; 86695x3; 86778	 	TORCH IgG & IgM Abs Evaluation	 	each	 	[***]*
	9911	 	86695x2; 86777	 	TORCH IgG Abs Evaluation	 	each	 	[***]*
	9915	 	86703	 	HIV-1/HIV-2 Antibodies Plus Confirmation	 	each	 	[***]*
	9921	 	86702	 	HIV-2 IgG Abs w/ reflex IB	 	each	 	[***]*
	9926	 	86689	 	HIV-2 IgG Abs; Confirmation	 	each	 	[***]*

38

 

	9932	 	82040; 82784x2; 83883; 86606x2	 	Aspergillus IgG Antibody Index	 	each	 	[***]*
	9941	 	86003; 86606x3	 	Aspergillus Abs Panel [EIA]	 	each	 	[***]*
	9946	 	86606	 	Aspergillus IgM Abs	 	each	 	[***]*
	9961	 	86606	 	Aspergillus IgG Abs [EIA]	 	each	 	[***]*
	12990	 	88233	 	Fibroblast Culture	 	each	 	[***]*
	1015F	 	86431x2	 	Fluid	 	each	 	[***]*
	1020F	 	83883; 86160x2	 	Complement Panel Fluid	 	each	 	[***]*
	1040F	 	86332x4	 	Circulating Immune Complex Detector Fluid	 	each	 	[***]*
	1043/12	 	86609x12; 86648; 86774	 	Humoral Immune Evaluation (Pneumo 12)	 	each	 	[***]*
	1043P	 	86609x8; 86648x2; 86774x2	 	Humoral Immune Evaluation Pre/Post Vacc	 	each	 	[***]*
	1043P/12	 	86609x24; 86648x2; 86774x2	 	Humoral Immune Evaluation (Pneumo 12) Pre-Post Vacc	 	each	 	[***]*
	1045C	 	82784x3	 	IgA; IgG & IgM Immunoglobulin Quantitation CSF	 	each	 	[***]*
	1048/12	 	82784x3; 82785; 82787; 86609x12; 86648; 86774	 	Humoral Immune Status Survey (Pneumo 12)	 	each	 	[***]*
	1048P	 	82784x3; 82785; 82787; 86609x8; 86648x2; 86774x2	 	Humoral Immune Status Survey (Pneumo 4) Pre/Post Vacc	 	each	 	[***]*
	1048P/12	 	82784x3; 82785; 82787; 86609x24; 86648x2; 86774x2	 	Humoral Immune Status Survey (Pneumo 12) Pre/Post Vacc	 	each	 	[***]*
	1056C	 	83873	 	Myelin Basic Protein Autoantibodies CSF (MBP-CSF)	 	each	 	[***]*
	1070S	 	86618x2; 86625; 86631; 86632; 86768x3; 86771; 86793x3	 	Reactive Arthritis Evaluation Serum (without HLA-B27)	 	each	 	[***]*
	1080S	 	86147x3; 86148x3	 	Antiphospholipid Syndrome Evaluation w/o LA	 	each	 	[***]*
	1086/12	 	86609x12; 86648; 86684; 86774	 	Humoral Immune Eval + Pneumo 12 & H. influenzae b	 	each	 	[***]*
	1086P	 	86609x8; 86648x2; 86684x2; 86774x2	 	Humoral Immune Eval + H. influenzae b Pre/Post Vacc	 	each	 	[***]*
	1086P/12	 	86609x24; 86648x2; 86684x2; 84774x2	 	Humoral Immune Eval + Pneumo 12 & H. influenzae b Pre/Post	 	each	 	[***]*
	1100F	 	86038	 	Antinuclear Abs w/ International Units & Pattern Body Fluid	 	each	 	[***]*
	1145F	 	82784	 	IgD Fluid	 	each	 	[***]*
	1168C	 	86256	 	Neuronal Nuclear IgG Abs Type 1 (Hu) CSF	 	each	 	[***]*
	1168CS	 	86256x2	 	Neuronal Nuclear IgG Abs Type 1 (Hu) Serum & CSF	 	each	 	[***]*
	1171C	 	86256x2	 	Paraneoplastic Syndrome Evaluation CSF	 	each	 	[***]*
	1171CS	 	86256x4	 	Paraneoplastic Syndrome Evaluation Serum & CSF	 	each	 	[***]*
	1176C	 	86256	 	CSF	 	each	 	[***]*
	1176CS	 	86256x2	 	Purkinje Cell Cytoplasmic IgG Abs Type 1 (Yo) Serum & CSF	 	each	 	[***]*

39

 

	1186C	 	84181	 	Neuronal Nuclear Abs Type 1 (Hu) CSF	 	each	 	[***]*
	1187C	 	84181	 	Purkinje Cell Cytoplasmic Autoabs Type 1 (Yo) CSF	 	each	 	[***]*
	1198C	 	88180	 	Neuronal IgG Autoabs for CNS Lupus CSF	 	each	 	[***]*
	1198CS	 	83520; 88180	 	Neuronal IgG Autoabs for CNS Lupus Serum & CSF	 	each	 	[***]*
	1230F	 	86332	 	Immune Complex Assay; Raji Cell Fluid	 	each	 	[***]*
	1240P	 	85810	 	Viscosity Plasma	 	each	 	[***]*
	1245F	 	82785	 	IgE Fluid	 	each	 	[***]*
	1271C	 	83520	 	Ribosomal P Protein IgG Autoabs CSF	 	each	 	[***]*
	1271CS	 	83520x2	 	Ribosomal P Protein IgG Autoabs Serum & CSF	 	each	 	[***]*
	12995W	 	86890	 	Isolation of Lymphocytes (Cellular Immunology)	 	each	 	[***]*
	1320U	 	82570	 	Creatinine 24hr Urine	 	each	 	[***]*
	1320UR	 	82570	 	Creatinine Random Urine	 	each	 	[***]*
	1324C	 	84165	 	Protein; Total CSF	 	each	 	[***]*
	1324F	 	84155	 	Protein; Total Fluid	 	each	 	[***]*
	1324SF	 	84155	 	Protein; Total Synovial Fluid	 	each	 	[***]*
	1324U	 	84165	 	Protein; Total 24 hour Urine	 	each	 	[***]*
	1324UR	 	84165	 	Protein; Total Urine Random	 	each	 	[***]*
	1331P	 	86648x2; 86774x2	 	Tetanus & Diptheria Toxoid IgG Abs Pre/Post Vaccination	 	each	 	[***]*
	1334P	 	86774x2	 	Tetanus Toxoid IgG Abs Pre/Post Vaccination	 	each	 	[***]*
	1401F	 	86332	 	Fluid	 	each	 	[***]*
	1402F	 	86332	 	Conglutinin Solid Phase Immune Complex Assay Fluid	 	each	 	[***]*
	1403F	 	86332	 	Immune Complex Assay; Polyethylene Glycol Fluid	 	each	 	[***]*
	1415P	 	86648x2	 	Diptheria Toxoid IgG Abs Pre/Post Vaccination	 	each	 	[***]*
	1441C	 	83520	 	Ganglioside Monosialic Acid Autoabs CSF	 	each	 	[***]*
	14505W	 	86890	 	Lymphocytes Isolation and Storage	 	each	 	[***]*
	1461C	 	82784	 	IgM; low concentrations <1.1 mg/dL CSF	 	each	 	[***]*
	1466C	 	82784	 	IgA; Low Concentrations (<1.1 mg/dL) CSF	 	each	 	[***]*
	1481F	 	83520	 	Hyaluronic Acid Fluid	 	each	 	[***]*
	1486C	 	86160	 	Complement Split Product Concentration: C3a CSF	 	each	 	[***]*
	1498C	 	83520x2	 	IgA (Autoantibodies) IgG & IgM Ab Panel CSF	 	each	 	[***]*
	1501F	 	86160	 	Complement Protein Concentration: C3 Body Fluid	 	each	 	[***]*
	1504F	 	86160	 	Complement protein Concentration: C4 Fluid	 	each	 	[***]*
	1505C	 	82784	 	IgG CSF	 	each	 	[***]*
	1505F	 	82784	 	IgG Fluid	 	each	 	[***]*
	1505U	 	82784	 	IgG 24hr Urine	 	each	 	[***]*
	1505UR	 	82784	 	IgG Urine Random	 	each	 	[***]*
	1506F	 	82784	 	IgA Fluid	 	each	 	[***]*
	1506U	 	82784	 	IgA 24hr Urine	 	each	 	[***]*
	1506UR	 	82784	 	IgA Urine Random	 	each	 	[***]*

40

 

	1508F	 	82784	 	IgM Fluid	 	each	 	[***]*
	1508U	 	82784	 	IgM 24hr Urine	 	each	 	[***]*
	1508UR	 	82784	 	IgM Urine Random	 	each	 	[***]*
	1510C	 	83883	 	Albumin CSF	 	each	 	[***]*
	1510F	 	83883	 	Albumin Fluid	 	each	 	[***]*
	1511F	 	83883	 	Complement Protein Concentration: Factor B Fluid	 	each	 	[***]*
	1512U	 	83883	 	Alpha-2-Macroglobulin Urine	 	each	 	[***]*
	1535C	 	86140	 	C-Reactive Protein CSF	 	each	 	[***]*
	1540F	 	86431	 	Rheumatoid Factor IgM Abs [NEPH] Fluid	 	each	 	[***]*
	1580C	 	84165	 	Electrophoresis; Protein CSF	 	each	 	[***]*
	1580U	 	84165	 	Electrophoresis; Protein Urine Random	 	each	 	[***]*
	1588U	 	84165	 	Bence-Jones Protein; Qualitative Urine	 	each	 	[***]*
	1600F	 	86162	 	Fluid	 	each	 	[***]*
	1600SF	 	86162	 	Complement Functional Activity: Total CH50 Synovial Fluid	 	each	 	[***]*
	1615F	 	83883	 	Complement Protein Concentration: C1q Fluid	 	each	 	[***]*
	1656NY	 	85048; 85595; 86361	 	CBC	 	each	 	[***]*
	1656SR	 	85048; 85595; 86361	 	Lymphocyte Enumeration; Helper/Inducer w/ Serial Report	 	each	 	[***]*
	1657NY	 	85048; 85595; 86360	 	CBC	 	each	 	[***]*
	1678C	 	88180	 	Additional Surface Marker [Oncology]	 	each	 	[***]*
	1678C2	 	88180x2	 	Additional Surface Marker -2 [Oncology]	 	each	 	[***]*
	1694W	 	88180	 	Terminal Deoxynucleotidyl Transferase Whole Blood	 	each	 	[***]*
	1711C	 	86148x3	 	CSF	 	each	 	[***]*
	1731U	 	83883	 	Kappa Light Chain; Quant 24hr Urine	 	each	 	[***]*
	1731UR	 	83883	 	Kappa Light Chain Urine Random	 	each	 	[***]*
	1736U	 	83883	 	Lambda Light Chain; Quant 24hr Urine	 	each	 	[***]*
	1736UR	 	83883	 	Lambda Light Chain Urine Random	 	each	 	[***]*
	1741U	 	83883x2	 	Kappa & Lambda Light Chain; Quant 24hr Urine	 	each	 	[***]*
	1741UR	 	83883x2	 	Kappa & Lambda Light Chain Urine Random	 	each	 	[***]*
	1751C	 	83520x3	 	Phosphatidylcholine IgG; IgM & IgA Abs CSF	 	each	 	[***]*
	1771C	 	83520x3	 	Phosphatidic Acid IgG; IgM & IgA Abs CSF	 	each	 	[***]*
	1791C	 	83520x3	 	Phosphatidylethanolamine IgG; IgM & IgA Abs CSF	 	each	 	[***]*
	1804T	 	84233; 84234; 88182	 	Non-breast Cancer Profile 1- Paraffin	 	each	 	[***]*
	1926C	 	83520	 	CSF	 	each	 	[***]*
	1992C	 	83520	 	Complement Split Product Concentration: SC5b-9 Complex CSF	 	each	 	[***]*
	2102C	 	86781	 	Treponema pallidum IgM Abs; FTA CSF	 	each	 	[***]*
	2104C	 	86781	 	Treponema pallidum Total Abs; FTA CSF	 	each	 	[***]*
	2106U	 	87299	 	Cytomegalovirus Immediate-early Ag Urine	 	each	 	[***]*
	2116F	 	86665	 	Fluid	 	each	 	[***]*
	2121F	 	86665	 	Fluid	 	each	 	[***]*
	2126F	 	86663	 	Fluid	 	each	 	[***]*

41

 

	2131F	 	86663	 	Epstein-Barr Virus Early Ag (EA) IgA Abs Fluid	 	each	 	[***]*
	2156F	 	86713x12	 	Legionella pneumophila IgG & IgM Abs; Serotypes 1-6 Fluid	 	each	 	[***]*
	2161C	 	86753x2	 	Babesia microti IgG & IgM Abs CSF	 	each	 	[***]*
	2211E	 	86663; 86664; 86665x2	 	Epstein-Barr Virus Evalution Endpoint	 	each	 	[***]*
	2211F	 	86663; 86664; 86665x2	 	Epstein-Barr Virus Evaluation; Fluid	 	each	 	[***]*
	2231C	 	86645; 86694; 86695; 86762; 86778	 	TORCH IgM Abs Evaluation CSF	 	each	 	[***]*
	2261C	 	86777x2; 86778x2	 	Toxoplasma Antibody Evaluation CSF	 	each	 	[***]*
	2261F	 	86777x2; 86778x2	 	Toxoplasma Antibody Evaluation Fluid	 	each	 	[***]*
	2266F	 	86664	 	Epstein-Barr Virus Nuclear Ag (EBNA) IgG Abs Fluid	 	each	 	[***]*
	2271F	 	86664	 	Epstein-Barr Virus Nuclear Ag (EBNA) IgM Abs Fluid	 	each	 	[***]*
	2321F	 	86185	 	Teichoic Acid Abs Fluid	 	each	 	[***]*
	2326C	 	86606	 	Aspergillus Total Abs [DD] CSF	 	each	 	[***]*
	2328C	 	86612	 	Blastomyces Total Abs [DD] CSF	 	each	 	[***]*
	2332C	 	86635	 	Coccidioides Total Abs [DD] CSF	 	each	 	[***]*
	2334C	 	86698x2	 	Histoplasma Abs [DD] CFS	 	each	 	[***]*
	2366C	 	86592	 	VDRL CSF	 	each	 	[***]*
	2370P	 	86609x8	 	Pre/Post	 	each	 	[***]*
	2386P	 	86609x24	 	Pre/Post	 	each	 	[***]*
	2445B	 	86803	 	Hepatitis C Virus IgG Abs w/ reflex RIBA + bands	 	each	 	[***]*
	2447B	 	86804	 	Hepatitis C Virus Abs RIBA Confirmation + bands	 	each	 	[***]*
	2450R	 	86708	 	Hepatitis A Virus Total Abs w/ reflex IgM	 	each	 	[***]*
	2475C	 	86762	 	Rubella IgM Abs CSF	 	each	 	[***]*
	2486C	 	86645	 	Cytomegalovirus IgM Abs CSF	 	each	 	[***]*
	2491C	 	86793	 	Yersinia enterocolitica IgG Abs CSF	 	each	 	[***]*
	2496C	 	86793	 	Yersinia enterocolitica IgM Abs CSF	 	each	 	[***]*
	2501C	 	86603	 	Adenovirus Abs CSF	 	each	 	[***]*
	2506C	 	86606	 	Aspergillus Total Abs [CF] CSF	 	each	 	[***]*
	2511C	 	86612	 	Blastomyces total Abs [CF] CSF	 	each	 	[***]*
	2516C	 	86609	 	Neisseria gonorrhoeae Abs CSF	 	each	 	[***]*
	2521C	 	86631	 	Chlamydia spp. Total Abs [CF] CSF	 	each	 	[***]*
	2526C	 	86635	 	Coccidioides Total Abs [CF] CSF	 	each	 	[***]*
	2536C	 	86658x4	 	Coxsackievirus A Abs; Serotypes 7; 9; 10; 16 CSF	 	each	 	[***]*
	2541C	 	86658x6	 	Coxsackievirus B Abs; Serotypes 1-6 CSF	 	each	 	[***]*
	2546C	 	86658x10	 	Coxsackievirus A & B Abs Evaluation CSF	 	each	 	[***]*
	2551C	 	86664	 	Cytomegalovirus Total Abs CSF	 	each	 	[***]*
	2566C	 	86658x4	 	Echovirus Abs; Serotypes 4; 9; 11 & 30 CSF	 	each	 	[***]*
	2571C	 	86694	 	Herpes Simplex Virus Total Abs CSF [CF]	 	each	 	[***]*
	2581C	 	86698x2	 	Histoplasma Abs [CF] CSF	 	each	 	[***]*
	2586C	 	86710	 	Influenza Virus Abs; Type A CSF	 	each	 	[***]*
	2591C	 	86710	 	Influenza Virus Abs; Type B CSF	 	each	 	[***]*
	2601C	 	86727	 	Lymphocytic Choriomeningitis Abs CSF	 	each	 	[***]*
	2606C	 	86729	 	Lymphogranuloma Venereum Abs CSF	 	each	 	[***]*
	2621C	 	86710x3	 	Parainfluenza Virus Types 1-3 Abs CSF	 	each	 	[***]*

42

 

	2626C	 	86658x3	 	Poliovirus Abs Serotypes 1-3 CSF	 	each	 	[***]*
	2631C	 	86631	 	Chlamydia spp. Abs CSF	 	each	 	[***]*
	2641C	 	86790	 	Reovirus Antibodies CSF [CF]	 	each	 	[***]*
	2646C	 	86756	 	Respiratory Syncytial Virus Abs CSF	 	each	 	[***]*
	2676C	 	86790	 	Polyomavirus Abs CSF	 	each	 	[***]*
	2701C	 	86603; 86631; 86710x5; 86738	 	Respiratory Infection Abs; Adult CSF	 	each	 	[***]*
	2711C	 	86603; 86631; 86710x5; 86738; 86756	 	Respiratory Infection Abs; Child/Infant CSF	 	each	 	[***]*
	2726C	 	86694; 86727; 86735x2; 86765x2; 86787x2	 	Encephalitis Viral Abs CSF	 	each	 	[***]*
	2731C	 	86606; 86612; 86635; 86698x2	 	Fungal Abs [CF] CSF	 	each	 	[***]*
	2741C	 	86710x2	 	Influenza Virus Abs; Types A & B CSF	 	each	 	[***]*
	2746C	 	86658x17	 	Paralytic Viral Ab Evaluation CSF	 	each	 	[***]*
	2771C	 	86603; 86644; 86651; 86652; 86653; 86654; 86658x14; 86694; 86710x2; 86727; 86735x2; 86765x2; 86787x2	 	Meningoencephalomyelitis Viral Ab Evaluation CSF	 	each	 	[***]*
	2771CS	 	86603x2; 86644x2; 86651x2; 86652x2; 86653x2; 86654x2; 86658x28; 86694x2; 86710x4; 86727x2; 86735x4; 86765x4; 86787x4	 	Meningoencephalomyelitis Viral Ab Evaluation CSF & Serum	 	each	 	[***]*
	2780C	 	86612; 86635; 86698x2	 	Fungal Antibody Panel: Invasive CSF	 	each	 	[***]*
	2785C	 	86606; 86612; 86635; 86641; 86698x2; 87449	 	Fungal Antibody Panel: Opportunistic CSF	 	each	 	[***]*
	2790C	 	86612; 86635; 86641; 86698x2; 87449	 	Fungal Antibody Panel: Systemic CSF	 	each	 	[***]*
	3012B	 	86689	 	HIV-1 Abs Confirmation Immunoblot + bands	 	each	 	[***]*
	3012C	 	86689	 	HIV-1 Abs Confirmation Immunoblot CSF	 	each	 	[***]*
	3012NY	 	86689	 	HIV-1 Abs Confirmation Immunoblot; New York	 	each	 	[***]*
	3012NYB	 	86689	 	York	 	each	 	[***]*
	3013B	 	86689	 	HIV-1 Abs Confirmation + bands w/ reflex to HIV-2 + bands	 	each	 	[***]*
	3015B	 	86689x2	 	HIV-1 & 2 Abs Confirmation [IB] + Bands	 	each	 	[***]*
	3017SR	 	84275; 86316	 	Uterine Cancer Monitor w/ Serial Graphics	 	each	 	[***]*
	3091B	 	85613	 	HIV-1 IgG Abs w/ Reflex Ib + Bands (Priority)	 	each	 	[***]*
	3021B	 	86689	 	HIV-1 Abs Confirmation Immunoblot + Bands Plus HIV-2 Conf IB	 	each	 	[***]*
	3024SR	 	82378; 86316	 	Colorectal Cancer Monitor w/ Serial Graphics	 	each	 	[***]*
	3028SR	 	82105; 84702	 	Alpha-Fetoprotein & Human Chorionic Gonadotropin w/ Serial Gr	 	each	 	[***]*

43

 

	3032F	 	84066; 84153	 	Prostate Cancer Monitor Fluid	 	each	 	[***]*
	3032SR	 	84066; 84153	 	Prostate Cancer Monitor w/ Serial Graphics	 	each	 	[***]*
	3038BK	 	88182; 88342x2	 	Ovarian Cancer Prognosis—Paraffin	 	each	 	[***]*
	3038FZ	 	88182; 88342x2	 	Ovarian Cancer Prognosis—Frozen	 	each	 	[***]*
	3100F	 	84066	 	Prostatic Acid Phosphatase Fluid	 	each	 	[***]*
	3100SR	 	84066	 	Prostatic Acid Phosphatase w/ Serial Graphics	 	each	 	[***]*
	3104U	 	82088	 	Aldosterone; 24hr Urine	 	each	 	[***]*
	3104UR	 	82088	 	Aldosterone; Urine Random	 	each	 	[***]*
	3109C	 	82105	 	Alpha-Fetoprotein CSF	 	each	 	[***]*
	3109F	 	82106	 	Alpha-Fetoprotein Body Fluid—not for prenatal testing	 	each	 	[***]*
	3109SR	 	82105	 	Alpha-Fetoprotein—Tumor Marker w/ Serial Graphics	 	each	 	[***]*
	3114C	 	82164	 	Angiotensin Converting Enzyme CSF	 	each	 	[***]*
	3119SR	 	86316	 	CA 15-3 w/ Serial Graphics	 	each	 	[***]*
	3120F	 	86316	 	CA 19-9 Fluid	 	each	 	[***]*
	3120NY	 	86316	 	CA 19-9 New York	 	each	 	[***]*
	3120 SR	 	86316	 	CA 19-9 w/ Serial Graphics	 	each	 	[***]*
	3121F	 	86316	 	CA 125 Fluid	 	each	 	[***]*
	3121NY	 	86316	 	CA 125 New York	 	each	 	[***]*
	3121SR	 	86316	 	CA 125 w/ Serial Graphics	 	each	 	[***]*
	3123PL	 	82482	 	Cholinesterase Plasma	 	each	 	[***]*
	3123PLSR	 	82482	 	Cholinesterase Plas Serial Graphics	 	each	 	[***]*
	3123R	 	82482	 	Cholinesterase; RBC	 	each	 	[***]*
	3123RSR	 	82482	 	Cholinesterase; RBC w/ Serial Graphics	 	each	 	[***]*
	3123SR	 	82480	 	Cholinesterase w/ Serial Graphics	 	each	 	[***]*
	3125C	 	86334	 	Monoclonal Gammopathies; CSF	 	each	 	[***]*
	3125U	 	86334	 	Monoclonal Gammopathies; Urine	 	each	 	[***]*
	3128U	 	82530; 82570	 	Cortisol; Free 24hr Urine	 	each	 	[***]*
	3128UR	 	82530	 	Cortisol Free Urine Random	 	each	 	[***]*
	3134NY	 	86316	 	CA27.29 New York	 	each	 	[***]*
	3134SR	 	86316	 	CA27.29 w/ Serial Graphics	 	each	 	[***]*
	3140U	 	82570; 84681	 	C-Peptide Urine	 	each	 	[***]*
	3143C	 	82232	 	Beta-2-Microglobulin CSF	 	each	 	[***]*
	3143F	 	82232	 	Beta-2-Microglobulin Fluid	 	each	 	[***]*
	3143SR	 	82232	 	Beta-2-Microglobulin w/ Serial Graphics	 	each	 	[***]*
	3143U	 	82232	 	Beta-2-Microglobulin Urine	 	each	 	[***]*
	3158U	 	82570; 82677	 	Estriol; Total 24hr Urine	 	each	 	[***]*
	3172SR	 	82728; 86316	 	Neuroblastoma Monitor w/ Serial Graphics	 	each	 	[***]*
	3182MO	 	83003	 	Growth Hormone Response Test; Timed	 	each	 	[***]*
	3182M1	 	83003	 	Growth Hormone Response Test; Timed Sample #1	 	each	 	[***]*
	3182M2	 	83003	 	Growth Hormone Response Test; Timed Sample #2	 	each	 	[***]*
	3182M3	 	83003	 	Growth Hormone Response Test; Timed Sample #3	 	each	 	[***]*
	3182M4	 	83003	 	Growth Hormone Response Test; Timed Sample #4	 	each	 	[***]*
	3182M5	 	83003	 	Growth Hormone Response Test; Timed Sample #5	 	each	 	[***]*

44

 

	3182M6	 	83003	 	Growth Hormone Response Test; Timed Sample #6	 	each	 	[***]*
	3182M7	 	83003	 	Growth Hormone Response Test; Timed Sample #7	 	each	 	[***]*
	3184C	 	84702	 	Human Chorionic Gonadotropin CSF	 	each	 	[***]*
	3184F	 	84702	 	Human Chorionic Gonadotropin Fluid	 	each	 	[***]*
	3184SR	 	84702	 	Human Chorionic Gonadotropin w/ Serial Graphics	 	each	 	[***]*
	3204U	 	83935	 	Osmolality Urine	 	each	 	[***]*
	3204UR	 	83935	 	Osmolality; Random Urine	 	each	 	[***]*
	3214M	 	80408	 	Saline Suppression Test	 	each	 	[***]*
	3258C	 	82378	 	Carcinoembyronic Ag CSF	 	each	 	[***]*
	3258F	 	83278	 	Carcinoembryonic Ag Body Fluid	 	each	 	[***]*
	3258NY	 	82378	 	Carcinoembryonic Ag New York	 	each	 	[***]*
	3258SR	 	82378	 	Carcinoembryonic Ag w/ Serial Graphics	 	each	 	[***]*
	3270U	 	82382	 	Epinephrine 24hr Urine	 	each	 	[***]*
	3275I	 	84202	 	Zinc Protoporphyrin; Industrial	 	each	 	[***]*
	3282C	 	83520	 	Neopterin CSF	 	each	 	[***]*
	3286U	 	84260	 	5-Hydroxytryptamine 24hr Urine [Serotonin]	 	each	 	[***]*
	3286UR	 	84260	 	5-Hydroxytryptamine Urine Random [Serotonin]	 	each	 	[***]*
	3290C	 	83520	 	Interferon-alpha CSF	 	each	 	[***]*
	3294BW	 	82397	 	Tumor Necrosis Factor-alpha Bronchial Wash	 	each	 	[***]*
	3294C	 	82397	 	Tumor Necrosis Factor-alpha CSF	 	each	 	[***]*
	3304U	 	82384	 	Catecholamines; Fractionated 24hr Urine	 	each	 	[***]*
	3304UR	 	82384	 	Catecholamines; Fractionation Urine Random	 	each	 	[***]*
	3310UR	 	82570; 83497	 	5-Hydroxyindoleacetic Acid Urine Random	 	each	 	[***]*
	3315UR	 	82570; 83835	 	Metanephrines; Fractionation Urine Random	 	each	 	[***]*
	3316UR	 	82570; 83835	 	Metanephrines; Total Urine Random	 	each	 	[***]*
	3318U	 	84585	 	Vanillylmandelic Acid; 24hr Urine	 	each	 	[***]*
	3318UR	 	84585	 	Vanillylmandelic Acid; Urine Random	 	each	 	[***]*
	3334U	 	82131	 	Homocyst(e)ine UltraQuant Urine	 	each	 	[***]*
	3369U	 	83690	 	Lipase; Urine	 	each	 	[***]*
	3446E	 	82172	 	Lipoprotein (a); Endpoint	 	each	 	[***]*
	3496U	 	83918	 	Methylmalonic Acid Urine	 	each	 	[***]*
	3515F	 	84425	 	Vitamin B1 Fluid	 	each	 	[***]*
	3515W	 	84425	 	Vitamin B1 Whole Blood	 	each	 	[***]*
	3522B	 	82747	 	Folate RBC	 	each	 	[***]*
	3546F	 	84153	 	Prostate-Specific Ag Fluid	 	each	 	[***]*
	3546NY	 	84153	 	Prostate-Specific Ag New York	 	each	 	[***]*
	3546SR	 	84153	 	Prostate-Specific Ag w/ Serial Graphics	 	each	 	[***]*
	3547SR	 	84153; 84154	 	Graphics	 	each	 	[***]*
	3624C	 	83520	 	Endotoxin CSF	 	each	 	[***]*
	3624F	 	85130	 	Endotoxin Fluid	 	each	 	[***]*
	3822BW	 	83520	 	Interleukin-8 Bronchial Wash	 	each	 	[***]*
	3832C	 	83520	 	Interleukin-2 Receptor CSF	 	each	 	[***]*
	3832SF	 	83520	 	Interleukin-2 Receptor; Soluble Synovial Fluid	 	each	 	[***]*
	3857SR	 	84275; 86316	 	Melanoma Monitor w/ Serial Graphics	 	each	 	[***]*

45

 

	3858SR	 	84275	 	Lipid-Associated Sialic Acid w/ Serial Graphics	 	each	 	[***]*
	3860C	 	84999	 	Neuron-specific Enolase CSF	 	each	 	[***]*
	3868C	 	83520	 	Interleukin-1 beta CSF	 	each	 	[***]*
	3870C	 	83520	 	Interleukin-2 CSF	 	each	 	[***]*
	3872 UR	 	83520	 	Pancreatitis DetectR; Urine Random	 	each	 	[***]*
	3908C	 	83520	 	Tumor Necrosis Factor-binding Proteins CSF	 	each	 	[***]*
	3943SR	 	82310; 83970	 	Graph	 	each	 	[***]*
	3946UR	 	83150	 	Homovanillic Acid; Urine Random	 	each	 	[***]*
	3970U	 	82507; 82570	 	Citrate; 24hr Urine	 	each	 	[***]*
	3970UR	 	82507; 82570	 	Citrate Urine Random	 	each	 	[***]*
	4011C	 	83520	 	Ganglioside Asialo-GM1 Autoabs CSF	 	each	 	[***]*
	4021C	 	83520x4; 86256; 86334	 	Motor & Sensory Neuropathy Evaluation CSF	 	each	 	[***]*
	4026C	 	83520x7; 86334	 	Motor Neuropathy Evaluation CSF	 	each	 	[***]*
	4041C	 	83520	 	Ganglioside GD1b Autoabs CSF	 	each	 	[***]*
	4080U	 	82175; 83655; 83825	 	Heavy Metal Screen 24hr Urine	 	each	 	[***]*
	4080UR	 	82175; 83655; 83825	 	Heavy Metal Screen Urine Random	 	each	 	[***]*
	4080W	 	82175; 83655; 83825	 	Heavy Metal Screen Whole Blood	 	each	 	[***]*
	4099UR	 	83520	 	Leukotriene B4 (LTB4)	 	each	 	[***]*
	4102U	 	82055	 	Alcohol; Ethyl Urine	 	each	 	[***]*
	4102W	 	82055	 	Alcohol; Ethyl Whole Blood	 	each	 	[***]*
	4103U	 	80101	 	Lysergic Acid Diethylamide (LSD) Screen; Urine	 	each	 	[***]*
	4106U	 	82145	 	Amphetamine/Methamphetamine Urine	 	each	 	[***]*
	4108U	 	80101	 	Barbiturates Urine	 	each	 	[***]*
	4110U	 	80101	 	Benzodiazepine Screen Urine	 	each	 	[***]*
	4118U	 	80101	 	Cocaine Metabolites Urine	 	each	 	[***]*
	4125U	 	80101	 	Drugs of Abuse Screen Urine	 	each	 	[***]*
	4132U	 	80101	 	Cannabinoids Urine	 	each	 	[***]*
	4134U	 	83840	 	Methadone Urine	 	each	 	[***]*
	4138U	 	83925	 	Opiates Urine	 	each	 	[***]*
	4140U	 	83992	 	Phencyclidine Urine	 	each	 	[***]*
	4149U	 	80299	 	Propoxyphene Urine	 	each	 	[***]*
	4266U	 	82523; 82570	 	N-Telopeptides w/ Creatinine	 	each	 	[***]*
	4311SR	 	80158	 	Cyclosporin A & Metabolites Whole Blood [FPIA-Monoclonal] w/ SR	 	each	 	[***]*
	4332U	 	83945	 	Oxalate 24hr Urine	 	each	 	[***]*
	4332UR	 	83945	 	Oxalate Random Urine	 	each	 	[***]*
	4333U	 	84560	 	Uric Acid; 24hr Urine	 	each	 	[***]*
	4333UR	 	84560	 	Uric Acid Random Urine	 	each	 	[***]*
	4397U	 	83018	 	Antimony 24hr Urine	 	each	 	[***]*
	4397UR	 	83018	 	Antimony Urine Random	 	each	 	[***]*
	4397W	 	83018	 	Antimony Whole Blood	 	each	 	[***]*
	4500UR	 	82232; 82300x2; 82570	 	Cadmium Exposure Panel—OSHA—Random Urine	 	each	 	[***]*
	4501U	 	82232; 82300; 82570	 	Cadmium Exposure Panel 24hr Urine	 	each	 	[***]*
	4501UR	 	82232; 82300; 82570	 	Cadmium Exposure Panel Urine Random	 	each	 	[***]*
	4502U	 	82300; 82570	 	Cadmium Exposure Panel 24hr Urine—Limited	 	each	 	[***]*

46

 

	4502UR	 	82300; 82570	 	Cadmium Exposure Panel Urine Random—Limited	 	each	 	[***]*
	4836U	 	82340	 	Calcium; Total 24hr Urine	 	each	 	[***]*
	4836UR	 	82340	 	Calcium; Urine Random	 	each	 	[***]*
	48611	 	83655	 	Lead Industrial (OSHA) Whole Blood	 	each	 	[***]*
	4861NY	 	83655	 	Lead Whole Blood New York	 	each	 	[***]*
	4861U	 	83655	 	Lead 24hr Urine	 	each	 	[***]*
	4861UR	 	83655	 	Lead Urine Random	 	each	 	[***]*
	4861W	 	83655	 	Lead Whole Blood	 	each	 	[***]*
	4862D	 	82108	 	Aluminum Dialysate	 	each	 	[***]*
	4862SR	 	82108	 	Aluminum Serial Graphics	 	each	 	[***]*
	4862U	 	82108	 	Aluminum 24hr Urine	 	each	 	[***]*
	4862UR	 	82108	 	Aluminum Urine Random	 	each	 	[***]*
	4862W	 	82108	 	Aluminum Whole Blood	 	each	 	[***]*
	4866R	 	83735	 	Magnesium RBC	 	each	 	[***]*
	4866U	 	83735	 	Magnesium 24hr Urine	 	each	 	[***]*
	4866UR	 	83735	 	Magnesium Urine Random	 	each	 	[***]*
	4867L	 	82175	 	Arsenic; Liquid	 	each	 	[***]*
	4867U	 	82175	 	Arsenic 24hr Urine	 	each	 	[***]*
	4867UI	 	82175; 82570	 	Arsenic Urine Industrial	 	each	 	[***]*
	4867UR	 	82175	 	Arsenic Urine Random	 	each	 	[***]*
	4867W	 	82175	 	Arsenic Whole Blood	 	each	 	[***]*
	4868U	 	82300	 	Cadmium 24hr Urine	 	each	 	[***]*
	4868UR	 	82300	 	Cadmium Urine Random	 	each	 	[***]*
	4868W	 	82300	 	Cadmium Whole Blood	 	each	 	[***]*
	4870PL	 	82525	 	Copper Plasma	 	each	 	[***]*
	4870R	 	82525	 	Copper RBC	 	each	 	[***]*
	4870U	 	82525	 	Copper 24hr Urine	 	each	 	[***]*
	4870UR	 	82525	 	Copper Urine Random	 	each	 	[***]*
	4871U	 	80178	 	Lithium 24hr Urine	 	each	 	[***]*
	4871UR	 	80178	 	Lithium Urine Random	 	each	 	[***]*
	4872R	 	83785	 	Manganese RBC	 	each	 	[***]*
	4872U	 	83785	 	Manganese 24hr Urine	 	each	 	[***]*
	4872UR	 	83785	 	Manganese Urine Random	 	each	 	[***]*
	4872W	 	83785	 	Manganese Whole Blood	 	each	 	[***]*
	4873U	 	83825	 	Mercury 24hr Urine	 	each	 	[***]*
	4873UI	 	82570; 83825	 	Mercury Urine Industrial	 	each	 	[***]*
	4873UR	 	83825	 	Mercury Urine Random	 	each	 	[***]*
	4873W	 	83825	 	Mercury Whole Blood	 	each	 	[***]*
	4874R	 	84132	 	Potassium RBC	 	each	 	[***]*
	4875R	 	84255	 	Selenium RBC	 	each	 	[***]*
	4875U	 	84255	 	Selenium 24hr Urine	 	each	 	[***]*
	4875UR	 	84255	 	Selenium Random Urine	 	each	 	[***]*
	4875W	 	84255	 	Selenium Whole Blood	 	each	 	[***]*
	4877PL	 	84630	 	Zinc Plasma	 	each	 	[***]*
	4877R	 	84630	 	Zinc RBC	 	each	 	[***]*
	4877U	 	84630	 	Zinc 24hr Urine	 	each	 	[***]*
	4877UR	 	84630	 	Zinc Urine Random	 	each	 	[***]*
	4880W	 	83018	 	Molybdenum; Whole blood	 	each	 	[***]*
	4900P	 	80150x2	 	Amikacin Peak & Trough	 	each	 	[***]*
	4901P	 	80170x2	 	Gentamicin Peak & Trough	 	each	 	[***]*

47

	 	 	 	 	 	 	 	 	 each

  

	4902P	 	80200x2	 	Tobramycin Peak & Trough	 	each	 	[***]*
	4903P	 	80202x2	 	Vancomycin Peak & Trough	 	each	 	[***]*
	4908P	 	80299x2	 	5-Fluorocytosine Peak & Trough	 	each	 	[***]*
	4915P	 	80299x2	 	Isoniazid Peak & Trough	 	each	 	[***]*
	4919P	 	80299x2	 	Rifampin Peak & Trough	 	each	 	[***]*
	4925P	 	80201x2	 	Topiramate Peak & Trough	 	each	 	[***]*
	4988UR	 	83874	 	Myoglobin Urine Random	 	each	 	[***]*
	5301C	 	82947	 	Glucose; CSF	 	each	 	[***]*
	5301P	 	82947	 	Glucose; Plasma	 	each	 	[***]*
	5303C	 	82438	 	Chloride CSF	 	each	 	[***]*
	5303U	 	82436	 	Chloride; 24hr Urine	 	each	 	[***]*
	5303UR	 	82436	 	Chloride; Urine Random	 	each	 	[***]*
	5306U	 	84300	 	Sodium; 24hr Urine	 	each	 	[***]*
	5306UR	 	84300	 	Sodium Urine ISE Random	 	each	 	[***]*
	5308U	 	84105	 	Phosphorus; 24Hr Urine	 	each	 	[***]*
	5311C	 	84999	 	Potassium; CSF	 	each	 	[***]*
	5311U	 	84133	 	Potassium; 24hr Urine	 	each	 	[***]*
	5311UR	 	84133	 	Potassium Urine Random	 	each	 	[***]*
	5400BK	 	88182	 	DNA Ploidy & Cell Cycle Analysis Block	 	each	 	[***]*
	5400FZ	 	88182	 	DNA Ploidy & Cell Cycle Analysis Frozen	 	each	 	[***]*
	5400NI	 	88182	 	DNA Analysis [FC; No Interpretation]	 	each	 	[***]*
	5400TBK	 	88182	 	NonBreast DNA Ploidy & Cell Cycle Analysis Block	 	each	 	[***]*
	5400TFZ	 	88182	 	NonBreast DNA Ploidy & Cell Cycle Analysis Frozen	 	each	 	[***]*
	5400U	 	88182	 	DNA Ploidy & Cell Cycle Analysis Bladder/Urine	 	each	 	[***]*
	5402NI	 	88182	 	DNA Analysis [IA; No Interpretation]	 	each	 	[***]*
	5652CLA	 	87190	 	AFB Suscept: Custom Disk Diffusion-Clarithromycin	 	each	 	[***]*
	5652ETH	 	87190	 	AFB Suscept: Custom Disk Diffusion-Ethambutol	 	each	 	[***]*
	5652MIN	 	87190	 	AFB Suscept: Custom Disk Diffusion-Minocycline	 	each	 	[***]*
	5652RIF	 	87190	 	AFB Suscept: Custom Disk Diffusion-Rifampin	 	each	 	[***]*
	5652TRI	 	87190	 	AFB Suscept: Custom Disk Diffusion-Trim/Sulfa	 	each	 	[***]*
	5654AM	 	87190	 	Amikacin	 	each	 	[***]*
	5654CA	 	87190	 	AFB Suscept: Custom Drug Radiometric Assay-Capreomycin	 	each	 	[***]*
	5654CI	 	87190	 	AFB Suscept: Custom Drug Radiometric Assay-Ciprofloxacin	 	each	 	[***]*
	5654CL	 	87190	 	AFB Suscept: Custom Drug Radiometric Assay-Clofazamine	 	each	 	[***]*
	5654ET1	 	87190	 	AFB Suscept: Custom Drug Radiometric Assay-Ethambutol	 	each	 	[***]*
	5654ET2	 	87190	 	AFT Suscept: Custom Drug Radiometric Assay-Ethionamide	 	each	 	[***]*
	5654IS	 	87190	 	Isoniazid	 	each	 	[***]*
	5654KA	 	87190	 	Kanamycin	 	each	 	[***]*

48

 

	5654PAS	 	87190x2	 	AFT Suscept: Custom Drug Radiomet Assay-p-Aminosalic Acid	 	each	 	[***]*
	5654PY	 	87190	 	AFB Suscept: Custom Drug Radiometric Assay-Pyrazinamide	 	each	 	[***]*
	5654RI	 	87190	 	Rifampin	 	each	 	[***]*
	5654ST	 	87190	 	AFB Suscept: Custom Drug Radiometic Assay-Streptomycin	 	each	 	[***]*
	5655AMI	 	87190	 	Amikacin	 	each	 	[***]*
	5655CEF	 	87190	 	Cefoxitin	 	each	 	[***]*
	5655CIP	 	87190	 	AFB Suscept: Custom Drug for Rapid Growers-Ciprofloxacin	 	each	 	[***]*
	5655CLA	 	87190	 	AFB Suscept: Custom Drug for Rapid Growers-Clarithromycin	 	each	 	[***]*
	5655DOX	 	87190	 	AFB Suscept: Custom Drug for Rapid Growers-Doxycycline	 	each	 	[***]*
	5655ERY	 	87190	 	AFB Suscept: Custom Drug for Rapid Growers-Erythromycin	 	each	 	[***]*
	5655GEN	 	87190	 	Gentamicin	 	each	 	[***]*
	5655IMI	 	87190	 	Imipenem	 	each	 	[***]*
	5655KAN	 	87190	 	Kanamycin	 	each	 	[***]*
	5655MIN	 	87190	 	AFB Suscept: Custom Drug for Rapid Growers-Minocycline	 	each	 	[***]*
	5655OFL	 	87190	 	Ofloxacin	 	each	 	[***]*
	5655TOB	 	87190	 	AFB Suscept: Custom Drug for Rapid Growers-Tobramycin	 	each	 	[***]*
	5661AM	 	87192	 	Fungus Susceptibility: Custom MIC-Amphotericin B	 	each	 	[***]*
	5661FC	 	87192	 	Fungus Susceptibility: Custom MIC-5-Fluorocytosine	 	each	 	[***]*
	5661FL	 	87192	 	Fungus Susceptibility: Custom MIC-Fluconazole	 	each	 	[***]*
	5661IT	 	87192	 	Fungus Susceptibility: Custom MIC-Itraconazole	 	each	 	[***]*
	5661KE	 	87192	 	Fungus Susceptibility: Custom MIC-Ketoconazole	 	each	 	[***]*
	5661MI	 	87192	 	Fungus Susceptibility: Custom MIC-Miconazole	 	each	 	[***]*
	5662AM	 	87187; 87192	 	Fungus Susceptibility: Custom MIC & MFC-Amphotericin B	 	each	 	[***]*
	5662FC	 	87187; 87192	 	Fungus Susceptibility: Custom MIC & MFC-5-Fluorocytosine	 	each	 	[***]*
	5662FL	 	87187; 87192	 	Fluconazole	 	each	 	[***]*
	5662IT	 	87187; 87192	 	Itraconazole	 	each	 	[***]*
	5662KE	 	87187; 87192	 	Ketoconazole	 	each	 	[***]*
	5662MI	 	87187; 87192	 	Fungus Susceptibility: Custom MIC & MFC-Miconazole	 	each	 	[***]*
	5668AMD	 	87181	 	Aerobic Suscept: Custom Drug-Amdinocillin	 	each	 	[***]*
	5668AMI	 	87181	 	Aerobic Suscept: Custom Drug-Amikacin	 	each	 	[***]*
	5668AMP1	 	87181	 	Aerobic Suscept: Custom Drug-Ampicillin	 	each	 	[***]*
	5668AUG	 	87181	 	Aerobic Suscept: Custom Drug-Augmentin	 	each	 	[***]*
	5668AZI	 	87181	 	Aerobic Suscept: Custom Drug-Azithromycin	 	each	 	[***]*

49

 

	5668AZT	 	87181	 	Aerobic Suscept: Custom Drug-Aztreonam	 	each	 	[***]*
	5668CAR	 	87181	 	Aerobic Suscept: Custom Drug-Carbenicillin	 	each	 	[***]*
	5668CEF1	 	87181	 	Aerobic Suscept: Custom Drug-Cefaclor	 	each	 	[***]*
	5668CEF3	 	87181	 	Aerobic Suscept: Custom Drug-Cefazolin	 	each	 	[***]*
	5668CEF4	 	87181	 	Aerobic Suscept: Custom Drug-Cefixime	 	each	 	[***]*
	5668CEF5	 	87181	 	Aerobic Suscept: Custom Drug-Cefonicid	 	each	 	[***]*
	5668CEF6	 	87181	 	Aerobic Suscept: Custom Drug-Cefoperazone	 	each	 	[***]*
	5668CEF8	 	87181	 	Aerobic Suscept: Custom Drug-Cefotetan	 	each	 	[***]*
	5668CEF9	 	87181	 	Aerobic Suscept: Custom Drug-Cefoxitin	 	each	 	[***]*
	5668CF10	 	87181	 	Aerobic Suscept: Custom Drug-Ceftazidime	 	each	 	[***]*
	5668CF11	 	87181	 	Aerobic Suscept: Custom Drug-Ceftizoxime	 	each	 	[***]*
	5668CF12	 	87181	 	Aerobic Suscept: Custom Drug-Ceftriaxone	 	each	 	[***]*
	5668CF13	 	87181	 	Aerobic Suscept: Custom Drug-Cefuroxime	 	each	 	[***]*
	5668CF14	 	87181	 	Aerobic Suscept: Custom Drug-Ceftibuten	 	each	 	[***]*
	5668CF15	 	87181	 	Aerobic Suscept: Custom Drug-Cefpodoxime	 	each	 	[***]*
	5668CHL	 	87181	 	Aerobic Suscept: Custom Drug-Chloramphenicol	 	each	 	[***]*
	5668CIP	 	87181	 	Aerobic Suscept: Custom Drug-Ciprofloxacin	 	each	 	[***]*
	5668CLA	 	87181	 	Aerobic Suscept: Custom Drug-Clarithromycin	 	each	 	[***]*
	5668CLI	 	87181	 	Aerobic Suscept: Custom Drug-Clindamycin	 	each	 	[***]*
	5668ERY	 	87181	 	Aerobic Suscept: Custom Drug-Erythromycin	 	each	 	[***]*
	5668GEN	 	87181	 	Aerobic Suscept: Custom Drug-Gentamicin	 	each	 	[***]*
	5668IMI	 	87181	 	Aerobic Suscept: Custom Drug-Imipenem	 	each	 	[***]*
	5668LEV	 	87181	 	Aerobic Suscept: Custom Drug-Levofloxacin	 	each	 	[***]*
	5668NET	 	87181	 	Aerobic Suscept: Custom Drug-Netilmicin	 	each	 	[***]*
	5668NIT	 	87181	 	Aerobic Suscept: Custom Drug-Nitrofurantoin	 	each	 	[***]*
	5668NOR	 	87181	 	Aerobic Suscept: Custom Drug-Norfloxacin	 	each	 	[***]*
	5668OXA	 	87181	 	Aerobic Suscept: Custom Drug-Oxacillin	 	each	 	[***]*
	5668PEN	 	87181	 	Aerobic Suscept: Custom Drug-Penicillin G	 	each	 	[***]*
	5668PIP1	 	87181	 	Aerobic Suscept: Custom Drug-Piperacillin	 	each	 	[***]*
	5668RIF	 	87181	 	Aerobic Suscept: Custom Drug-Rifampin	 	each	 	[***]*
	5668STR	 	87181	 	Aerobic Suscept: Custom Drug-Streptomycin	 	each	 	[***]*
	5668TET	 	87181	 	Aerobic Suscept: Custom Drug-Tetracycline	 	each	 	[***]*
	5668TIC	 	87181	 	Aerobic Suscept: Custom Drug-Ticarcillin	 	each	 	[***]*
	5668TOB	 	87181	 	Aerobic Suscept: Custom Drug-Tobramycin	 	each	 	[***]*
	5668TRI	 	87181	 	Aerobic Suscept: Custom Drug-Trimethoprim/Sulfamethoxazole	 	each	 	[***]*
	5668VAN	 	87181	 	Aerobic Suscept: Custom Drug-Vancomycin	 	each	 	[***]*
	5675AMI	 	87186	 	Aerobic Suscept: Custom MIC—Amikacin	 	each	 	[***]*
	5675AMP1	 	87186	 	Aerobic Suscept: Custom MIC—Ampicillin	 	each	 	[***]*
	5675AMP2	 	87186	 	Aerobic Suscept: Custom MIC—AMP/Sulbactam	 	each	 	[***]*
	5675AUG	 	87186	 	Aerobic Suscept: Custom MIC—Augmentin	 	each	 	[***]*
	5675AZI	 	87186	 	Aerobic Suscept: Custom MIC—Azithromycin	 	each	 	[***]*
	5675AZT	 	87186	 	Aerobic Suscept: Custom MIC—Aztreonam	 	each	 	[***]*
	5675BEN	 	87186	 	Aerobic Suscept: Custom MIC—Benzylpenicillin	 	each	 	[***]*
	5675CAR	 	87186	 	Aerobic Suscept: Custom MIC—Carbenicillin	 	each	 	[***]*

50

 

	5675CEF1	 	87186	 	Aerobic Suscept: Custom MIC—Cefaclor	 	each	 	[***]*
	5675CEF3	 	87186	 	Aerobic Suscept: Custom MIC—Cefazolin	 	each	 	[***]*
	5675CEF4	 	87186	 	Aerobic Suscept: Custom MIC—Cefixime	 	each	 	[***]*
	5675CEF6	 	87186	 	Aerobic Suscept: Custom MIC—Cefoperazone	 	each	 	[***]*
	5675CEF7	 	87186	 	Aerobic Suscept: Custom MIC—Cefotaxime	 	each	 	[***]*
	5675CEF8	 	87186	 	Aerobic Suscept: Custom MIC—Cefotetan	 	each	 	[***]*
	5675CEF9	 	87186	 	Aerobic Suscept: Custom MIC—Cefoxitin	 	each	 	[***]*
	5675CEP	 	87186	 	Aerobic Suscept: Custom MIC—Cephalothin	 	each	 	[***]*
	5675CF10	 	87186	 	Aerobic Suscept: Custom MIC—Ceftazidime	 	each	 	[***]*
	5675CF11	 	87186	 	Aerobic Suscept: Custom MIC—Ceftizoxime	 	each	 	[***]*
	5675CF12	 	87186	 	Aerobic Suscept: Custom MIC—Ceftriaxone	 	each	 	[***]*
	5675CF13	 	87186	 	Aerobic Suscept: Custom MIC—Cefuroxime	 	each	 	[***]*
	5675CF14	 	87186	 	Aerobic Suscept: Custom MIC—Cefepime	 	each	 	[***]*
	5675CF15	 	87186	 	Aerobic Suscept: Custom MIC—Cefpodoxime	 	each	 	[***]*
	5675CHL	 	87186	 	Aerobic Suscept: Custom MIC—Chloramphenicol	 	each	 	[***]*
	5675CIP	 	87186	 	Aerobic Suscept: Custom MIC—Ciprofloxacin	 	each	 	[***]*
	5675CLA	 	87190	 	Aerobic Suscept: Custom MIC—Clarithromycin	 	each	 	[***]*
	5675CLI	 	87186	 	Aerobic Suscept: Custom MIC—Clindamycin	 	each	 	[***]*
	5675ERY	 	87186	 	Aerobic Suscept: Custom MIC—Erythromycin	 	each	 	[***]*
	5675GEN	 	87186	 	Aerobic Suscept: Custom MIC—Gentamicin	 	each	 	[***]*
	5675IMI	 	87186	 	Aerobic Suscept: Custom MIC—Imipenem	 	each	 	[***]*
	5675LEV	 	87186	 	(Levaquin)	 	each	 	[***]*
	5675LOM	 	87186	 	Aerobic Suscept: Custom MIC—Lomefloxacin	 	each	 	[***]*
	5675MEZ	 	87186	 	Aerobic Suscept: Custom MIC—Mezlocillin	 	each	 	[***]*
	5675MIN	 	87186	 	Aerobic Suscept: Custom MIC—Minocycline	 	each	 	[***]*
	5675NIT	 	87186	 	Aerobic Suscept: Custom MIC—Nitrofurantoin	 	each	 	[***]*
	5675NOR	 	87186	 	Aerobic Suscept: Custom MIC—Norfloxacin	 	each	 	[***]*
	5675OFL	 	87186	 	Aerobic Suscept: Custom MIC—Ofloxacin	 	each	 	[***]*
	5675OXA	 	87186	 	Aerobic Suscept: Custom MIC—Oxacillin	 	each	 	[***]*
	5675PEN	 	87186	 	Aerobic Suscept: Custom MIC—Penicillin G	 	each	 	[***]*
	5675PIP1	 	87186	 	Aerobic Suscept: Custom MIC—Piperacillin	 	each	 	[***]*
	5675PIP2	 	87186	 	Piperacillin/Tazobactam	 	each	 	[***]*
	5675QUI	 	87186	 	Quinupristin/Dalfopristin	 	each	 	[***]*
	5675RIF	 	87186	 	Aerobic Suscept: Custom MIC—Rifampin	 	each	 	[***]*
	5675STR	 	87186	 	Aerobic Suscept: Custom MIC—Streptomycin	 	each	 	[***]*
	5675SUL1	 	87186	 	Aerobic Suscept: Custom MIC—Sulfadiazine	 	each	 	[***]*
	5675TET	 	87186	 	Aerobic Suscept: Custom MIC—Tetracycline	 	each	 	[***]*
	5675TIM	 	87186	 	Aerobic Suscept: Custom MIC—Timentin	 	each	 	[***]*
	5675TOB	 	87186	 	Aerobic Suscept: Custom MIC—Tobramycin	 	each	 	[***]*
	5675TRI	 	87186	 	Aerobic Suscept: Custom MIC—Trim/Sulfa	 	each	 	[***]*
	5675TRO	 	87186	 	Aerobic Suscept: Custom MIC—Trovafloxacin	 	each	 	[***]*

51

 

	5675VAN	 	87186	 	Aerobic Suscept: Custom MIC—Vancomycin	 	each	 	[***]*
	5676AMI	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Amikacin	 	each	 	[***]*
	5676AMP1	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Ampicillin	 	each	 	[***]*
	5676AMP2	 	87186; 87187	 	AMP/Sulbactam	 	each	 	[***]*
	5676AZT	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Aztreonam	 	each	 	[***]*
	5676CAR	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Carbenicillin	 	each	 	[***]*
	5676CEF1	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Cefaclor	 	each	 	[***]*
	5676CEF3	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Cefazolin	 	each	 	[***]*
	5676CEF4	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Cefixime	 	each	 	[***]*
	5676CEF6	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Cefoperazone	 	each	 	[***]*
	5676CEF7	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Cefotaxime	 	each	 	[***]*
	5676CEF8	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Cefotetan	 	each	 	[***]*
	5676CEF9	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Cefoxitin	 	each	 	[***]*
	5676CEP	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Cephalothin	 	each	 	[***]*
	5676CF10	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Ceftazidime	 	each	 	[***]*
	5676CF11	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Ceftizoxime	 	each	 	[***]*
	5676CF12	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Ceftriaxone	 	each	 	[***]*
	5676CF13	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Cefuroxime	 	each	 	[***]*
	5676CF14	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Cefepime	 	each	 	[***]*
	5676CF15	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Cefpodoxime	 	each	 	[***]*
	5676CHL	 	87186; 87187	 	Chloramphenicol	 	each	 	[***]*
	5676CIP	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Ciprofloxacin	 	each	 	[***]*
	5676CLA	 	87187; 87190	 	Aerobic Suscept: Custom MIC & MBC—Clarithromycin	 	each	 	[***]*
	5676CLI	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Clindamycin	 	each	 	[***]*
	5676ERY	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Erythromycin	 	each	 	[***]*
	5676GEN	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Gentamicin	 	each	 	[***]*
	5676IMI	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Imipenem	 	each	 	[***]*

52

 

	5676LEV	 	87186; 87187	 	Aerobic Suscept: Custom Mic & Mbc—Levofloxacin (Levaquin)	 	each	 	[***]*
	5676NIT	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Nitrofurantoin	 	each	 	[***]*
	5676NOR	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Norfloxacin	 	each	 	[***]*
	5676OFL	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Ofloxacin	 	each	 	[***]*
	5676OXA	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Oxacillin	 	each	 	[***]*
	5676PEN	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Penicillin G	 	each	 	[***]*
	5676PIP1	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Piperacillin	 	each	 	[***]*
	5676PIP2	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Piperacillin/Tazobactam	 	each	 	[***]*
	5676QUI	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Quinupristin/Dalfopristin	 	each	 	[***]*
	5676RIF	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Rifampin	 	each	 	[***]*
	5676STR	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Streptomycin	 	each	 	[***]*
	5676TET	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Tetracycline	 	each	 	[***]*
	5676TOB	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Tobramycin	 	each	 	[***]*
	5676TRI	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Trimethoprim/Sulfa	 	each	 	[***]*
	5676TRO	 	87186; 87187	 	Aerobic Suscept: Custom MIC & MBC—Trovafloxacin	 	each	 	[***]*
	5676VAN	 	87186; 87187	 	Aerobic Suscept: Custom MIC &MBC—Vancomycin	 	each	 	[***]*
	5721AZT	 	87252	 	HIV-1 Anti-Viral Drug Study: AZT IC50 Value	 	each	 	[***]*
	5721DDC	 	87252	 	HIV-1 Anti-Viral Drug Study;: ddC IC50 Value	 	each	 	[***]*
	5721DDI	 	87252	 	HIV-1 Anti-Viral Drug Study: ddI IC50 Value	 	each	 	[***]*
	5768AMI	 	87190	 	Amikacin	 	each	 	[***]*
	5768ANS	 	87190	 	AFB Suscept: Custom Drug Mycobacterium spp.—Ansamycin	 	each	 	[***]*
	5768AZI	 	87190	 	AFB Suscept: Custom Drug Mycobacterium spp.—Azithromycin	 	each	 	[***]*
	5768CAP	 	87190	 	AFB Suscept: Custom Drug Mycobacterium spp.—Capreomycin	 	each	 	[***]*
	5768CIP	 	87190	 	AFB Suscept: Custom Drug Mycobacterium spp.—Ciprofloxacin	 	each	 	[***]*
	5768CLA	 	87190	 	AFB Suscept: Custom Drug Mycobacterium spp.—Clarithromycin	 	each	 	[***]*
	5768CLO	 	87190	 	AFB Suscept: Custom Drug Mycobacterium spp.—Clofazimine	 	each	 	[***]*

53

 

	5768CYC	 	87190	 	AFB Suscept: Custom Drug Mycobacterium spp.—Cycloserine	 	each	 	[***]*
	5768ET1	 	87190	 	AFB Suscept: Custom Drug Mycobacterium spp.—Ethambutol	 	each	 	[***]*
	5768ET2	 	87190	 	AFB Suscept: Custom Drug Mycobacterium spp.—Ethionamide	 	each	 	[***]*
	5768ISO	 	87190	 	Isoniazid	 	each	 	[***]*
	5768PAS	 	87190	 	AFB Suscept: Custom Drug Mycobacterium spp.—p Aminosalicylic	 	each	 	[***]*
	5768PYR	 	87190	 	AFB Suscept: Custom Drug Mycobacterium spp.—Pyrazinamide	 	each	 	[***]*
	5768RIF	 	87190	 	Rifampin	 	each	 	[***]*
	5768STR	 	87186	 	AFB Suscept: Custom Drug Mycobacterium spp.—Streptomycin	 	each	 	[***]*
	5946AD	 	85576	 	Platelet Aggregation; ADP	 	each	 	[***]*
	5946AR	 	85576	 	Platelet Aggregation; Arachidonic Acid	 	each	 	[***]*
	5946CO	 	85576	 	Platelet Aggregation; Collagen	 	each	 	[***]*
	5946EP	 	85576	 	Platelet Aggregation; Epinephrine	 	each	 	[***]*
	5946RT	 	85576	 	Platelet Aggregation; Ristocetin	 	each	 	[***]*
	5946SP	 	85576	 	Platelet Aggregation; Spontaneous	 	each	 	[***]*
	7221C	 	86606x3; 86612; 86635x3; 86698x3	 	Fungal Abs [EIA] CSF	 	each	 	[***]*
	7224C	 	86606; 86612; 86635; 86698	 	Fungal IgG Abs CSF	 	each	 	[***]*
	7476SR	 	87522	 	Hepatitis C Virus RNA AccuQuant rflx GenotypR w/Serial Graph	 	each	 	[***]*
	7477NY	 	83891x14; 83898x4; 83904x6; 83912	 	HIV-1 GenotypR (Reverse Transcriptase Inhibitor) New York	 	each	 	[***]*
	7478A	 	87536	 	HIV-1 RNA Quant by Roche rflx Ultrasensitive+GenotypeR (RTI)	 	each	 	[***]*
	7478ASR	 	87536	 	HIV-1 RNA Quant by Roche rfx Ultrasens+GenotypR RTI w/SerRep	 	each	 	[***]*
	7478NY	 	87536	 	HIV-1 RNA Quant by Roche reflex HIV GenotypR (RTI) New York	 	each	 	[***]*
	7478NYSR	 	87536	 	HIF-1 RNA Quant by Roche rfx HIV GenotypR RTI New York w/SR	 	each	 	[***]*
	7478SR	 	87536	 	HIV-1 RNA UltraQuant reflx to HIV GenotypR (RTI) w/Ser Rep	 	each	 	[***]*
	7479NY	 	83891x4; 83898x2; 83904x2; 83912	 	HIV-1 GentypR (Protease Inhibitor) New York	 	each	 	[***]*
	7480NY	 	83891x13; 83898x5; 83904x8; 83912	 	HIV-1 GenotypR PLUS (Rev Trans & Prot Inhib) New York	 	each	 	[***]*
	7482A	 	87536	 	HIV-1 RNA Quant by Roche rfx to Ultrasensitive+GenotypR PLUS	 	each	 	[***]*
	7482ASR	 	87536	 	HIV-1 RNA Quant by Roche rflx Ultrasens + GentypR PLUS w/SR	 	each	 	[***]*
	7482NY	 	87536	 	HIV-1 RNA Quant by Roche reflex HIV GenotypR PLUS New York	 	each	 	[***]*
	7482NYSR	 	87536	 	HIV-1 RNA Quant by Roche rfx HIV GenotypR PLUS New York w/SR	 	each	 	[***]*

54

 

	7482SR	 	87536	 	HIV-1 RNA UltraQuant reflx to HIV GenotypR PLUS w/ Serial Rep	 	each	 	[***]*
	7483A	 	87536	 	HIV-1 RNA Quant by Roche reflx Ultrasens + GenotypR (PI)	 	each	 	[***]*
	7483ASR	 	87536	 	HIV-1 RNA Quant by Roche reflx Ultrasens + GenotypR (PI); Ser R	 	each	 	[***]*
	7483NY	 	87536	 	HIV-1 RNA UltraQuant reflx to HIV GenotypR (PI) New York	 	each	 	[***]*
	7483NYSR	 	87536	 	HIV-1 RNA UltraQuant rfx HIV GenotypR (PI) New York w/ Serial	 	each	 	[***]*
	7483SR	 	87536	 	HIV-1 RNA UltraQuant reflex to HIV GenotypR (PI) w/ Ser Rep	 	each	 	[***]*
	7485A	 	87536	 	HIV-1 RNA Quant by Roche Ultrasensitive	 	each	 	[***]*
	7485ASR	 	87536	 	HIV-1 RNA Quant by Roche Ultrasensitive with Serial Graphics	 	each	 	[***]*
	7486SR	 	87522	 	Hepatitis C Virus RNA AccuQuant w/ Serial Graphics	 	each	 	[***]*
	7491B	 	86804	 	Hepatitis C Virus RIBA Evaluation with reflex PCR	 	each	 	[***]*
	7560C	 	86781	 	CSF	 	each	 	[***]*
	7561C	 	86781	 	Treponema Pallidum IgG Abs CSF	 	each	 	[***]*
	7565F	 	86781x2	 	Treponema Pallidum IgG & IgM Abs Fluid	 	each	 	[***]*
	7566C	 	87285	 	Treponema Pallidum IgM Abs CSF	 	each	 	[***]*
	7576SR	 	87522	 	Hepatitis C Virus RNA UltraQuant w/ Serial Graph	 	each	 	[***]*
	7578SR	 	87522	 	Hepatitis C Virus RNA UltraQuant w/ Serial Graph reflex to HCV Genotyper	 	each	 	[***]*
	7584C	 	87799	 	Epstein-Barr Virus Dna UltraRapid CSF	 	each	 	[***]*
	7584PL	 	87799	 	Epstein-Barr Virus DNA UltraQuant Plasma	 	each	 	[***]*
	7596C	 	86790	 	Japanese Encephalitis Virus Total Abs CSF	 	each	 	[***]*
	7601C	 	86790	 	Dengue Virus Total Abs CSF	 	each	 	[***]*
	7621C	 	86720x2	 	Leptospira IgG & IgM Abs CSF	 	each	 	[***]*
	7646C	 	86790	 	Dengue Virus IgM Abs CSF	 	each	 	[***]*
	7661C	 	86778	 	Toxoplasma IgM Abs [ISAGA] CSF	 	each	 	[***]*
	7661F	 	86778	 	Toxoplasma IgM Abs [ISAGA] Fluid	 	each	 	[***]*
	7675C	 	86778	 	Toxoplasma IgM Abs [MAC EIA] CSF	 	each	 	[***]*
	7675F	 	86778	 	Toxoplasma IgM Abs [MAC EIA] Fluid	 	each	 	[***]*
	7711B	 	86617x2	 	Borrelia Burgdorferi IgG & IgM Abs [IB] + bands	 	each	 	[***]*
	7711BNY	 	86618x2	 	bands	 	each	 	[***]*
	7711C	 	86617x2	 	Borrelia Burgdorferi IgG & IgM Abs [IB] CSF	 	each	 	[***]*
	7711CB	 	86617x2	 	Borrelia Burgdorferi IgG & IgM Abs [IB] CSF + bands	 	each	 	[***]*
	7711SF	 	86617x2	 	Borrelia Burgdorferi IgG & IgM Abs [IB] Syn Fluid	 	each	 	[***]*
	7711SFB	 	86617x2	 	bands	 	each	 	[***]*
	7716B	 	86617x2; 86618x2	 	Borrelia Burgdorferi IgG & IgM Abs with IB + bands	 	each	 	[***]*
	7716BNY	 	86618x4	 	Borrelia Burgdorferi IgG & IgM Abs with IB + bands	 	each	 	[***]*

55

 

	7716C	 	86617x2; 86618x2	 	Borrelia Burgdorferi IgG & IgM Abs with IB CSF	 	each	 	[***]*
	7716CB	 	86617x2; 86618x2	 	bands	 	each	 	[***]*
	7716SF	 	86617x2; 86618x2	 	Borrelia Burgdorferi IgG & IgM Abs with Ib Syn Fluid	 	each	 	[***]*
	7751C	 	86674x3	 	Giardia Lamblia IgG; IgM & IgA Abs CSF	 	each	 	[***]*
	7776C	 	86790x2	 	Herpesvirus-6 Human Early Ag IgG & IgM Abs CSF	 	each	 	[***]*
	7780B	 	86689	 	HTLV-I/II Abs Confirmation + bands	 	each	 	[***]*
	7780C	 	86689	 	HTLV-I/II Abs Confirmation CSF	 	each	 	[***]*
	7780CB	 	86689	 	HTLV-I/II Abs Confirmation + bands CSF	 	each	 	[***]*
	7786C	 	86790	 	Herpesvirus-6 Human Early Ag IgG Abs CSF	 	each	 	[***]*
	7796C	 	86790	 	Herpesvirus-6 Human Early Ag IgM Abs CSF	 	each	 	[***]*
	7844C	 	86609x2	 	Ehrlichia equi IgG & IgM (HGE) Abs CSF	 	each	 	[***]*
	7844NY	 	86609x2	 	Ehrlichia equi IgG & IgM Abs; HGE New York	 	each	 	[***]*
	7848NY	 	86609x4	 	Ehrlichia chaffeensis (HME) & E. equi (HGE) IgG & IgM Abs—NY	 	each	 	[***]*
	7856C	 	86759	 	Rotavirus Abs CSF	 	each	 	[***]*
	7876C	 	86609x4	 	Rickettsia rickettsii & R. typhi IgG & IgM Abs Eval CSF	 	each	 	[***]*
	7896C	 	86609x2	 	Rickettsia rickettsii IgG & IgM Abs CSF	 	each	 	[***]*
	7911C	 	86609x2	 	Rickettsia typhi IgG & IgM Abs CSF	 	each	 	[***]*
	7951C	 	86609x2	 	Rickettsia conorii IgG & IgM Abs CSF	 	each	 	[***]*
	7960SF	 	82784x4; 86618x4; 87476	 	Neuroborreliosis AccuDx; Synovial Fluid	 	each	 	[***]*
	7970SF	 	82784x4; 86618x4	 	Borrelia Burgdorferi IgG & IgM Antibody Index Synovial Fluid	 	each	 	[***]*
	8051C	 	86694x2; 86695x2	 	Herpes Simplex Virus Types 1 and 2 IgG & IgM Abs CSF	 	each	 	[***]*
	8056C	 	86603	 	Adenovirus IgG Abs CSF	 	each	 	[***]*
	8071P	 	86631x2; 86632x2	 	Chlamydia pneumoniae Total & IgM Abs Paired	 	each	 	[***]*
	8076P	 	86631x2	 	Chlamydia pneumoniae Total Abs Paired	 	each	 	[***]*
	8091P	 	86658x6	 	Poliovirus Abs Paired	 	each	 	[***]*
	8147C	 	87799	 	JC Virus UltraRapid CSF	 	each	 	[***]*
	8151C	 	86744	 	Nocardia IgG Abs CSF	 	each	 	[***]*
	8171C	 	86668x3	 	Francisella Tularensis IgG; IgM & IgA Abs CSF	 	each	 	[***]*
	8176C	 	86651	 	California-LaCrosse Encephalitis IgM Abs CSF	 	each	 	[***]*
	8181C	 	86652	 	Eastern Equine Encephalitis IgM Abs CSF	 	each	 	[***]*
	8186C	 	86653	 	St. Louis Encephalitis IgM Abs CSF	 	each	 	[***]*
	8191C	 	86654	 	Western Equine Encephalitis IGM Abs CSF	 	each	 	[***]*
	8221C	 	86747x2	 	Parvovirus B19 IgG & IgM Abs [EIA] CSF	 	each	 	[***]*
	8226C	 	86651; 86652; 86653; 86654	 	Arbovirus IgM Abs CSF [IFA]	 	each	 	[***]*
	8236C	 	86747x2	 	Parvovirus B19 IgG & IgM Abs [IB] CSF	 	each	 	[***]*

56

 

	8241C	 	86609x2	 	Burkholderia (Pseudomonas) pseudomallei IgG & IgM Abs CSF	 	each	 	[***]*
	8246C	 	86713	 	CSF	 	each	 	[***]*
	8251C	 	86723	 	Listeria Monocytogenes IgG Abs CSF	 	each	 	[***]*
	8261C	 	86747x2; 87798	 	Parvovirus B19 Evaluation CSF	 	each	 	[***]*
	8286C	 	86671x3	 	Sporothrix IgG; IgM & IgA Abs CSF	 	each	 	[***]*
	8311C	 	86698x3	 	Histoplasma IgG; IgM & IgA Abs CSF	 	each	 	[***]*
	8315UR	 	87449	 	Histoplasma Antigen In Urine	 	each	 	[***]*
	8316C	 	86635	 	Coccidioides IgM Abs CSF	 	each	 	[***]*
	8321C	 	86635	 	Coccidioides IgG Abs CSF	 	each	 	[***]*
	8331C	 	86635x3	 	Coccidioides IgG; IgM & IgA Abs CSF	 	each	 	[***]*
	8346C	 	86612	 	Blastomyces IgG Abs CSF	 	each	 	[***]*
	8351C	 	86682x2	 	Schistosoma IgG and IgM Abs CSF	 	each	 	[***]*
	8371C	 	86750x2	 	Malaria Antibodies IgG & IgM Abs CSF [EIA]	 	each	 	[***]*
	8421C	 	86682	 	Fasciola IgG Abs CSF	 	each	 	[***]*
	8426C	 	86682x2	 	Fasciola IgG & IgM Abs CSF	 	each	 	[***]*
	8441C	 	86753x3	 	Entamoeba Histolytica IgG; IgM & IgA Abs CSF	 	each	 	[***]*
	8451C	 	86682	 	Echinococcus IgG Abs CSF	 	each	 	[***]*
	8516C	 	86710x6	 	Influenza Virus A & B IgG; IgM & IgA Abs CSF	 	each	 	[***]*
	8566C	 	86682	 	Strongyloides IgG Abs CSF	 	each	 	[***]*
	8576C	 	86771x4	 	Shigella Abs CSF	 	each	 	[***]*
	8666C	 	86658x10; 86710x2	 	Myopericarditis Viral Antibodies Evaluation CSF	 	each	 	[***]*
	8676C	 	86793	 	Yersinia enterocolitica Abs Serotype 0:3 CSF	 	each	 	[***]*
	8681C	 	86793	 	Yersinia enterocolitica Abs Serotype 0:8 CSF	 	each	 	[***]*
	8686C	 	86793	 	Yersinia enterocolitica Abs Serotype 0:9 CSF	 	each	 	[***]*
	8691C	 	86756x2	 	Respiratory Synctyial Virus IgG & IgM Abs CSF	 	each	 	[***]*
	8696C	 	86793x3	 	Yersinia Enterocolitica Abs Serotypes 0:3; 0:8; 0:9 CSF	 	each	 	[***]*
	8711C	 	86793	 	Yersinia Pseudotuberculosis Total Abs CSF	 	each	 	[***]*
	8721C	 	86793	 	Yersinia enterocolitica IgA Abs CSF	 	each	 	[***]*
	8731C	 	86738	 	Mycoplasma Pneumoniae IgA Abs CSF	 	each	 	[***]*
	8736C	 	86738x3	 	CSF	 	each	 	[***]*
	8741C	 	86738x2	 	Mycoplasma pneumoniae IgG & IgM Abs CSF	 	each	 	[***]*
	8741P	 	86738x4	 	Mycoplasma pneumoniae IgG & IgM Abs Paired	 	each	 	[***]*
	8746C	 	86738	 	Mycoplasma pneumoniae IgG Abs CSF	 	each	 	[***]*
	8751C	 	86738	 	Mycoplasma pneumoniae IgM Abs CSF	 	each	 	[***]*
	8756C	 	86787x2	 	Varicella-zoster Virus SeroDx; IgG & IgM Abs CSF	 	each	 	[***]*
	8760C	 	87799	 	Varicella-Zoster Virus Dna UltraRapid CSF	 	each	 	[***]*
	8761C	 	86787	 	Varicella-zoster Virus IgG Abs CSF	 	each	 	[***]*
	8766C	 	86787	 	Varicella-zoster Virus IgM Abs CSF	 	each	 	[***]*
	8771C	 	86765x2	 	Measles IgG & IgM Abs CSF	 	each	 	[***]*
	8776C	 	86765	 	Measles IgG Abs CSF	 	each	 	[***]*
	8781C	 	86765	 	Measles IgM Abs CSF	 	each	 	[***]*

57

 

	8831C	 	86622x3	 	Brucella abortus IgG; IgM & IgA Abs CSF	 	each	 	[***]*
	8836C	 	86622	 	Brucela abortus IgG Abs CSF	 	each	 	[***]*
	8841C	 	86723	 	Listeria Monocytogenes Abs CSF	 	each	 	[***]*
	8851C	 	86317x2	 	Bartonella henselae IgG 7 IgM Abs CSF	 	each	 	[***]*
	8866C	 	86625	 	Campylobacter jejuni Total Abs [EIA] CSF	 	each	 	[***]*
	8881C	 	86625	 	Campylobacter fetus Total Abs CSF	 	each	 	[***]*
	8886C	 	86625	 	Campylobacter jejuni Total Abs [CF] CSF	 	each	 	[***]*
	8921C	 	86653	 	St. Louis Encephalitis Total Abs CSF	 	each	 	[***]*
	8926C	 	86651	 	California-La Crosse Encephalitis Total ABS CSF	 	each	 	[***]*
	8931C	 	86654	 	Western Equine Encephalitis Total Abs CSF	 	each	 	[***]*
	8936C	 	86652	 	Eastsern Equine Encephalitis Total Abs CSF	 	each	 	[***]*
	8941C	 	86618x2	 	Borrelia burgdorferi IgG & IgM Abs [EIA] CSF	 	each	 	[***]*
	8941SF	 	86618x2	 	Borrelia burgdorferi IgG & IgM Abs [EIA] Syn Fluid	 	each	 	[***]*
	8945SF	 	82784x2; 86618x2	 	Borrelia burgdorferi IgG Antibody Index Synovial Fluid	 	each	 	[***]*
	8951C	 	86618	 	Borrelia burgdorferi IgG Abs CSF	 	each	 	[***]*
	8951SF	 	86618	 	Borrelia burgdorferi IgG Abs Syn Fluid	 	each	 	[***]*
	8961C	 	86618	 	Borrelia burgdorferi IgM Abs CSF	 	each	 	[***]*
	8961SF	 	86618	 	Borrelia burgdorferi IgGM Abs Syn Fluid	 	each	 	[***]*
	8981F	 	86665	 	Fluid	 	each	 	[***]*
	9099C	 	86641	 	Cryptococcus Abs CSF	 	each	 	[***]*
	9189C	 	87449	 	Cryptococcus Ag CSF	 	each	 	[***]*
	9189U	 	87449	 	Cryptococcus Ag Urine	 	each	 	[***]*
	9301C	 	86682x2	 	Filaria IgG & IgM Abs CSF	 	each	 	[***]*
	9371C	 	86638x2	 	Coxiella burnetii IgG Abs; Phase 1 & 2 CSF	 	each	 	[***]*
	9376C	 	86638x2	 	Coxiella burnetii IgM Abs; Phase 1 & 2 CSF	 	each	 	[***]*
	9381C	 	86638x6	 	Coxiella burnetii IgG; IgM; & IgA Abs; Phase 1 & 2 CSF	 	each	 	[***]*
	9386C	 	86784	 	Trichinella IgG Abs CSF	 	each	 	[***]*
	9391C	 	86631	 	Chlamydia trachomatis IgA Abs CSF	 	each	 	[***]*
	9396C	 	86619x2	 	Borrelia hermsii IgG & IgM Abs CSF	 	each	 	[***]*
	9401C	 	86631x2; 86632	 	Chlamydia trachomatis IgG; IgM & IgA Abs CSF	 	each	 	[***]*
	9406C	 	86631	 	Chlamydia trachomatis IgG Abs [EIA] CSF	 	each	 	[***]*
	9411C	 	86632	 	Chlamydia trachomatis IgM Abs [EIA] CSF	 	each	 	[***]*
	9416F	 	86762	 	Rubella IgG Abs Fluid	 	each	 	[***]*
	9421C	 	86762x2	 	Rubella IgG & IgM Abs CSF	 	each	 	[***]*
	9426C	 	86777	 	Toxoplasma IgG Abs CSF	 	each	 	[***]*
	9426F	 	86777	 	Toxoplasma IgG Abs Fluid	 	each	 	[***]*
	9430C	 	 	 	Cytomegalovirus Dna Ultraquant CSF	 	each	 	[***]*
	9430SR	 	87497	 	Cytomegalovirus DNA Ultraquant w/ Serial Graphics	 	each	 	[***]*
	9431C	 	86644	 	Cytomegalovirus IgG Abs CSF	 	each	 	[***]*
	9436C	 	86644; 86645	 	Cytomegalovirus IgG & IgM Abs CSF	 	each	 	[***]*
	9446C	 	86694; 86695	 	Herpes Simplex Virus Types 1 & 2 IgG Abs CSF	 	each	 	[***]*
	9451C	 	86695	 	Herpes SimplexVirus Type 1 IgG Abs CSF	 	each	 	[***]*
	9456C	 	86695	 	Herpes Simplex Virus Type 1 IgM Abs CSF	 	each	 	[***]*

58

 

	9461C	 	86694	 	Herpes Simplex Virus Type 2 IgG Abs CSF	 	each	 	[***]*
	9466C	 	86694	 	Herpes Simplex Virus Type 2 IgM Abs CSF	 	each	 	[***]*
	9471C	 	86694; 86695	 	Herpes Simplex Virus Type 1 & 2 IgM Abs CSF	 	each	 	[***]*
	9474C	 	87530	 	Herpes Simplex Virus Dna Ultraquant CSF	 	each	 	[***]*
	9476C	 	86695x2	 	Herpes Simplex Virus Type 1 IgG & IgM Abs CSF	 	each	 	[***]*
	9481C	 	86694x2	 	Herpes Simplex Virus Type 2 IgG & IgM Abs CSF	 	each	 	[***]*
	9521C	 	86651; 86652; 86653; 86654	 	Arbovirus Total Abs CSF	 	each	 	[***]*
	9601C	 	86588x2; 87449x7	 	Bacterial Ag Detection cSF	 	each	 	[***]*
	9601U	 	86588x2; 87449x7	 	Bacterial Ag Detection—Urine	 	each	 	[***]*
	9606C	 	87449	 	Haemophilus influenzae b Ag CSF	 	 	 	[***]*
	9606U	 	87449	 	Haemophilus influenzae b Ag Urine	 	each	 	[***]*
	9636C	 	86588	 	Streptococcus pheumoniae Ag CSF	 	each	 	[***]*
	9636U	 	86588	 	Streptococcus pneumoniae Ag Urine	 	each	 	[***]*
	9641C	 	86588	 	Streptococcus Group B Ag CSF	 	each	 	[***]*
	9641U	 	86588	 	Streptococcus Group B Ag Urine	 	each	 	[***]*
	9671C	 	86615	 	Bordetella pertussis/parapertussis IgG Abs CSF	 	each	 	[***]*
	9676C	 	86615x3	 	Bordetella pertussis/parapertussis IgG; IgM && IgA Abs CSF	 	each	 	[***]*
	9681C	 	86615x2	 	CSF	 	each	 	[***]*
	9711C	 	86735x2	 	Mumps IgG & IgM Abs CSF	 	each	 	[***]*
	9716C	 	86735	 	Mumps IgG Abs CSF	 	each	 	[***]*
	9721C	 	86735	 	Mumps IgM Abs CSF	 	each	 	[***]*
	9741C	 	86784x3	 	Trichinella IgG; IgM & IgA Abs CSF	 	each	 	[***]*
	9751C	 	86793x3	 	Yersinia enterocolitica IgG; IgM & IgA Abs CSF	 	each	 	[***]*
	9761F	 	86682x3	 	Toxocara IgG; IgM & IgA Abs Fluid	 	each	 	[***]*
	9816C	 	86682	 	Cysticercus IgG Abs CSF	 	each	 	[***]*
	9816CS	 	86682x2	 	Cysticercus IgG Abs Evaluation [Serum & CSF]	 	each	 	[***]*
	9861P	 	86684x2	 	Vaccination	 	each	 	[***]*
	9866c	 	86311	 	HIV-1 Ag Neutralization Confirmation Test CSF	 	each	 	[***]*
	9872SR	 	85048; 85595; 86361; 87536	 	HIV-1 RNA UltraQuant & CD4 Cell Count w/ Serial Report	 	each	 	[***]*
	9874A	 	87536	 	HIV-1 RNA Quant by Roche reflx Ultrasensitive	 	each	 	[***]*
	9874ASR	 	87536	 	HIV-1 RNA Quant by Roche w/ reflx Ultrasensitive w/ Serial Rep	 	each	 	[***]*
	9874NY	 	87536	 	HIV-1 RNA UltraQuant New York	 	each	 	[***]*
	9874NYSR	 	87536	 	HIV-1 RNA UltraQuant New York w/Serial Reporting	 	each	 	[***]*
	9874SR	 	87536	 	HIV-1 RNA UltraQuant with Serial Reporting	 	each	 	[***]*
	9876NY	 	87539	 	HIV-2 DNA Detector Qual New York	 	each	 	[***]*
	9881C	 	87390	 	HIV-1 Free Ag CSF	 	each	 	[***]*
	9881NYD	 	86311	 	HIV-1 Free Ag New York Diagnostic	 	each	 	[***]*

59

 

	9881NYP	 	86311	 	HIV-1 Free Ag New York Prognostic	 	each	 	[***]*
	9884A	 	87536	 	HIV-1 RNA Quant by Roche Amplicor	 	each	 	[***]*
	9884ASR	 	87536	 	Reporting	 	each	 	[***]*
	9884NYP	 	87536	 	HIV-1 RNA Quantitation New York Prognostic	 	each	 	[***]*
	9884NYPS	 	87536	 	HIV-1 RNA Quantitation New York Prognostic w/ Serial Report	 	each	 	[***]*
	9885N	 	87535	 	HIV-1 DNA DetectR Non-blood	 	each	 	[***]*
	9885NYP	 	87535	 	HIV-1 DNA Detector New York Prognostic	 	each	 	[***]*
	9886NY	 	87536	 	York	 	each	 	[***]*
	9898C	 	86849	 	HTLV I/II IgG Abs CSF	 	each	 	[***]*
	9901C	 	80090; 86645; 86695x2; 86778	 	TORCH IgG & IgM Abs Evaluation CSF	 	each	 	[***]*
	9911C	 	80090; 86695	 	TORCH IgG Abs Evaluation CSF	 	each	 	[***]*
	9915B	 	86703	 	HIV-1/ HIV-2 Antibodies Plus Confirmation W/ Bands	 	each	 	[***]*
	9915NY	 	86703	 	HIV-1/HIV-2 Antibodies Plus Confirmation New York	 	each	 	[***]*
	9915NYB	 	86703	 	HIV-1/HIV-2 Antibodies Plus Confirmation W/Bands New York	 	each	 	[***]*
	9921B	 	86702	 	HIV-2 IgG Abs w/ reflex IB + bands	 	each	 	[***]*
	9921C	 	86702	 	HIV-2 IgG Abs w/ reflex IB CSF	 	each	 	[***]*
	9921NY	 	86702	 	HIV-2 IgG Abs w/ reflex IB New York	 	each	 	[***]*
	9926B	 	86689	 	HIV-2 IgG Abs; Confirmation + bands	 	each	 	[***]*
	9926C	 	86689	 	HIV-2 IgG Abs; Confirm; CSF	 	each	 	[***]*
	9941C	 	86606x3	 	Aspergillus Abs Panel CSF [EIA]	 	each	 	[***]*
	9946C	 	86606	 	Aspergillus IgM Abs CSF	 	each	 	[***]*
	9961C	 	86606	 	Aspergillus IgG Abs CSF [EIA]	 	each	 	[***]*
	EX1	 	86005	 	RAST-Animal Mix: EX1	 	each	 	[***]*
	EX2	 	86005	 	RAST-Animal Mix: EX2	 	each	 	[***]*
	EX70	 	86003	 	RAST-Animal-Rodent Mix: EX70	 	each	 	[***]*
	EX71	 	86003	 	RAST-Animal-Feather Mix: EX71	 	each	 	[***]*
	EX72	 	86003	 	RAST-Animal-Caged Bird Mix: EX72	 	each	 	[***]*
	EX73	 	86003	 	RAST-Animal-Feather Mix: EX73	 	each	 	[***]*
	FX1	 	86005	 	RAST-Food-Nut Mix: FX1	 	each	 	[***]*
	FX2	 	86005	 	RAST-Food-Seafood Mix: FX2	 	each	 	[***]*
	FX3	 	86003	 	RAST-Food-Cereal Mix: FX3	 	each	 	[***]*
	FX5	 	86005	 	RAST-Food-Children's Food Mix: FX5	 	each	 	[***]*
	FX70	 	86005	 	RAST-Food-Spice Mix: FX70	 	each	 	[***]*
	FX71	 	86005	 	RAST-Food-Spice Mix: FX71	 	each	 	[***]*
	FX72	 	86005	 	RAST-Food-Spice Mix: FX72	 	each	 	[***]*
	FX73	 	86005	 	RAST-Food-Meat Mix: FX73	 	each	 	[***]*
	FX74	 	86005	 	RAST-Food-Fish Mix: FX74	 	each	 	[***]*
	GX1	 	86005	 	RAST-Grass Mix: GX1	 	each	 	[***]*
	GX2	 	86005	 	RAST-Grass Mix: GX2	 	each	 	[***]*
	GX3	 	86005	 	RAST-Grass Mix: GX3	 	each	 	[***]*
	GX4	 	86005	 	RAST-Grass Mix: GX4	 	each	 	[***]*
	HX2	 	86005	 	RAST-House Dust Mix: HX3	 	each	 	[***]*
	IHC00	 	88342	 	IHC Marker	 	each	 	[***]*
	IHC00A	 	88342	 	IHC Marker	 	each	 	[***]*
	IHC00B	 	88342	 	IHC Marker	 	each	 	[***]*

60

 

	IHC00C	 	88342	 	IHC Marker	 	each	 	[***]*
	IHC01BK	 	88342	 	IHC Estrogen Receptor Block	 	each	 	[***]*
	IHC02BK	 	88342	 	IHC Progesterone Receptor Block	 	each	 	[***]*
	IHC04BK	 	88342	 	IHC HER-1/neu Oncoprotein Block	 	each	 	[***]*
	IHC06BK	 	88342	 	IHC Ki-67 Block	 	each	 	[***]*
	IHC07BK	 	88342	 	IHC pS2 Block	 	each	 	[***]*
	IHC08BK	 	88342	 	IHC p53 Block	 	each	 	[***]*
	IHC1	 	88342	 	IHC Assay [Pathologist Interpretation]	 	each	 	[***]*
	IHC10BK	 	88342	 	IHC PCNA block	 	each	 	[***]*
	IHC130BK	 	88342	 	IHC HAM 56 Macrophage Block	 	each	 	[***]*
	IHC131BK	 	88342	 	IHC Lysozyme Block	 	each	 	[***]*
	IHC14BK	 	88342	 	IHC BCL-2 Block	 	each	 	[***]*
	IHC153BK	 	88342	 	IHC Cytokeratin 7 Block	 	each	 	[***]*
	IHC161BK	 	82024	 	IHC ACTH Block	 	each	 	[***]*
	IHC162BK	 	88342	 	IHC FSH Block	 	each	 	[***]*
	IHC163BK	 	88342	 	IHC GH Block	 	each	 	[***]*
	IHC164BK	 	88342	 	IHC LH Block	 	each	 	[***]*
	IHC165BK	 	88342	 	IHC Prolactin Block	 	each	 	[***]*
	IHC166BK	 	88342	 	IHC TSH Block	 	each	 	[***]*
	IHC170BK	 	88342	 	IHC Thyroglobulin Block	 	each	 	[***]*
	IHC171BK	 	88342	 	IHC Calcitonin Block	 	each	 	[***]*
	IHC184BK	 	88342	 	IHC Amyloid A Block	 	each	 	[***]*
	IHC185BK	 	88342	 	IHC Collagen Type IV Block	 	each	 	[***]*
	IHC21BK	 	88342	 	IHC CD45 (LCA) Block	 	each	 	[***]*
	IHC22BK	 	88342	 	IHC CD20 (Pan-B Cell) Block	 	each	 	[***]*
	IHC23BK	 	88342	 	IHC CD3 (Pan-T Cell) Block	 	each	 	[***]*
	IHC24BK	 	88342	 	IHC CD43 Block	 	each	 	[***]*
	IHC25BK	 	88342	 	IHC CD4 (T-Helper Cell) Block	 	each	 	[***]*
	IHC26BK	 	88342	 	IHC CD68 Block	 	each	 	[***]*
	IHC28BK	 	88342	 	IHC MAC387 Block	 	each	 	[***]*
	IHC29BK	 	88342	 	IHC CD30 (Ki-1) Block	 	each	 	[***]*
	IHC30BK	 	88342	 	IHC CD15 Block	 	each	 	[***]*
	IHC31BK	 	88342	 	IHC Kappa Light Chain Block	 	each	 	[***]*
	IHC32BK	 	88342	 	IHC Lambda Light Chain Block	 	each	 	[***]*
	IHC33BK	 	88342	 	IHC CD45RA Block	 	each	 	[***]*
	IHC35BK	 	88342	 	IHC CD45RO Block	 	each	 	[***]*
	IHC39BK	 	88342	 	IHC CD57 Block	 	each	 	[***]*
	IHC41BK	 	88342	 	IHC PSA (Prostate-Specific Ag) Block	 	each	 	[***]*
	IHC42BK	 	88342	 	IHC Pap Block	 	each	 	[***]*
	IHC43BK	 	88342	 	IHC CEA Block	 	each	 	[***]*
	IHC45BK	 	88342	 	IHC Cytokeratin (HMW) Block	 	each	 	[***]*
	IHC46BK	 	88342	 	IHC Cytokeratin (LMW) Block	 	each	 	[***]*
	IHC47BK	 	88342	 	IHC Vimentin Block	 	each	 	[***]*
	IHC48BK	 	88342	 	IHC NSE Block	 	each	 	[***]*
	IHC49BK	 	88342	 	IHC EMA Block	 	each	 	[***]*
	IHC50BK	 	88342	 	IHC Pancreatic Amylase Block	 	each	 	[***]*
	IHC55BK	 	88342	 	IHC Pan-Cytokeratin Block	 	each	 	[***]*
	IHC57BK	 	88342	 	IHC OC125 Block	 	each	 	[***]*
	IHC61BK	 	88342	 	IHCS-100 Block	 	each	 	[***]*
	IHC62BK	 	88342	 	IHC HMB-45 (Melanoma) Block	 	each	 	[***]*
	IHC71BK	 	82105	 	IHC AFP Block	 	each	 	[***]*

61

 

	IHC73BK	 	88342	 	IHC Beta-hCG Block	 	each	 	[***]*
	IHC74BK	 	88342	 	IHC Placental Alkaline Phosphatase Block	 	each	 	[***]*
	IHC81BK	 	88342	 	IHC Chromogranin Block	 	each	 	[***]*
	IHC82BK	 	88342	 	IHC Serotonin Block	 	each	 	[***]*
	IHC84BK	 	88342	 	IHC GFAP Block	 	each	 	[***]*
	IHC85BK	 	88342	 	IHC Neurofilament	 	each	 	[***]*
	IHC86BK	 	88342	 	IHC Synaptophysin Block	 	each	 	[***]*
	IHC87BK	 	88342	 	IHC Insulin Block	 	each	 	[***]*
	IHC88BK	 	88342	 	IHC Glucagon Block	 	each	 	[***]*
	IHC89BK	 	88342	 	IHC Gastrin Block	 	each	 	[***]*
	ICH92BK	 	88342	 	IHC Smooth Muscle Block	 	each	 	[***]*
	IHC93BK	 	88342	 	IHC Desmin Block	 	each	 	[***]*
	IHC95BK	 	88342	 	IHC Myoglobin Block	 	each	 	[***]*
	IHC97BK	 	88342	 	IHC Factor VIII Ag Block	 	each	 	[***]*
	IHCSTAIN1	 	88342	 	IHC1 Stain	 	each	 	[***]*
	MX1	 	86005	 	RAST-Mold Mix: MX1	 	each	 	[***]*
	MX2	 	86005	 	RAST-Mold Mix: MX2	 	each	 	[***]*
	PAX1	 	86005	 	RAST Combination Mix: PAX1	 	each	 	[***]*
	PAX2	 	86005	 	RAST-Storage Mite Mix: PAX2	 	each	 	[***]*
	PAX3	 	86005	 	RAST Combination Mix: PAX3	 	each	 	[***]*
	PAX4	 	86005	 	RAST Combination Mix: PAX4	 	each	 	[***]*
	PAX5	 	86005	 	RAST-Occupational Mix: PAX5	 	each	 	[***]*
	PAX6	 	86005	 	RAST-Occupational Mix: PAX6	 	each	 	[***]*
	RAST1	 	86003	 	RAST-Allergen Testing-Single Allergen	 	each	 	[***]*
	RFX10	 	86005	 	FAST-Food-Meat & Egg Mix: RFX10	 	each	 	[***]*
	RFX11	 	86005	 	RAST-Food-Vegetable Mix: RFX11	 	each	 	[***]*
	RFX12	 	86005	 	RAST-Food-Vegetable & Grain Mix: RFX12	 	each	 	[***]*
	RFX13	 	86005	 	RAST-Food-Vegetable Mix: RFX13	 	each	 	[***]*
	RFX14	 	86005	 	RAST-Food-Vegetable Mix: RFX14	 	each	 	[***]*
	RFX15	 	86005	 	RAST-Food-Fruit Mix: RFX15	 	each	 	[***]*
	RFX16	 	86005	 	RAST-Food-Fruit Mix: RFX16	 	each	 	[***]*
	RFX17	 	86005	 	RAST-Food-Fruit Mix: RFX17	 	each	 	[***]*
	RFX18	 	86005	 	RAST-Food-Vegetable Mix: RFX18	 	each	 	[***]*
	RFX19	 	86005	 	RAST-Food-Vegetable Mix: RFX19	 	each	 	[***]*
	RFX20	 	86005	 	RAST-Food-Grain Mix: RFX20	 	each	 	[***]*
	RFX21	 	86005	 	RAST-Food-Fruit Mix: RFX21	 	each	 	[***]*
	RFX22	 	86005	 	RAST-Food-Nut Mix RFX22	 	each	 	[***]*
	RFX8	 	86003	 	RAST-Food-Fruit & Nut Mix: RFX8	 	each	 	[***]*
	RFX9	 	86005	 	RAST-Food-Fruit & Nut Mix: RFX9	 	each	 	[***]*
	RGX6	 	86005	 	RAST-Grass Mix: RGX6	 	each	 	[***]*
	RRX1	 	86005	 	RAST-Grass; Weed; & Tree Mix: RRX1	 	each	 	[***]*
	RRX2	 	86005	 	RAST-Mite; Epidermal; & Mold Mix: RRX2	 	each	 	[***]*
	RRX3	 	86005	 	RAST-Grass; Weed; & Tree Mix: RRX3	 	each	 	[***]*
	RRX4	 	86005	 	RAST-Grass;Weed; & Tree Mix: RRX4	 	each	 	[***]*
	RTX10	 	86005	 	RAST-Tree Mix: RTX10	 	each	 	[***]*
	RW209	 	86005	 	RAST-Weed Mix: RW209	 	each	 	[***]*
	TX1	 	86005	 	RAST-Tree Mix: TX1	 	each	 	[***]*
	TX2	 	86005	 	RAST Tree Mix: TX2	 	each	 	[***]*
	TX3	 	86005	 	RAST Tree Mix: TX3	 	each	 	[***]*
	TX4	 	86005	 	RAST Tree Mix: TX4	 	each	 	[***]*
	TX5	 	86005	 	RAST Tree Mix: TX5	 	each	 	[***]*

62

 

	TX6	 	86005	 	RAST Tree Mix: TX6	 	each	 	[***]*
	TX7	 	86005	 	RAST Tree Mix: TX7	 	each	 	[***]*
	TX8	 	86005	 	RAST Tree Mix: TX8	 	each	 	[***]*
	TX9	 	86005	 	RAST Tree Mix: TX9	 	each	 	[***]*
	WX1	 	86005	 	RAST-Weed Mix:WX1	 	each	 	[***]*
	WX2	 	86005	 	RAST-Weed Mix:WX2	 	each	 	[***]*
	WX3	 	86005	 	RAST-Weed Mix:WX3	 	each	 	[***]*
	WX4	 	86005	 	RAST-Weed Mix:WX4	 	each	 	[***]*
	WX5	 	86005	 	RAST-Weed Mix:WX5	 	each	 	[***]*
	WX6	 	86005	 	RAST-Weed Mix:WX6	 	each	 	[***]*
	WX7	 	86005	 	RAST-Weed Mix:WX7	 	each	 	[***]*

63

	 	 	 	 	 	 	 	 	 each

  

 
 

EXHIBIT B
  
    NON-PRICE SPECIFICATIONS    
  

	Term:	 	Three year agreement beginning May 1, 2001 through April 30, 2004 with two one-year option years at Novation's option.
	

Marketing Fee:	
 	

[***]* on all sales.
	

 	
 	

Baseline Sales = May 1, 2000 through April 30, 2001 Years 1, 2, & 3: Target Sales = [***]* Measurement Sales for each year = May 1 - April 30
	

 	
 	

Measurement sales in excess of target sales, as defined above, will be paid at a [***]* marketing fee (an [***]* on any dollar above target sales). Upon achievement, the [***]* will be payable to Novation no later than 90 days
after the end of the measurement sales year (due by July 31).
	

 	
 	

Should Novation elect to exercise one or both of the optional extension years, Target Sales will be defined as:
	

 	
 	

Year 4: Target Sales = [***]*

Year 5: Target Sales = [***]*
	

 	
 	

Upon achievement, the [***]* will be payable to Novation no later than 90 days after the end of the measurement sales year (due by July 31).
	

 	
 	

Example:

Baseline Sales (May 1, 2000 - April 30, 2001) = [***]*

Target Sales: [***]*

Measurement Sales: May 1, 2001 - April 30, 2002: [***]*

[***]* marketing fee on sales of [***]*

[***]* marketing fee on sales above target [***]*

Total marketing fee for year: [***]*
	

Information Services Offering:	
 	

The following offering will be available to Members and considered included as part of the service by meeting the following minimum monthly volumes:

	 	 	Interface Type	 	Client Minimum

Monthly Sales
	

 	
 	

DataPassportTM:	
 	

[***]*
	 	 	Traditional CPU-to-CPU Interface:	 	[***]*
	 	 	DataPassportMDTM with hardware:	 	[***]*
	 	 	DataPassportMDTM without hardware:	 	[***]*
	 	 	Flash Link Printer:	 	[***]*

	 	 	Test result reports are provided back to Members either by manual or electronic reporting. Hardcopy test results are available through flashlink printers, fax transmission, or U.S. mail

* CONFIDENTIAL TREATMENT IS REQUESTED FOR CONFIDENTIAL INFORMAITON ENCLOSED IN THE BRACKETS AND UNDERLINED. 

1

 

	

Coverage:	
 	

Supplier will provide reference laboratory testing to all Members as defined in Section 2a of the Supplier Agreement.
	

Courier Service:	
 	

Supplier will provide specimen pick-up services to Members. Supplier will work with Members to establish pick up times that meet business and turn-around time needs. Supplier will add additional services as appropriate to properly service members
that best optimizes its assay schedules and sample preparation. Supplier will not charge any additional fees to Members for standard courier services of specimens to Supplier. All specimens will be shipped by same day or overnight services to
Supplier's laboratory at Supplier's expense. Members will ship specimens via same day or overnight services at no additional charge where a courier service is not available. Supplier does not provide STAT service or charge STAT fees due to the
specialized nature of Supplier's standard testing services.
	

Supplies:	
 	

All supplies required for the collection, processing, handling and transportation of specimens will be paid for by Supplier. Supplies can be ordered by calling client services at (800) 421-4449 or by faxing a copy of the order form to
(310) 828-5213.
	

Consultations:	
 	

Supplier provides consultative services as part of the service to Participating Members through a team of expert physicians and doctoral level scientists.
	

Conversion Assistance:	
 	

Supplier will provide, but arc not limited to, the following assistance to a Participating Member that is converting from a competitive reference laboratory:

	

 	
 	

1.	
 	

Test Methodology Verification: Samples may be submitted to verify methodologies and reference ranges. While it is generally acceptable that Supplier provides the "gold standard" for which other reference laboratories verify their assays, comparison
samples will be analyzed at [***]*. This comparison discount will be available for ninety (90) days from the date the Letter of Participation is received by Supplier.
	

 	
 	

2.	
 	

Sample Reports: Most test procedures have standard report formats. Some assays have multiple parameters and customized reporting is necessary. Samples of these reports will be made available to the medical director at each facility, if
required.
	

 	
 	

3.	
 	

Information Systems Conversion Reimbursement: In order to off-set the cost incurred by any Novation member, Supplier will credit [***]* that is revised in the laboratory's information system. This will be in the form of a credit on the invoice of the
first full month of use. For Meditech users, a "Test Building Utility" has been developed and this credit will not apply.

2

 

	

 	
 	

4.	
 	

Physician Education: As part of Supplier's on-going efforts to transfer the technological advances developed through research and development, physician education programs will be made available. These may include but will not be limited to lectures,
teleconferences, technical notes, etc.
	

 	
 	

5.	
 	

Staff Development: Each local Supplier sales representative will work with the Technical Services department to insure that laboratory staff are sufficiently trained in all aspects of specimen processing, report retrieval and other functions
associated with referral testing.

	

Cost Containment:	
 	

Supplier provides the following as part of the service to Participating Members:
	

 	
 	

Clinical Consultation: Supplier's Medical Directors and Scientific staff are available for development of alternative clinical pathways, standing orders and treatment monitoring. As with all cost reduction initiatives, these programs are available to
all Participating Members. Cost savings vary from case to case.
	

 	
 	

Utilization Review: Statistical review of physician orders and utilization can, provide each facility with information regarding any series of tests that may be out-dated or non-contributory.
	

 	
 	

Secondary Lab Consolidation: For facilities that utilize several reference labs, Supplier provides the opportunity to consolidate these sources for esoteric testing. Existing staff, dedicated to specimen processing, shipping and report retrieval can
be re-assigned.
	

 	
 	

Advanced Test Introduction: Participating Members receive information updates on new tests on a regular basis. These advances in laboratory science lead to better patient management and cost reductions.
	

 	
 	

Improved Turn-around time: Supplier's assay schedule is more aggressive than any other laboratory. Providing testing in one unified location, complex tests are resulted faster, reducing the time needed for clinical decision making by individual
physicians.
	

 	
 	

Test Selection: With over 3,700 tests in the active test menu, fewer samples are referred to other laboratories. This reduces overall processing time, expedites result verification and reduces specimen shipping errors.
	

 	
 	

On-Site Lab Technical Support for Participating Members: Additional support will be provided as deemed necessary on a case by case basis. For those facilities that require on-site technical support, staff will be available.
	

 	
 	

CEU Programs: Continuing education programs exist and are encouraged. Every effort will be made to provide qualified speakers and materials to meet existing CEU schedules, These include seminars for CE programs, grand rounds and Supplier's
Conferences.

3

 

	

 	
 	

Training Seminars and/or Training Implementation Teams: All necessary training and education, complete with documentation and test data will be provided at each facility.
	

 	
 	

Joint Marketing Services: An entire menu of joint marketing services is available for enhancing a hospital's outreach program. Federal regulations require Supplier to charge the fair market value for these services. These include, but are not limited
to;

	

 	
 	

•	
 	

Market opportunity assessment
	 	 	•	 	Managed care program development
	 	 	•	 	Joint directory of services
	 	 	•	 	Joint sales calls
	 	 	•	 	Sales training
	 	 	•	 	Sales management training
	 	 	•	 	Client service training
	 	 	•	 	Courier network development
	 	 	•	 	Marketing materials development
	 	 	•	 	Laboratory operations assessment
	 	 	•	 	Regulatory compliance services
	 	 	•	 	Billing consultation
	 	 	•	 	Continuing education
	 	 	•	 	Consulting services
	 	 	•	 	Inter-institutional connectivity
	 	 	•	 	Continuing Education
	 	 	•	 	Consulting Services
	 	 	•	 	Inter-institutional Connectivity

4

 
 

EXHIBIT B-1
  
    Specialty Laboratories, Inc.—Clinical Reference Laboratory Testing LB00051
  
    LETTER OF PARTICIPATION    
  

	Health Care Organization:	 	 
	 	 	

	Member Street Address:	 	 
	 	 	

	Member City, State and ZIP Code:	 	 
	 	 	

	Effective Date:	 	 	 	 
	 	 	
	 	 

I agree to participate as a designated VHA, HPPI or UHC member or affiliate under the terms of the Clinical Reference Laboratory Testing Agreement dated
            ,            , between Novation and Specialty Laboratories with no commitment on the part of the health
care
organization. Pricing will not be effective until this Letter of Participation has been received by Specialty Laboratories. 

In
the case of a conflict between the individual health care organization's purchase order terms and the terms of this Agreement, this Agreement will control. The Letter of Participation may be
terminated by Member with 30 days written notice to Novation. Novation will then notify the Supplier to remove Novation pricing. 

Health
Care Organization: 

	By:	 	 	 	 
	 	 	
	 	 

	Print Name:	 	 	 	 
	 	 	
	 	 

	Title:	 	 	 	 
	 	 	
	 	 

	Date:	 	 	 	 
	 	 	
	 	 

Copy and fax this letter of participation to Novation at (972) 581-5764 Attn: Laboratory 

* CONFIDENTIAL TREATMENT IS REQUESTED FOR CONFIDENTIAL INFORMATION ENCLOSED IN THE BRACKETS AND UNDERLINED. 

 
 

EXHIBIT C
  
    SPECIAL CONDITIONS
  [Final Special Conditions]    
  

 
 

EXHIBIT D
  
    AWARD LETTER
  
    [Final Letter of Award]    
  

 
 
 

NovationTM
  The Supply Company of VHA & UHC
  
    125 East John Carpenter Freeway
  Suite 1500
  Irving, TX 75062-2324

P.O. Box 140909
  Irving, TX 75014-0909
  972-581-5000    

March 5,
2001 

Mr. Otto
Schaefer

Manager of Group Purchasing and Managed Care

Specialty Laboratories, Inc.

2211 Michigan Ave.

Santa Monica, CA 90404-3900 

Subject:  Acceptance
of Bid (Supplier Agreement # LB00051) 

Dear
Mr. Schaefer, 

    Novation,
LLC ("Novation"), acting in its capacity as agent for VHA, UHC, and HPPI, respectively (and not collectively) and certain of their respective subsidiaries and affiliates,
accepts your multi-source proposal for clinical reference laboratory testing in response to our Invitation To Bid for Clinical Reference Laboratory Testing dated March 31, 2000, which was
signed and dated by you on May 4, 2000. Also, attached to this Award Letter is Exhibit F (Exceptions to Supplier Agreement # LB00051). 

    The
"Agreed Percentage" for the Marketing Fee will be [***]*. In addition, if during the time period of May 1 through
April 30 of each year of the Agreement, Novation achieves sales in excess of the target sales [***]*, dollars in excess of target sales will
be paid an [***]* marketing fee. 

    The
term of this Agreement will be for a period of three years, effective May 1, 2001, with two one-year renewal options at Novation's discretion. 

    Novation
looks forward to a successful implementation of this Agreement. 

Sincerely, 

Eldon
Petersen

Group Senior Vice President

Novation, LLC 

* CONFIDENTIAL TREATMENT IS REQUESTED FOR CONFIDENTIAL INFORMATION ENCLOSED IN THE BRACKETS AND UNDERLINED. 

  

 
 

EXHIBIT E
  
    OTHER INFORMATION REQUIREMENTS    
  

    Novation and Supplier desire to facilitate contract administration transactions ("Transactions") by electronically transmitting and receiving data in agreed
formats in substitution for conventional paper-based documents and to assure that such Transactions are not legally invalid or unenforceable as a result of the use of available electronic technologies
for the mutual benefit of the parties. 

    The
parties agree as follows: 

1.  PREREQUISITES.  

    a.  Documents; Standards.  Each party will electronically
communicate to or receive from the other party all «f the required documents listed in the Novation Electronic Communication Requirements Schedule attached hereto (collectively
"Documents"). All Documents will be communicated in accordance with the standards set forth in the applicable sections of the Novation Information Requirements Guidebook ("Guidebook"). Supplier agrees
that the Guidebook is the Confidential Information of Novation and will not disclose information contained therein to any other party. 

    b.  Third Party Service Providers.  Documents will be
communicated electronically to each party, as specified in the Guidebook, through any third party service provider ("Provider") with which either party may contract or VHAseCure.netTM.
Either party may modify its election to use, not use or change a Provider upon thirty (30) days' prior written notice. Each party will be responsible for the costs of any Provider with which it
contracts, unless the parties otherwise mutually agree in writing. 

    c.  Signatures.  Each party will adopt as its signature
an electronic identification consisting of symbol(s) or code(s) which are to be affixed to or contained in each Document transmitted by such party ("Signatures"). Each party agrees that any Signature
of such party affixed to or contained in any transmitted Document will be sufficient to verify such party originated and intends to be bound by such Document. Neither party will disclose to any
unauthorized person the Signatures of the other party. 

2.  TRANSMISSIONS.  

    a.  Verification.  Upon proper receipt of any Document,
the receiving party will promptly and properly transmit a functional acknowledgment in return, unless otherwise specified in the Guidebook. 

    b.  Acceptance.  If acceptance of a Document is required
by the Guidebook, any such Document which has been properly received will not give rise to any obligation unless and until the party initially transmitting such Document has properly received in
return an Acceptance Document (as specified in the Guidebook). 

    c.  Garbled Transmission.  If any properly transmitted
Document is received in an unintelligible or garbled form, the receiving party will promptly notify the originating party (if identifiable from the received Document) in a reasonable manner. In the
absence of such a notice, the originating party's records of the contents of such Document will control. 

* CONFIDENTIAL TREATMENT IS REQUESTED FOR CONFIDENTIAL INFORMAITON ENCLOSED IN THE BRACKETS AND UNDERLINED. 

1

 

3.  TRANSACTION TERMS.  

    a.  Confidentiality.  No information contained in any
Document or otherwise exchanged between the parties will be considered confidential, except to the extent provided by written agreement between the parties, or by applicable law. 

    b.  Validity, Enforceability.  Any Document properly
transmitted pursuant to this Agreement will be considered, in connection with any Transaction, to be a "writing" or "in writing"; and any such Document when containing, or to which there is affixed, a
Signature ("Signed Documents") will be deemed for all purposes to have been "signed" and to constitute an "original" when printed from electronic files or records established and maintained in the
normal course of business. 

4.  STANDARDS.  

ASC × 12—Novation
Information Requirements Guidebook 

5.  THIRD PARTY SERVICE PROVIDERS.  

(If
the parties will be transmitting Documents directly, insert "NONE") 

	Company
 
	 	VAN Name
	 	Address

Number
	 	Telephone

	Novation	 	AT&T	 	12976 Hollander Drive	 	800/624-5672
	 	 	Bridgeton, MO 63044	 	 	 	 

6.  CONTRACT PRICING (PHARMACY).  Supplier will transmit contract pricing
information electronically, to include new contracts, contract renewals and any changes to a current contract. This
will be sent in a timely manner and in compliance with ANSI ASC X12-845 (Price Authorization) and Novation Contract Pricing Guidelines. Contract pricing information will include the
following: 

Supplier
Identification Number

HIN (Health Industry Number if Supplier is a HIN subscriber)

DEA Number (if HIN is not available)

Supplier Assigned Number (if HIN and DEA are not available) 

Supplier
Name

Supplier Contract Number

MFG Contract Number

Contract Effective Date

Contract Expiration Date

Member(s) (Member name, HIN or DEA number, Member start/stop dates)

Product Identifier

    NDC

    UPC (if NDC is not available)

Trade Name

Package Count

Package UOM

Selling Unit Price

Item Contract Effective Date

Item Contract Expiration Date 

7.  CONTRACT PRICING (MEDICAL/SURGICAL).  Supplier will communicate
contract pricing information electronically, to include new contracts, contract renewals and any changes to the current contract. This will be sent in a timely manner and in compliance with the
Guidebook. 

2

 
 
 

Novation Electronic Communication
  Requirements Schedule    
  

	Company Name: 
	 	Date: 

	

Your Name: 
	
 	

Your Title 

	

Phone: 
	
 	

Fax: 
	
 	

E-mail 

	

Technical Contact: 
	
 	

Title 

	

Phone: 
	
 	

Fax 
	
 	

E-mail: 

	NOVATION REQUIREMENT
	 	NOVATION EXPECTATION
	 	MANDATORY DUE DATES

& FORMATS TO BE USED

	Requirement 1:
 New Contract Launch

Section 4.1, page 21 of the 2000 Guidebook	 	This only applies to new contacts, unless your company never provided this information. If needed, your Novation product manager will contact you. UPN must be included with all line item files.	 	Due 60 days prior to the Contract Effective Date
	
Requirement 2:

Ongoing Contract Maintenance

Section 4.2, page 27 of the 2000 Guidebook	
 	

Novation must receive contract item and pricing updates as prices change, and when items are added or deleted from contract.	
 	
Due 60 days prior to the effective date of the line item add/delete/change

Information will be sent via

(check one):

( ) EDI 832

( ) Interim File Format (Excel Spreadsheet)
	
Requirement 3

Summary Sales Reporting

Section 4.3, page 43 of the 2000 Guidebook	
 	

Current paper reports must be converted to electronic reporting immediately.	
 	
Due at the first contract reporting period
	
Requirement 4:

Detailed Line Item Sales Reporting

Section 4.4, page 51 of the 2000 Guidebook	
 	

Plan for a 90-day testing for this requirement.	
 	
Begin testing within 120 days of Contract Effective Date

Information will be sent via

(check one):

( ) EDI 867

( ) Other

3

 

	
Requirement 5:

Membership

Section 4.5, page 63 of the 2000 Guidebook	
 	

You must be able to receive and process monthly membership updates.	
 	
Due immediately
	
Requirement 6:

Commitment Forms

Section 4.6, page 73 of the 2000 Guidebook	
 	

Details which members have and have not signed your contract enrollment forms, if needed.	
 	
Due immediately, if applicable
	
Requirement 7:

Sales Representative

Contact Information

Section 4.7, page 77 of the 2000 Guidebook	
 	

Able to update Sales Representative Information from a Business Partner Repository System download.	
 	
Due within 30 days of the Contract Effective Date
	
Requirement 8:

Product Cross-referencing

Section 4.8, pages 81 of the 2000 Guidebook	
 	

Must to update the items on contract with competitive cross-reference information	
 	
Due within 90 days of the Contract Effective Date.
	

Business Partner Repository System

(BPRS)

Access

Section 3, page 13 of the 2000 Guidebook	
 	

Able to connect to Novation BPRS via the VHAseCURE.netTM	
 	
Due within 60 days of the Contract Effective Date

4

  

 
 

EXHIBIT F
  
    SUPPLIER AGREEMENT EXCEPTION RESPONSE FORM    
  

	SUPPLIER NAME:  Specialty Laboratories, Inc.	 	 
	

PRINTED NAME:  Michael K. Bond	
 	

 
	

AUTHORIZED SIGNATURE:	
 	

	

TITLE:  Director, Contract Administration	
 	

DATE  March 6, 2001

	Page #
	 	Para #
	 	Define Exception Being Taken

	1	 	1b	 	Supplier.

Delete paragraph and replace with "Supplier is the manufacturer of products listed on Exhibit A, the provider of installation, training and maintenance service for such products, or the provider of any other services listed on Exhibit A (such
products and/or services are collectively referred to herein as "Products")."
	

2	
 	

2a	
 	

Letter of Award.

Insert after first sentence: "Supplier agrees to extend pricing to all Members (VHA, UHC Members and HPPI Clients and Members) with the exception of long term care facilities, home health agencies and any competitor of Supplier which is a VHA, UHC
Member or HPPI Client and/or Member that has a current or will have a future Agreement with Novation, VHA, UHC or HPPI in its capacity as a supplier, during the term of this Novation Agreement."
	

2	
 	

2c	
 	

Market Competitive Terms.

Delete the second and third sentences and replace with "In the event that a significant amount of Supplier's business is conducted with any customer of Supplier pursuant to an arrangement with terms which, considered [***]* hereunder, Supplier
shall notify Novation of such arrangement. In the event that Novation shall notify Supplier that maintaining [***]* so requires, Supplier then shall [***]* to Novation members who purchase [***]* from Supplier as is necessary to
ensure market competitiveness. Additionally, any Member eligible for governmental pricing or research-related endeavors through a university based project, shall have such [***]* by Supplier."
	
* CONFIDENTIAL TREATMENT IS REQUESTED FOR CONFIDENTIAL INFORMAITON ENCLOSED IN THE BRACKETS AND UNDERLINED.

1

 

	

2	
 	

2f	
 	

Underutilized Businesses.

In line five, replace "provide, on request" with "develop a system to provide".
	

3	
 	

3b	
 	

Change (1) to "Supplier materially breaches this Agreement; or"
	

3	
 	

3c	
 	

Termination by Supplier.

Delete paragraph and replace with "Supplier may terminate the Agreement at any time for any reason whatsoever by delivering not less than ninety (90) days' prior written notice thereof to Novation."
	

3	
 	

4a	
 	

Delivery and Invoicing'

Delete third sentence and replace with "Payment terms are [***]*."
	

4	
 	

4d	
 	

Discontinuation of Product.

Delete 4(d) and substitute the following: "Supplier reserves the right to add, delete, or modify test offerings, methods, and related services whenever Supplier's medical personnel make a professional judgement that such changes are in the best
interest of' patient care. Supplier continually develops new tests and evaluates existing methodologies for improvement. Supplier will notify each Member of planned changes to existing methodology and/or reference ranges and provide method comparison
data, upon request of the Member. Supplier agrees that it will not make changes to its test offerings, methods, and related services except for changes made based upon good faith professional judgment. Supplier will not utilize this provision to make
broad changes in the scope of its services for the purpose of directly or indirectly changing its overall commitment to Members within the scope of the Supplier Agreement between Supplier and Novation. Whenever Supplier determines that it is
reasonable to do so from a professional and practical standpoint, Supplier shall give Member the option to continue with an existing methodology."

2

 

	

11	
 	

12a	
 	

Policy Requirements.

Delete second sentence and replace with "Such insurance will contain a minimum combined single limit of liability for bodily injury and property damage in the amounts of not less than [***]*; will name Novation and the Clients, as their
interests may appear, as additional insureds, and will contain an endorsement providing that the carrier will provide directly to all named insured copies of all notices and endorsements."
	

12	
 	

14	
 	

Release and Indemnity.

Delete second sentence and replace with "Such indemnification, hold harmless and right to defense will not be applicable to the extent the claim, liability, damage, action, cost or expense arises as a result of an act or failure to act of
Indemnitees."
	

14	
 	

18a	
 	

Choice of Law.

In line two, strike "the Texas courts", and replace with "the state and federal courts in the state of Texas"
	

15	
 	

18g	
 	

Entire Agreement.

Delete paragraph and replace with "This Agreement, together with the exhibits listed below and each Member's purchase order and Letter of Participation will constitute the entire agreement between each Member and Supplier. In the event of any
inconsistency between this Agreement and a Member's purchase order or Letter of Participation, the terms of this Agreement will control, except that the Member's purchase order will supersede Sections 4 and 5 of this Agreement in the event of any
inconsistency with such Sections. No other terms and conditions in any document, acceptance, or acknowledgement will be effective or binding unless expressly agreed to in writing."

3

QuickLinks

Exhibit 10.1

INDEX OF DEFINED TERMS

EXHIBIT A PRODUCT AND SERVICE DESCRIPTION AND PRICING

Exhibit A Specialty Laboratories, Inc.

EXHIBIT B NON-PRICE SPECIFICATIONS

EXHIBIT B-1 Specialty Laboratories, Inc.—Clinical Reference Laboratory Testing LB00051 LETTER OF PARTICIPATION

EXHIBIT C SPECIAL CONDITIONS [Final Special Conditions]

EXHIBIT D AWARD LETTER [Final Letter of Award]

Novation Acceptance of Bid Letter

EXHIBIT E OTHER INFORMATION REQUIREMENTS

Novation Electronic Communication Requirements Schedule

EXHIBIT F SUPPLIER AGREEMENT EXCEPTION RESPONSE FORM

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}]]